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Continuous glucose monitoring in extremely preterm
infants in intensive care: the REACT RCT and pilot study
of ‘closed-loop’ technology
Kathryn Beardsall ,1,2* Lynn Thomson ,1 Catherine Guy ,1
Simon Bond ,3 Annabel Allison ,3 Beatrice Pantaleo ,3 Stavros Petrou ,4,5
Sungwook Kim ,4,5 David Dunger 1,6 and Roman Hovorka 6
1Department of Paediatrics, University of Cambridge, Cambridge, UK
2Neonatal Intensive Care Unit, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
3Cambridge Clinical Trials Unit, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
4Warwick Clinical Trials Unit, Warwick Medical School, University of Warwick, Coventry, UK
5Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK
6University of Cambridge Metabolic Research Laboratories, Wellcome Trust-MRC Institute of
Metabolic Science, Cambridge, UK
*Corresponding author kb274@cam.ac.uk
Background: Hyperglycaemia and hypoglycaemia are common in preterm infants and are associated
with increased mortality and morbidity. Continuous glucose monitoring is widely used to target glucose
control in adults and children, but not in neonates.
Objective: To evaluate the role of continuous glucose monitoring in the preterm infant.
Design: The REAl-time Continuous glucose moniToring in neonatal intensive care project combined
(1) a feasibility study, (2) a multicentre randomised controlled trial and (3) a pilot of ‘closed-loop’
continuous glucose monitoring. The feasibility study comprised a single-centre study (n = 20). Eligibility
criteria included a birthweight ≤ 1200 g and aged ≤ 48 hours. Continuous glucose monitoring was
initiated to support glucose control. The efficacy and safety outcomes guided the design of the
randomised controlled trial. The randomised controlled trial comprised a European multicentre trial
(n = 182). Eligibility criteria included birthweight ≤ 1200 g and aged ≤ 24 hours. Exclusion criteria
included any lethal congenital abnormality. Continuous glucose monitoring was initiated to support
glucose control within 24 hours of birth. In the intervention group, the continuous glucose monitoring
sensor provided real-time data on glucose levels, which guided clinical management. In control infants,
the continuous glucose monitoring data were masked, and glucose level was managed in accordance
with standard clinical practice and based on the blood glucose levels. The primary outcome measure
was the percentage of time during which the sensor glucose level was within the target range of
2.6–10 mmol/l. Secondary outcome measures included mean sensor glucose level, the percentage of
time during which the sensor glucose level was within the target range of 4–8 mmol/l, the percentage
of time during which the sensor glucose level was in the hyperglycaemic range (i.e. > 15 mmol/l) and
sensor glucose level variability. Safety outcomes included hypoglycaemia exposure. Acceptability
assessment and health economic analyses were carried out and further exploratory health outcomes
were explored. The mean percentage of time in glucose target range of 2.6–10 mmol/l was 9% higher
in infants in the continuous glucose monitoring group (95% confidence interval 3% to 14%; p = 0.002),
and the mean time in the target range of 4–8 mmol/l was 12% higher in this group (95% confidence
interval 4% to 19%; p = 0.004). There was no difference in the number of episodes of hypoglycaemia.
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Exploratory outcomes showed a reduced risk of necrotising enterocolitis in the intervention arm (odds
ratio 0.33, 95% confidence interval 0.13 to 0.78; p = 0.01). Health economic analyses demonstrated that
continuous glucose monitoring was cost-effective on the basis of the cost per additional case of adequate
glucose control between 2.6 and 10mmol/l. The ‘closed-loop’ study was a single-center pilot study, with
eligibility criteria including a birthweight of ≤ 1200 g and aged ≤ 48 hours. Infants underwent continuous
glucose monitoring for the first week of life (n = 21), with those in the intervention group receiving
closed-loop insulin delivery between 48 and 72 hours of age. The primary outcome of percentage of
time in the target range (i.e. sensor glucose 4–8 mmol/l) increased from a median of 26% (interquartile
range 6–64%) to 91% (interquartile range 78–99%) during closed-loop insulin delivery (p < 0.001).
Limitations: These studies have not defined the optimal targets for glucose control or the best
strategies to achieve them in these infants.
Future work: Studies are needed to evaluate the longer-term impact of targeting glucose control on
clinical outcomes.
Conclusions: Continuous glucose monitoring in extremely preterm infants can improve glucose control,
with closed-loop insulin delivery having further potential to target glucose levels. Staff and parents felt
that the use of continuous glucose monitoring improved care and the results of the health economic
evaluation favours the use of continuous glucose monitoring.
Trial registration: Current Controlled Trials ISRCTN12793535.
Funding: This project was funded by the Efficacy and Mechanism Evaluation (EME) programme,
a MRC and National Institute for Health Research (NIHR) partnership. This will be published in full
in Efficacy and Mechanism Evaluation; Vol. 8, No. 16. See the NIHR Journals Library website for further
project information. Medtronic plc provided some MiniMed™ 640G systems and Nova Biomedical
(Waltham, MA, USA) provided point-of-care devices.
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Both high and low blood sugar (glucose) levels are common in preterm babies and have been linkedto worse health outcomes. Managing the extremes of glucose levels is difficult as it requires
frequent invasive blood sampling. In addition, every baby responds differently to treatments. In children
with diabetes, who have similar difficulties, a continuous glucose monitor can be used to better target
glucose levels. Continuous glucose monitoring requires a small sensor to be inserted under the skin; this
can be left in place for up to a week. The REAl-time Continuous glucose moniToring in neonatal intensive
care project aimed to assess whether or not continuous glucose monitoring is helpful for the management
of preterm babies in intensive care. There were three parts to the project, each with protocols and patient
information sheets developed with support from parents:
1. a feasibility study to guide the design of a randomised clinical trial
2. a randomised clinical trial
3. a pilot study, combining continuous glucose monitoring with computer advice (i.e. the ‘closed-
loop study’).
The randomised clinical trial recruited 182 babies within 24 hours of their birth. A continuous glucose
monitor was inserted in all babies, but doctors used the results to support sugar control in only half
of the babies. The other half received standard care (continuous glucose monitor data were collected,
but were not made available to the clinical team).
The study was positive in that continuous glucose monitoring helped to target sugar levels without
increasing the risk of low blood sugar levels. The clinical team and parents felt that the continuous
glucose monitor improved the care of babies. In health economic calculations from birth to 36 weeks’
corrected gestational age, continuous glucose monitoring was, on average, less costly and more
effective than standard care. The closed-loop study showed that the use of a computer, combined
with continuous glucose monitoring, can further increase the time within the target sugar levels.
Further studies are required to determine the ideal target for sugar levels in these babies and
the impact on long-term health. A continuous glucose monitor provides the technology to support
such studies.
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Hyperglycaemia and hypoglycaemia have both been associated with increased mortality and morbidity
for preterm infants. However, controversy remains regarding the optimal management. This relates
to the unique challenges in the extremely preterm infant when aiming to optimise nutritional intake,
while also avoiding the risks of insulin-induced hypoglycaemia. Continuous glucose monitors are widely
used in adults and children with diabetes to target glucose control, and have been trialled in intensive
care, but they are not approved for use in neonates. Computer algorithms are also used to guide
glucose management in patients with diabetes and have been trialled in adult intensive care patients,
with variable benefits. This REAl-time Continuous glucose moniToring in neonatal intensive care
(REACT) project aimed to evaluate the potential role of continuous glucose monitoring to support the
use of insulin and additional glucose to target glucose control in the extremely preterm infant, both
alone and in combination with a bespoke computer algorithm.
Objectives
l To undertake a single-centre feasibility study of continuous glucose monitoring in preterm infants to
inform the design of a multicentre randomised controlled trial.
l To evaluate the clinical role of continuous glucose monitoring in terms of efficacy, safety, utility and
cost-effectiveness through a multicentre randomised controlled trial.




To inform the design of a multicentre randomised controlled trial through provisional assessment of
accuracy, safety and utility of the intervention, and to explore the primary outcome measure of time in
target (i.e. 2.6–10 mmol/l) to inform power calculations.
Methods
A single-centre study with eligibility criteria of birthweight ≤ 1200 g and aged ≤ 48 hours. The intervention
lasted for up to 7 days. Infants had an Enlite™ sensor (Medtronic plc, Watford, UK) inserted in their
lateral thigh and linked to a MiniMed™ Paradigm® Veo™ system (Medtronic plc). The sensor glucose data
were used alongside a paper guideline to support the clinical management of glucose control. The study
received all necessary ethics and regulatory approvals, and informed consent was received prior to any
study interventions.
Results
Twenty-one infants were recruited and one infant was withdrawn because of failure of sensor insertion.
Accuracy
Comparative data demonstrated a mean absolute relative difference of 10% and 11% between blood
glucose levels measured on the continuous glucose monitor and on the blood gas analyser and
Novostat (Nova Biomedical, Waltham, MA, USA) meter, respectively.
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Safety
There were no serious adverse device effects. Three infants had an episode of hypoglycaemia
(i.e. blood glucose of < 2.6 mmol/l) related to the loss of intravenous access, and the infants were
asymptomatic, clinically well and not on insulin. There were no concerns about skin integrity or
infection at the sensor site.
Utility and staff acceptability
Nursing staff were positive about the impact on care in terms of feeling more empowered to manage
the infant’s glucose control and reported that the use of continuous glucose monitoring led to better
care. However, staff found the use of both predictive and threshold alarms challenging. The median of
the mean number of blood samples per day for an infant was 4.1 (range 3.3–4.3).
Efficacy data
Sensor data were available from 20 infants. The median percentage of time in the primary target range
(i.e. 2.6–10mmol/l) was 78% (interquartile range 59–94%) and the median percentage of time in the
secondary target range (i.e. 4–8mmol/l) was 46% (interquartile range 35–66%), with a standard deviation
of sensor glucose of 2.39mmol/l (95% confidence interval 1.78 to 3.67 mmol/l).
Conclusion
Based on the feasibility data, the standard deviation of the primary outcome (time in target range of
2.6–10 mmol/l) was conservatively estimated at 22% and, therefore, it was calculated that the sample
size required to provide 90% power to detect a difference of 10%, at the 5% significance level,
was 200 infants. Consensus was reached among expert opinion from the Trial Steering Committee
and Data Monitoring and Ethics Committee that a 10% difference would be clinically meaningful.
Randomised controlled trial
Trial objectives
To evaluate the efficacy, safety, utility and cost-effectiveness of real-time continuous glucose
monitoring in preterm infants in neonatal intensive care.
Methods
Study design
A multicentre interventional randomised controlled trial comparing the use of continuous glucose
monitoring with standard clinical management of glucose control in preterm infants. Participants were
recruited from 13 level 3 neonatal intensive care units across Europe. Infants were recruited within
24 hours of their birth and underwent continuous glucose monitoring for the first 6 days of life.
Data were collected until 36 weeks’ corrected gestational age.
Eligibility
Preterm infants were eligible for trial entry if they weighed ≤ 1200 g at birth, were aged ≤ 24 hours
and ≤ 33+6 weeks gestation, and there was informed parental consent. Infants were excluded if they
had a lethal congenital abnormality, any congenital metabolic disorder or no realistic prospect of
survival at trial entry. Following consent, infants were randomised in a 1 : 1 ratio to either the control
or the intervention arm of the study using a web-based randomisation system.
Intervention: continuous glucose monitoring with guideline
Each infant had a subcutaneous Enlite sensor inserted and linked to a MiniMed™ 640G (Medtronic plc).
Clinical staff were advised to use the continuous glucose monitor glucose readings in combination with
a written guideline for management of glucose control. The guideline was developed during the REACT
feasibility study.
SCIENTIFIC SUMMARY
NIHR Journals Library www.journalslibrary.nihr.ac.uk
xx
Control: standard care
Each infant had a subcutaneous Enlite sensor inserted and linked to a MiniMed™ 640G. The device
collected glucose data continuously, but the display screen was masked to clinical staff. Glucose control
was managed in accordance with local standard clinical care using point-of-care blood glucose monitoring.
Outcomes
The primary outcome measure was the percentage of time during which the sensor glucose level was
in the target range of 2.6–10 mmol/l during the first 6 days of life.
The secondary outcome measures were categorised as efficacy, safety, acceptability or health
economics outcomes, or as exploratory clinical outcomes:
l efficacy –
¢ mean sensor glucose in the first 6 days of life
¢ percentage of time sensor glucose is in the target range of 4–8mmol/l within the first 6 days of life
¢ sensor glucose variability within individuals, as assessed by within-patient standard deviation
¢ percentage of time glucose levels are in the hyperglycaemic range (i.e. sensor glucose > 15 mmol/l)
l safety –
¢ incidence of hypoglycaemia, defined as any episode of blood glucose of > 2.2 mmol/l and
< 2.6 mmol/l
¢ incidence of hypoglycaemia, defined as a continuous episode of sensor glucose of < 2.6 mmol/l
for > 1 hour
¢ incidence of hypoglycaemia, defined as any episode of blood glucose of ≤ 2.2 mmol/l
l acceptability –
¢ clinical staff rating score of impact on clinical care
¢ frequency of blood glucose monitoring
¢ clinical use of guideline
l health economics –
¢ cost-effectiveness expressed in terms of incremental cost per additional case of adequate
glucose control (defined as > 80% time spent between 2.6 and 10 mmol/l)
l exploratory outcomes –
¢ mortality and morbidity before 36 weeks’ corrected gestational age.
An independent Data Monitoring Ethics Committee was established to review safety data from the
trial and trial management was overseen by the Trial Steering Committee.
Results
A total of 182 infants were recruited to the trial. The mean time in the glucose target range of
2.6–10 mmol/l was 9% higher in infants in the continuous glucose monitoring group than in infants
in the control arm (95% confidence interval 3% to 14%; p = 0.002). In the case of the glucose target
level range of 4–8 mmol/l, the mean percentage of time in the target range was 12% higher in the
intervention group (95% confidence interval 4% to 19%; p = 0.004). There was no difference in the
number of episodes of hypoglycaemia between the arms. Exploratory outcomes showed a reduced
risk of necrotising enterocolitis (odds ratio 0.33, 95% confidence interval 0.13 to 0.78; p = 0.01)
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in the intervention arm compared with the control arm. Both staff and parents reported that the use of
continuous glucose monitoring improved care and the continuous glucose monitoring was found to be
dominant in health economic terms.
Conclusions
Continuous glucose monitoring in preterm infants can support the use of insulin and glucose to optimise
glucose control, reducing exposure to hyperglycaemia without increasing the risk of hypoglycaemia.
Staff and parents felt that the use of continuous glucose monitoring improved care. Economic evaluation
demonstrated that, over the first 7 days, continuous glucose monitoring is, on average, more costly
and more effective than standard care. Assuming cost-effectiveness thresholds of £1000, £5000
and £10,000, the probability of cost-effectiveness for continuous glucose monitoring reached 90% at
approximately £6000, whereas the net monetary benefit associated with continuous glucose monitoring
became positive at a cost-effectiveness threshold of £5000. However, in terms of clinical impact over
a time horizon extending to 36 weeks’ corrected gestational age, continuous glucose monitoring was,
on average, less costly and more effective, and therefore dominant in health economic terms.
Closed-loop system
Objectives
Assessment of the potential for continuous glucose monitoring combined with a computer algorithm,
‘closed loop’, to be more effective in targeting glucose control in extremely preterm infants than the
use of continuous glucose monitoring combined with a simple paper guideline.
Methods
A single-centre study with eligibility criteria of birthweight ≤ 1200 g and aged ≤ 48 hours. All infants
underwent subcutaneous continuous glucose monitoring in the first week of life, with those in the
intervention group receiving closed-loop insulin delivery between 48 and 72 hours of age. The primary
outcome was percentage of time in target range (i.e. sensor glucose level of 4–8 mmol/l).
Results
Data from 20 infants showed the time in the target range increased from a median of 26% (interquartile
range 6–64%) with paper guidance to 91% (interquartile range 78–99%) during closed-loop insulin
delivery (p < 0.001), without increasing hypoglycaemia.
Conclusions
Closed-loop glucose control based on subcutaneous glucose measurements is feasible and has the
potential to further target glucose control in extremely preterm infants.
Implications for health care
The findings of these studies demonstrate that continuous glucose monitoring in preterm infants
can increase the time in the glucose target range of 2.6–10 mmol/l compared with standard clinical
care. The study highlighted the challenges of using devices that are not designed for preterm infants,
and the need for devices that can address the unique physiological and pathological challenges facing
these infants, and the staff and parents caring for them. Robust pathways are needed to encourage
the development and validation of devices for use in such vulnerable populations.
‘Closed-loop’ technology has the potential to provide a further personalised approach to targeting glucose
control. The trial data clearly demonstrated the wide variability between infants, and it is in this context
that such intelligent algorithms can help to optimise care. It could also help to address some of the
challenges of providing optimal care in very busy neonatal intensive care units where it is acknowledged
that there is sometimes a shortage of adequately trained nursing staff to deliver care. Importantly, despite
SCIENTIFIC SUMMARY
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the potential additional workload of a clinical trial, the staff and parents reported that they felt that the use
of continuous glucose monitors improved care. It will therefore be important to ensure that these devices
can be introduced into clinical practice in a robust manner to ensure adequate support and training for staff
so that the devices are used effectively and safely in this population.
Despite the challenges, the health economic analysis demonstrated the use of continuous glucose
monitors to be favourable even over a relatively short time horizon. Exploratory analysis also showed a
reduced risk of necrotising enterocolitis, but this trial was underpowered to determine the impact on
other clinical outcomes, and larger studies are needed to confirm if this is a robust finding and to look
at other impacts. Further studies are also needed to elucidate the optimal targets of glucose control to
improve long-term health outcomes. Continuous glucose monitor technology is well placed to support
such studies.
Recommendations for research
The findings of the REACT project raise the following important questions that need to be addressed
in further studies.
Short term
l What is the optimal glucose target range for preterm infants at this time?
l What is the prevalence of glucose dysregulation throughout the preterm course on a neonatal
intensive care unit?
l What is the role of continuous glucose monitoring in infants in the neonatal intensive care unit who
are at risk of glucose dysregulation for other reasons, such as following hypoxic–ischaemic insults
and during cooling?
Future
l Can we design a continuous glucose monitor that is better suited to the unique physiology and
pathology of the newborn?
l Can we design ‘closed-loop’ systems that will support staff in further safely targeting glucose levels
in these infants and save staff time?
Long term
l What is the impact of silent hypoglycaemia in preterm infants?
l What is the impact of ‘optimising’ glucose control in the preterm infant on health outcomes?
Trial registration
This trial is registered as ISRCTN12793535.
Funding
This project was funded by the Efficacy and Mechanism Evaluation (EME) programme, a MRC and
National Institute for Health Research (NIHR) partnership. This will be published in full in Efficacy
and Mechanism Evaluation; Vol. 8, No. 16. See the NIHR Journals Library website for further project
information. Medtronic plc provided some MiniMed™ 640G systems and Nova Biomedical (Waltham,
MA, USA) provided point-of-care devices.
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Increasing numbers of infants are being born preterm. These infants require intensive care and have
a high risk of early mortality and short-term morbidity.5 Among surviving infants, the incidence of
long-term health problems, including learning difficulties, is high, with significant long-term costs to
the NHS and society.6 Treatable neonatal causes of long-term health problems have been difficult
to establish. National priorities for research include investigation of the management of infants who
are born too early or too small, and evaluation of the reasons for variations in outcome of ‘high-risk’
neonates. Early postnatal glucose control may be an important and modifiable risk factor for clinical
outcomes. In utero, glucose levels are normally maintained between 4 and 6 mmol/l,7 but infants born
preterm are at risk of both hyperglycaemia (20–86%, depending on how it is defined) and hypoglycaemia
(17%; blood glucose level < 2.6 mmol/l).8
Existing research
Hyperglycaemia and hypoglycaemia in the preterm infant
Hyperglycaemia and hypoglycaemia have both been associated with increased mortality and morbidity
for preterm infants.9,10 Hyperglycaemia can lead to acute problems of persistent osmotic diuresis and
metabolic acidosis, which can be difficult to control, and has been associated with increased risk of
intraventricular haemorrhage.11 Hyperglycaemia has also been associated with increased long-term
morbidity, including increased risk of retinopathy of prematurity (ROP).9,12,13 Pivotal single-centre
studies in adult intensive care have demonstrated that tight glycaemic control can reduce both
mortality and morbidity.14 However, these results have been difficult to replicate because of the
risk of hypoglycaemia.15 A trial in paediatric intensive care, targeted to reduce hyperglycaemia,
demonstrated a reduction in length of intensive care admission and mortality, but a significant
increase in hypoglycaemia.16 This is of particular concern as attempts to reduce the prevalence of
hyperglycaemia may increase the risk of hypoglycaemia in preterm infants because of their variable
sensitivity to insulin. In addition, the developing brain appears to be particularly vulnerable to both
hyperglycaemic17 and hypoglycaemic insults. A Cochrane review9 has highlighted the need for further
studies into the impact of interventions to improve glucose control in these infants.
Current glucose monitoring in neonatal intensive care
Although glucose monitoring is implemented in all very preterm infants, it is currently limited to
intermittent blood sampling, with long periods when glucose levels are unknown. The reason for the
intermittent nature of glucose monitoring is that current methodologies for measurement of glucose
levels are dependent on blood sampling either from a central arterial line or by heel prick. The very
small circulating volumes of blood in preterm infants mean that it is also important to minimise the
number of blood samples and volume of blood sampled in this way. Furthermore, current practice
in neonatal intensive care units (NICUs) aims to reduce the frequency of handling of infants, as this
has been shown to improve outcomes.18 By contrast, other physiological parameters, such as oxygen
saturation, blood pressure and heart rate, are all monitored continuously to prevent wide fluctuations.
It is increasingly thought that fluctuations in glucose levels may also have a significant impact on
long-term outcomes.19
DOI: 10.3310/eme08160 Efficacy and Mechanism Evaluation 2021 Vol. 8 No. 16
© Queen’s Printer and Controller of HMSO 2021. This work was produced by Beardsall et al. under the terms of a commissioning contract issued by the Secretary of State
for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
1
If clinical interventions to optimise glucose control are to be safe and effective in the intensive care
setting, robust methods of monitoring glucose levels in real time need to be in place. Furthermore,
to fully understand the clinical significance of hyperglycaemia and hypoglycaemia, it is imperative
that robust data are available regarding their true prevalence throughout the period of intensive care.
Current follow-up studies are dependent on infrequent measurements of blood glucose, typically taken
for clinical reasons and with the inherent associated bias. Continuous glucose monitoring (CGM)
therefore has the potential to both safely guide acute clinical management to optimise control and
provide robust data on which to assess the long-term impact.
Continuous glucose monitoring
A range of technological methods have been tested for their abilities to support CGM. Currently, the
only CGM method used in clinical practice for the management of patients with diabetes involves
measurement of interstitial glucose levels, which are calibrated against blood glucose measurements.
CGM devices comprise a disposable subcutaneous oxidase-based platinum electrode that catalyses
interstitial glucose, generating an electrical signal that is transmitted to a monitor for recording or
display. Three companies have devices on the market for CGM: Dexcom Inc. (San Diego, CA, USA),
Abbott Laboratories UK (Berkshire, UK) and Medtronic plc (Watford, UK). However, because of
the size of extremely preterm infants and issues of insertion and attachment to these small infants,
only the Medtronic plc devices are currently suitable for use in the extremely preterm infant.
Although this is a rapidly changing field, early CGM devices were used to collect data in real time,
but these data could be downloaded only retrospectively to be reviewed and used to guide future
clinical treatment. This is useful (1) in the setting of research, (2) to provide advice on long-term
behavioural or medical interventions and (3) in the case of patients with stable diabetes, to review
patterns of glucose control over time. These devices have also been used in preterm infants without
side effects and identified significant periods of both hyperglycaemia and hypoglycaemia that were
undetected clinically.20–22 However, they are not suitable for providing data that is useful for acute
clinical management. Newer CGM devices allow the data to be viewed in real time, providing
information on glucose trends, with the potential to identify episodes of hyperglycaemia and
hypoglycaemia, thus allowing the possibility of earlier intervention and prevention.
Development of continuous glucose monitors
The development of CGM devices provides the opportunity for data on glucose levels to be recorded
every 5 minutes and viewed continuously. A number of different devices are available for clinical use
and they are increasingly found to help reduce glycated haemoglobin and glycaemic variability in
patients with type 1 diabetes without increasing the risk of hypoglycaemia. These devices allow patients
to monitor their glucose levels by displaying absolute glucose concentrations as well as trends. Some
systems depend on intravenous access, some use microdialysis and others measure interstitial glucose
levels. Their use has been trialled in adults in intensive care and in patients requiring cardiac surgery.23
Although these studies have been limited, they have shown that the devices are accurate and safe in
cardiac surgical patients and can reduce the risk of hypoglycaemia in adults in intensive care.24 Some
have raised concerns about the lack of absolute sensitivity of individual readings at glucose thresholds,
emphasising the potential importance of CGM as an early-warning system for both hyperglycaemia
and hypoglycaemia.25
These studies have highlighted the need for methodologies that can provide real-time data and allow
adjustment of clinical management in the setting of a rapidly changing clinical picture of intensive
care.26,27 These benefits have been seen in the adult intensive care setting, where blood glucose levels
are routinely measured much more frequently than in NICUs. Therefore, the potential for benefits in the
NICU setting, where the frequency of blood glucose measurements is much lower, is likely to be more
clinically significant. Key recent developments in these devices include extended sensor life, such that
sensors can now remain in situ for 6 days (previously 72 hours), and changes to the sensor construction
and the calibration algorithms, which have led to improved overall accuracy.28 This is particularly
important in terms of sensitivities to detect threshold levels of hypoglycaemia and hyperglycaemia.
INTRODUCTION
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Previous use of continuous glucose monitors in neonates
There is limited use of CGM in NICUs.We have used blinded CGM devices as part of an international
multicentre trial in preterm infants and assessed the accuracy of these devices compared with current
clinical practice.29,30 These studies suggested that the value of CGM could be in providing early warning
of fluctuations in glucose levels to guide the need for blood glucose assessment. In addition, by providing
a continuous readout, episodes of hyperglycaemia and hypoglycaemia could be anticipated and therefore
avoided. We have previously collected ‘blinded’ CGM data as part of the Neonatal Insulin Therapy
[Nirture (Neonatal Insulin Replacement Therapy in Europe Study)] trial using a CGM (Medtronic plc)21
and in a small feasibility study using the iPro™2 (Medtronic plc). In the small feasibility study of 10 infants
with a birthweight ≤ 1200 g monitored from birth for up to 7 days, infants had a median gestational age
at birth of 28.4 weeks and a median birthweight of 840 g. The median time in the target glucose range of
2.6–10mmol/l was 58% and the median time in the target glucose range of 4–8 mmol/l was 40%.
The REACT project
The purpose of the REACT project was to evaluate the role of CGMs in the detection and management
of hyperglycaemia and hypoglycaemia in NICUs. The project was funded by the National Institute for
Health Research Efficacy and Mechanism Evaluation programme, with additional support of CGM
equipment provided by Medtronic plc and sponsorship from the University of Cambridge Addenbrookes
Hospital NHS Trust (Cambridge, UK). There were three stages:
1. to undertake a single-centre feasibility study to inform the design of a multicentre randomised
controlled trial (RCT)
2. to evaluate the clinical role of CGMs, in terms of efficacy, safety, utility and cost-effectiveness,
through a multicentre RCT
3. to pilot the potential use of a closed-loop system for glucose control using CGMs.
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Chapter 2 Feasibility study
Aim
The aim of the study was to carry out preliminary evaluation of feasibility of real-time CGM to inform
the design of a larger RCT in the preterm population.
Objectives
The objectives of the feasibility study were to determine provisional data regarding:
l recruitment potential for a RCT
l accuracy and safety of the devices for use in the preterm population
l user acceptability, including the impact on clinical care and frequency of blood glucose testing




This was a single-centre study, with infants recruited from the NICU at Addenbrooke’s Hospital,
Cambridge, UK. Ethics and trust research and development approval were obtained prior to the start
of study recruitment, and informed parental consent was obtained prior to any study procedures.
Inclusion criteria were infants with a birthweight ≤ 1200 g and aged ≤ 48 hours for whom informed
parental consent had been received. Infants were excluded if they had a major congenital malformation
or an underlying metabolic disorder, or if the mothers had a pregnancy complicated with diabetes.
The intervention lasted for up to 7 days. Data regarding glucose levels, clinical condition and nutritional
intake, as well as insulin use, were collected prospectively.
Continuous glucose monitoring and management
Real-time CGM was performed using the Paradigm® Veo™ system (Medtronic plc) (Figure 1). Enlite™
sensors (Medtronic plc) were linked to the Paradigm® Veo™. The sensor glucose data could be viewed in
real time and were used in conjunction with the guideline to support clinical management. The guideline
provided simple guidance, was not a rigid guideline and had not undergone formal in silico testing.
The nurses recorded the sensory glucose value, alongside standard hourly clinical observation, using it
to guide the need for blood glucose testing. The guideline prompted review and intervention based on
both absolute glucose levels and change. The CGM devices were calibrated at least twice daily using
a blood glucose measured on the point-of-care (POC) StatStrip® meter (Nova Biomedical, Waltham,
MA, USA). The StatStrip meter was chosen because it has been validated for accuracy in the newborn
and intensive care settings.
Blood glucose monitoring
Blood glucose levels were measured using a combination of arterial, venous and capillary samples, and
were tested on the blood gas analyser (cobas b 221; Roche Diagnostics, Welwyn Garden City, UK) and
the Nova StatStrip.
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Analyses
Accuracy of the continuous glucose monitor
Prespecified comparative analyses were based on any glucose levels that were recorded within
5 minutes of each other. The median relative difference was calculated as the percentage difference
between the two measures. Absolute differences were determined at each time point in terms of
compliance with International Organization for Standardization (ISO) 2003 and 2013 standards.31,32
Bland–Altman analysis was used for assessment of error between glucose measurements and error
grid plots were used to explore potential clinical impact.
Safety of the continuous glucose monitor
Safety outcomes were defined as prevalence of hypoglycaemia (percentage of time with sensor glucose
level < 2.6 mmol/l) and any single blood glucose reading of < 2.6 mmol/l, and/or more than six sensor




FIGURE 1 Continuous glucose monitoring system. (a) Enlite sensor; (b) Paradigm Veo and MiniLink® REAL-Time
Transmitter (Medtronic plc) attached to a sensor; and (c) preterm infant with device in situ. Reproduced with permission
from Thomson et al.1 This is an Open Access article distributed in accordance with the terms of the Creative Commons
Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial
use, provided the original work is properly cited. See https://creativecommons.org/licenses/by/4.0/. The figure includes
minor additions and formatting changes to the original figure.
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Utility
The clinical care team were invited to complete a comments sheet daily for immediate feedback, as well
as an anonymised questionnaire for summative review. The questionnaires explored initial expectations
and experiences of using the CGM. These questionnaires were developed in collaboration with nurses
on the unit to ensure that questions were easy to understand and relevant to the individuals concerned.
Efficacy outcome
Predefined efficacy outcomes included time in target range (i.e. percentage of time with a sensor
glucose level 2.6–10 mmol/l or 4–8 mmol/l), prevalence of hyperglycaemia (i.e. percentage of time with
a sensor glucose level > 10 mmol/l) and prevalence of severe hyperglycaemia (i.e. percentage of time
with a sensor glucose level > 15 mmol/l).
Results are expressed as mean [standard deviation (SD)], median [interquartile range (IQR)] or
frequencies (percentages), as appropriate.
Results
Recruitment
Twenty-one infants were successfully recruited to the feasibility study. One infant was withdrawn
because of failure of sensor insertion. The baseline demographic details of the remaining 20 infants
with CGM data are shown in Table 1. The recruitment rate fluctuated widely from month to month
and was delayed by two factors: (1) availability of eligible infants to approach and (2) availability of
appropriately trained staff to undertake the study procedures. During the recruitment period, the
NICU underwent a period of reduced admissions associated with the introduction of a new electronic
medical records system, resulting in fewer infants being admitted and available for recruitment.
In addition, sensor insertion was initially limited to key study staff to facilitate a core of experience
within the team. However, the unpredictability of preterm deliveries, combined with the need for
many mothers to be transferred from other hospitals, resulted in a very small window for recruitment
and meant that staff with the key skills for sensor insertion were not always available.
TABLE 1 Feasibility study: baseline demographic data
Baseline demographic data Feasibility study (N= 20)
Gestational age at birth (weeks), mean (SD) 26.14 (1.9)
Birthweight (g), mean (SD) 809 (156)
Sex (male-to-female) 10 : 10
Antenatal variable, n (%)
Antenatal steroids 19 (95)




PROM, prelabour rupture of membranes.
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Accuracy of continuous glucose monitors
Comparative data providing more than two glucose measurements (blood glucose or sensor glucose)
taken within 5 minutes of each other were available at 247 time points. Bland–Altman analyses
provided a mean bias between POC and CGM of –0.27 [95% confidence interval (CI) –0.35 to –0.19]
(Figure 2). Error grid analyses (comparing sensor glucose with either blood glucose methodology)
demonstrated that 98% of values lay within area A or B (see Figure 2). Performance in relation to the
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FIGURE 2 Feasibility study: Bland–Altman and error grid plots.33 (a) Bland–Altman comparison of CGM sensor glucose
with StatStrip meter; (b) error grid plot comparing CGM sensor glucose with StatStrip meter or blood gas (cobas b 221)
glucose values; (c) Bland–Altman comparison of POC StatStrip meter with blood gas (cobas b 221) glucose values;
(d) error grid plot comparing POC StatStrip meter with blood gas (cobas b 221) glucose values; (e) Bland–Altman
comparison of CGM sensor glucose with blood gas (cobas b 221) glucose values; and (f) error grid plot comparing
CGM sensor glucose with blood gas (cobas b 221) glucose values. BG, blood glucose; SG, sensor glucose. Orange dots
represent outliers whose results were reviewed and were deemed to be secondary to pre-analytical error in blood
glucose sampling. The reference lines show the estimate of the mean difference, 95% CIs around the mean estimate
and the predictive interval, the region in which a new observation would be expected, with 95% confidence, to be
observed. Reproduced with permission from Thomson et al.1 This is an open access article distributed in accordance
with the Creative Commons Attribution (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform
and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and
indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/. The figure includes minor
additions and formatting changes to the original figure. (continued )
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FIGURE 2 Feasibility study: Bland–Altman and error grid plots.33 (a) Bland–Altman comparison of CGM sensor glucose
with StatStrip meter; (b) error grid plot comparing CGM sensor glucose with StatStrip meter or blood gas (cobas b 221)
glucose values; (c) Bland–Altman comparison of POC StatStrip meter with blood gas (cobas b 221) glucose values;
(d) error grid plot comparing POC StatStrip meter with blood gas (cobas b 221) glucose values; (e) Bland–Altman
comparison of CGM sensor glucose with blood gas (cobas b 221) glucose values; and (f) error grid plot comparing
CGM sensor glucose with blood gas (cobas b 221) glucose values. BG, blood glucose; SG, sensor glucose. Orange dots
represent outliers whose results were reviewed and were deemed to be secondary to pre-analytical error in blood
glucose sampling. The reference lines show the estimate of the mean difference, 95% CIs around the mean estimate
and the predictive interval, the region in which a new observation would be expected, with 95% confidence, to be
observed. Reproduced with permission from Thomson et al.1 This is an open access article distributed in accordance
with the Creative Commons Attribution (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform
and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and
indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/. The figure includes minor
additions and formatting changes to the original figure. (continued )
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FIGURE 2 Feasibility study: Bland–Altman and error grid plots.33 (a) Bland–Altman comparison of CGM sensor glucose
with StatStrip meter; (b) error grid plot comparing CGM sensor glucose with StatStrip meter or blood gas (cobas b 221)
glucose values; (c) Bland–Altman comparison of POC StatStrip meter with blood gas (cobas b 221) glucose values;
(d) error grid plot comparing POC StatStrip meter with blood gas (cobas b 221) glucose values; (e) Bland–Altman
comparison of CGM sensor glucose with blood gas (cobas b 221) glucose values; and (f) error grid plot comparing
CGM sensor glucose with blood gas (cobas b 221) glucose values. BG, blood glucose; SG, sensor glucose. Orange dots
represent outliers whose results were reviewed and were deemed to be secondary to pre-analytical error in blood
glucose sampling. The reference lines show the estimate of the mean difference, 95% CIs around the mean estimate
and the predictive interval, the region in which a new observation would be expected, with 95% confidence, to be
observed. Reproduced with permission from Thomson et al.1 This is an open access article distributed in accordance
with the Creative Commons Attribution (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform
and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and
indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/. The figure includes minor
additions and formatting changes to the original figure.
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Safety
There were no serious adverse device effects (SADEs). One infant died prior to discharge from
hospital, but after the intervention period. Death was due to prematurity and felt to be unrelated to
the study intervention. One infant was withdrawn from the study early as the mother became acutely
unwell and, in the light of the mother’s mental health, it was felt appropriate to withdraw the infant
from the study. One infant was withdrawn because of failure of sensor insertion. This was the second
infant recruited to the study. The Enlite sensor failed to insert on two attempts and remained within
the needle guard. There were no concerns about infection or trauma at the site of sensor insertion and
the CGM device did not interfere with clinical care.
There were three infants who had clinically documented episodes of hypoglycaemia, defined as any
blood glucose measurement < 2.6 mmol/l. In each of these infants, the falling sensor glucose level had
prompted action to be taken to check the blood glucose level. There were no concerns about the
infants during these episodes and without the falling sensor glucose level the blood glucose level would
not have been checked. After confirming a blood glucose level < 2.6 mmol/l, these infants were treated
with intravenous dextrose. In two cases, the falling sensor glucose level also revealed failure of central
access. In two of these episodes, sensor glucose values were also < 2.6 mmol/l (recorded on the CGM
devices as episodes lasting 40 and 25 minutes, respectively). In the other case, the lowest sensor
glucose value was 2.7 mmol/l. There was one further episode when the sensor glucose fell to
< 2.6 mmol/l for 70 minutes, but this was not documented clinically because of a protocol deviation,
as blood glucose was not measured at this time. There were no concerns about any of the infants
during any of these episodes and the infants were not receiving any insulin.
Utility
The overall assessment of the CGM devices by research and clinical staff was that they were easy to
use in terms of insertion and calibration. There were occasions when there was loss of connectivity
between the sensor and the monitor (e.g. if an infant was moved out of an incubator for kangaroo care
or someone stood between the infant and the monitor). On such occasions, it was evident that the
transmitter range was limited if transmission was blocked by objects between the sensor and the
monitor. This could be resolved by moving the monitor closer to the infant. Staff found the use of both
predictive and threshold alarms challenging, considering them an unnecessary addition to recording
sensor glucose levels hourly. As a result of frequent requests to silence these alarms, they were
subsequently turned off in the early stages of the study to ensure continued staff engagement.
TABLE 2 Feasibility study: comparison of sensor glucose measurements with POC glucose values
Standard Criterion Blood glucose (%) POC (%)
MARD Per cent difference between sensor glucose and reference
(sensor glucose – reference)/reference × 100
11 10
ISO 200331 Per cent of sensor glucose values within ± 20% of the blood
glucose value
84 90
ISO 201332 Per cent of sensor glucose values within ± 0.83 mmol/l of blood
glucose value
73 78
MARD, mean absolute relative difference.
Notes
System accuracy standards of 2003 (ISO 15197:2003)31 state that 95% of blood glucose results should be within
± 0.83 mmol/l of laboratory results at concentrations of < 4.2 mmol/l, or within ± 20% of laboratory results at
concentrations of > 4.2 mmol/l. System accuracy standards 2013 (ISO 15197:2013)32 require 95% of blood glucose
results to be within ± 0.83 mmol/l of laboratory results at concentrations of < 5.6 mmol/l, or within ± 20% of
laboratory results at concentrations of > 5.6 mmol/l.
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With a need for twice-daily calibrations, the median number of blood samples taken for glucose
measurement per 24-hour period did not appear to be excessive or significantly different from the
number of samples taken in other infants of similar gestational and postnatal age on the unit. The
median of the mean number of samples per day per infant was 4.1 (range 3.3–4.3).
Staff expectations varied greatly, with some nurses excited about the potential to limit the need for
frequent blood glucose sampling and avoiding ‘hurting the baby’; however, others had concerns about
increased workload, sensor insertion, risk of ‘tissue damage’ or difficulties in positioning an infant
following sensor insertion. Comments varied from ‘exciting’ to ‘how much extra time will it take up?’.
After caring for an infant using CGM, there was an over-riding view that the intervention improved the
quality of care (Figure 3). Comments included ‘found the monitor to be useful when the infant was on
insulin’, ‘the chart . . . is really useful’, ‘I think this is the best treatment’ and ‘it is not extra workload’.
Nursing staff reported positively about the impact on care in terms of feeling more empowered to
manage the infant’s glucose control. They did not report any significant negative effects for the infant






























































FIGURE 3 Feasibility study: staff assessment of the use of continuous glucose monitoring.1 (a) Do you think the baby is
distressed?; (b) How did you find the monitor to read and calibrate?; (c) Do you think the device has interfered with the
nursing care?; (d) Did having the baby on the monitor significantly affect your workload?; and (e) Did you think that being
able to monitor glucose continuously had an impact on clinical care? Data are presented as a per cent of the responses
received. Reproduced with permission from Thomson et al.1 This is an open access article distributed in accordance
with the Creative Commons Attribution (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform
and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and
indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/. The figure includes minor
additions and formatting changes to the original figure. (continued )
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FIGURE 3 Feasibility study: staff assessment of the use of continuous glucose monitoring.1 (a) Do you think the baby is
distressed?; (b) How did you find the monitor to read and calibrate?; (c) Do you think the device has interfered with the
nursing care?; (d) Did having the baby on the monitor significantly affect your workload?; and (e) Did you think that being
able to monitor glucose continuously had an impact on clinical care? Data are presented as a per cent of the responses
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additions and formatting changes to the original figure.
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Efficacy
A total of 2626 hours of CGM data were collected from 20 infants, with a median for individual
infants of 144 (range 7–166) hours. There was wide variability in glucose control in this population.
Data demonstrating the percentage of time within different target thresholds are provided in Table 3.
The median percentage of time in the target range of 2.6–10 mmol/l was 78% (IQR 59–94%), with
values > 10 mmol/l recorded 22% of the time.
Discussion
This study was the first to explore the potential role of ‘real-time’ CGM to support targeting of
glucose control, with guidance on insulin and glucose delivery in preterm infants. The feasibility
study highlighted the challenges of recruiting to a complex interventional study when recruitment
has to occur at unpredictable times and within a very short time frame. The devices were found to
be sufficiently accurate to guide clinical management and the sensors were well tolerated, despite
the infants’ low birthweight, limited subcutaneous tissue and potential risk of infection. Furthermore,
the staff felt that the intervention led to improved care.
Recruitment within the feasibility study was noted to be onerous to the research team. This was
related to the unpredictability of infants being delivered, combined with the tight time frame. The
feasibility study also showed that the burden of recruitment, combined with a complex intervention,
was likely to present considerable challenges to the delivery of a multicentre trial. In most units, key
staff are usually trained to undertake consent for trials, but interventions such as a change in feeding
practice or even investigational medicinal product delivery can be undertaken by core clinical staff. As
a device study, identifying the key skill sets needed to undertake the study and the optimal number of
staff needed to support recruitment was seen as critical. There was a need for staff with the key skills
TABLE 3 Feasibility study: efficacy outcomes relating to glucose control
Outcome Value (n= 20)
Percentage of time sensor glucose in range
2.6–10.0 mmol/la 78 (59–94)
4.0–8.0 mmol/l 46 (35–66)
> 10.0 mmol/l 22 (6–41)
< 2.6 mmol/l 0 (0–0)
Mean sensor glucose (mmol/l) 8.3 (7.4–9.4)
SD of sensor glucose (mmol/l) 2.39 (1.77–3.67)
Hypoglycaemia (sensor data)
Number of infants with more than one episode of hypoglycaemia 2
Number of episodes of hypoglycaemia 2
Total length of episodes (minutes) 40–70
Blood glucose (< 2.6 mmol/l)
Number of episodes of hypoglycaemia 3b
a Primary end point.
b A hypoglycaemic episode was defined as any blood glucose measurement of < 2.6 mmol/l or
sensor glucose measurement of < 2.6 mmol/l for > 30 minutes. There was one recording of
blood glucose < 2.6 mmol/l, but the sensor glucose level fell to a nadir of only 2.7 mmol/l.
Note
Data are presented as median (IQR).
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for sensor insertion and who were able to guide the clinical team regarding the protocol to be available
24 hours a day, 7 days a week, for optimal recruitment. This informed the development of training
packages for unit staff, including a video guide to sensor insertion and packages of example cases for
the use of the guideline for glucose control and further informed the plans for the subsequent RCT.
The data showed the CGM devices to be of comparable accuracy to the POC devices that are currently
used in clinical practice. The median absolute relative difference was similar to that reported in other
paediatric and intensive care studies.34,35 There were episodes when only one of sensor glucose or blood
glucose level reached the threshold for hypoglycaemia, but the trend in falling sensor glucose level had
prompted the measurement of blood glucose. The blood glucose level would not have been checked if the
sensor had not triggered a clinical concern and the episode of hypoglycaemia would have been clinically
undetected. Differences may, in part, be related to the physiological differences between blood and
interstitial glucose levels, particularly with rapidly changing blood glucose levels.36
There was no increase in risk of hypoglycaemia with a more proactive approach to management of
hyperglycaemia, that is when using the guideline alongside the real-time monitoring. This is in contrast
to previous attempts to target glucose control with insulin in adult or neonatal intensive care, which
have resulted in significant increases in the prevalence of hypoglycaemia.15 In this study, use of CGM
devices provided an opportunity to track changes in glucose control in real time. This was important
in providing guidance to clinical staff about glucose management in a population, that is infants in
the NICU, in whom drug infusions (both types of drugs and dosing), as well as insulin sensitivity and
secretion, change both frequently and rapidly, leading to a risk of hypoglycaemia. This was highlighted
by the fact that two infants experienced hypoglycaemic episodes (related to loss of central access) that
first became apparent because of the falling sensor glucose value.
The aim was not for CGM to replace blood glucose sampling, but to augment it, and the number of
blood glucose samples taken in these infants was comparable to the number of samples taken from
other infants of a similar gestational and postnatal age within the unit. This is in keeping with the advice
given to the clinical nurses during the study, which was to check blood glucose values before modifying
any aspect of the management of glucose control. For example, changes in insulin dosing were undertaken
only in response to a persistent rising glucose level on the CGM device and supported by a confirmatory
blood glucose measurement. During the study, however, nursing staff became more confident in the
accuracy of the sensor glucose values and, with the guideline, they began to change dosing based on
sensor glucose values alone. They began to use blood glucose values in a more proactive way to confirm
observed trends in the CGM. Increasing confidence in the accuracy of CGM devices and the desire to
limit handling of preterm infants may lead to reduced blood glucose sampling in the future.
One infant (the second infant recruited) was withdrawn from the study because of failure on two
occasions to successfully place a sensor. For this infant, on both occasions, the sensor remained within
the needle guard and did not insert into the thigh. This event had been previously reported in
paediatric and adult patients, but had not been experienced by the research team with previous
Softsense sensors (Medtronic plc). On reviewing the potential causes, the advice on insertion technique
was modified to focus on ensuring that the needle and sensor remained at 90° to the hub until after
the introducer needle was removed. There were no further occurrences during the feasibility study.
The sensor appeared to be safe, with no reports of infection or debridement of skin at the sensor site
in this preterm population.
The lack of benefit from predictive trend alarms was disappointing, but it may be that with more
experience the alarms could be used. However, the system was reported by the nursing staff to be
beneficial to clinical care. The clinical team reported feeling that the combination of the CGM device
and guideline was useful in caring for the infant.
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We chose a strategy that aimed to optimise nutritional intake, using the intervention to inform
decisions on insulin and glucose therapy in the event of hyperglycaemia or hypoglycaemia. Other
strategies can also be used to target glucose control in preterm infants, each with different risks
and benefits. One such alternative strategy, that of reducing parenteral intake, risks compromised
nutritional delivery, as found in a recent study in preterm infants using CGM and a computer algorithm
to modify glucose intake in response to hyperglycaemia.37 Our study is unique in combining the use
of a CGM with a guideline for the use of insulin and glucose therapy. This design is easy to adopt in
clinical practice as it does not involve the need for frequent changes to parenteral nutrition, which may
affect nutritional and electrolyte delivery, as well as staff workload and cost. Moreover, we have shown
in this feasibility study that this strategy does not increase the risk of hypoglycaemia.
The efficacy outcome of percentage of time with glucose level in the target range (i.e. 2.6–10 mmol/l)
was reviewed by the trial statistician to inform power calculations for the planned multicentre RCT
of real-time CGM compared with standard care. The data were used to confirm sample size considerations
based on a final analysis comparing the percentage of time in the target range (2.6–10mmol/l), that is a
continuous variable, in terms of the mean values between the treatment arms. Based on these data, the
SD of this end point was conservatively estimated at 22%; hence, a sample size of 200 infants would
provide 90% power to detect a difference of 10% at the 5% significance level. Consensus was reached
among expert opinion at the Trial Steering Committee (TSC) and Data Monitoring Ethics Committee
(DMEC) meetings that a 10% difference would be clinically meaningful. The comparison between the
mean values in Table 3 provides support to an effect size of 10%, or more being plausible.
Summary
The feasibility study confirmed reasonable accuracy and utility of the combination of CGM plus the
guideline for blood glucose testing and subsequent intervention within a clinical trial. It further
informed the need to innovate to maximise recruitment potential and staff engagement, while
providing data to substantiate the power calculations for the primary outcomes within such a trial.
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Chapter 3 REACT trial design
Introduction
Data from the feasibility study helped to design this RCT. Those involved in recruitment pointed
out that the short time period from birth to study entry was a challenge and, therefore, an online
training video was developed to enable training of a larger number of staff in recruiting sites to
support recruitment and delivery of the intervention. There were no safety flags in terms of the
CGM device itself. In the context of using CGM as an adjunct to current methods of blood glucose
monitoring, CGM was confirmed to be sufficiently accurate to safely support glucose management.
Provisional data on the combination of the CGM and guideline to guide targeting of glucose control
did not give rise to any safety concerns in terms of risks of hypoglycaemia. Data on the prevalence
of the anticipated primary outcome measure of time in glucose target range (i.e. 2.6–10 mmol/l)
confirmed an estimated SD of 22%, which was in keeping with the planned sample size of 200 infants.
Furthermore, the staff questionnaire demonstrated that the clinical team caring for infants felt that
CGM has the potential to improve clinical care.
Aim
To evaluate the clinical role of CGM in the preterm infant, in terms of efficacy, safety, utility and
cost-effectiveness, through a multicentre RCT.
Hypothesis
We hypothesised that the use of real-time CGM could increase the amount of time that an infant’s
glucose levels (measured using CGM) are within the target range of 2.6–10 mmol/l (i.e. the widely
accepted clinical target for glucose control) compared with standard clinical practice (with blinded
CGM data collection).
Trial objectives
The primary efficacy outcome was percentage of time for which glucose levels were within the glucose
target range of 2.6–10 mmol/l over 6 days, following recruitment within 24 hours of birth.
Secondary outcomes related to:
l efficacy (i.e. mean sensor glucose level, percentage of time sensor glucose levels are in the target
range of 4–8 mmol/l, sensor glucose level variability, percentage of time sensor glucose levels
are > 15 mmol/l)
l safety, as measured by both device effects and incidence of hypoglycaemia
l utility assessed by staff and parent questionnaires
l cost-effectiveness
l exploratory analyses.
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This study was an international open-label parallel-group RCT, with infants recruited between July 2016
and January 2019 from 13 NICUs in the UK, Spain and the Netherlands. The protocol has been published.2
Eligibility criteria
Infants were eligible if they were within 24 hours of birth, weighed ≤ 1200 g and were born at
≤ 36+6 weeks gestation, and if written parental consent had been obtained. Exclusion criteria
included any lethal congenital malformations and any congenital metabolic disorder known at trial
entry. Infants were also ineligible if, in the opinion of the treating clinical consultant, they had no
realistic prospect of survival.
Recruitment procedure
All infants were recruited within 24 hours of birth at one of the NICUs that had been approved for
study participation as a level 3 unit with capacity and capability to recruit. Owing to the short time
frame from birth to recruitment, potentially eligible infants were identified in a number of ways:
(1) liaison with the obstetric team to highlight mothers at risk of preterm delivery, (2) liaison with
the neonatal transport team to identify infants who had been born in local units and being transferred
to a study centre and (3) liaison with the NICU clinical team of study centres. Screening of eligible
infants was undertaken in collaboration with the clinical team and families were approached
for consent only if they were considered eligible. Screening logs were reviewed regularly by the
co-ordinating centre to identify any issues around recruitment. The investigator or a suitably qualified
person designated by the principal investigator was able to receive written informed consent from
the infant’s parent/legally acceptable representative before any trial-specific activity was performed.
Randomisation and blinding
Randomisation to the standard-care and CGM arms of the study in a 1 : 1 ratio was undertaken
centrally using a web randomisation system, Trans European Network ALEA software (TENALEA; ALEA
Clinical, Abcoude, The Netherlands). This used block randomisation, with blocks of random size (i.e. 4,
6, 8) stratifying by recruiting centre and gestation (< 26 or ≥ 26 weeks’ gestation). The management of
glucose control and use of CGM from recruitment at aged ≤ 24 hours until day 7 were predetermined
in the protocol for each study arm.2 Clinical outcome data were collected until 36 weeks’ corrected
gestational age. No other aspects of concomitant care were prohibited during the trial.
Intervention
All infants were fitted with a sensor (i.e. the Enlite glucose sensor) that was linked to a MiniMed™
640G System (Medtronic plc). Sensors were inserted subcutaneously (into the thigh) by hand and
not using the standard insertion device, thereby ensuring that the sensor was inserted into the
subcutaneous tissue. The sensors are soft and flexible, approximately 8.75 mm in length, and are
mounted inside a hollow needle to allow for subcutaneous insertion. Once the sensor was inserted,
the introducer needle was withdrawn and the sensor attached to a small Guardian™ 2 Link transmitter
[Medtronic plc; Conformité Européenne (CE) Mark 2013; certificate number 8858] for data transfer to
the MiniMed 640G System for data viewing. The sensors were secured with a clear occlusive dressing
so that the insertion site could be inspected daily. A blood sample was required every 12 hours for
calibration. For consistency across sites, all units were provided with Nova StatStrip meters for
calibration of the CGM.
Intervention: real-time continuous glucose monitoring with guideline
The CGM data were available to view by the clinical team during the first week of life. Clinical staff
were advised to read and record the sensor glucose data hourly as part of standard clinical care.
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They were provided with a specifically designed guideline to guide the management of glucose control
and the use of insulin. The guideline was developed during the REACT feasibility study.1
Control: standard care with blinded continuous glucose monitor data collection
Blinding of the study intervention between study groups was not feasible. To ensure that CGM data
were not available to the clinical team caring for infants in the standard-care arm, the monitors were
secured in an opaque bag with a tamper-proof seal. The bags were opened for calibration every 12 hours
and a time log was kept of when the tamper tag was broken/resealed to document compliance.
Infants’ glucose control was monitored and managed in accordance with standard clinical practice
based on intermittently sampled blood glucose levels. Nutritional requirement and insulin delivery
were prescribed in accordance with standard clinical guidelines within each unit. The CGM device
collected glucose data continuously, but the clinical team were masked to the data, as described above.
Medical devices: MiniMed 640G System
The MiniMed 640G System is indicated for glucose monitoring for the management of diabetes
(Figure 4). The system being used comprised the Enlite sensor linked using the Guardian™ 2 Link
transmitter to the MiniMed 640G. The Enlite sensor (CE certificate number 21024) has been described
previously and comprises a disposable subcutaneous oxidase-based platinum electrode that catalyses
interstitial glucose, generating an electrical current every 10 seconds that is transmitted to a monitor.
The data were recorded as an averaged value every 5 minutes, giving a total of 288 readings per day.
Glucose values outside the range of 2.2–24 mmol/l (40–430 mg/dl) are reported as < 2.2 mmol/l
(40 mg/dl) or > 24 mmol/l (430 mg/dl).
Data management and schedule of assessments
Data collection was undertaken from birth to 36 weeks’ corrected gestational age, and comprised
the collection of clinical data recorded on a paper case report form (CRF) and electronic transfer of
CGM data. Key time points for clinical data collection were recruitment, daily for the first week, day
14 followed by end of study at 36 weeks’ corrected gestational age and, if appropriate, at the point of
withdrawal from the study. Parent and staff questionnaires were completed in the CGM group at study
days 3 and 7. CGM data were transferred electronically after download from the CGM device on study
day 7 or the day of sensor removal. Safety data were collected and reported in accordance with
regulatory guidance. If an infant was discharged from their recruiting NICU, the research team used
local and national databases, local contacts and links with parents to ensure that complete follow-up
data were obtained. All CRF data were sent to the co-ordinating centre in Cambridge to be entered
onto a macro-database. All CGM files were sent to the co-ordinating centre in Cambridge for validation
on format and consistency before processing and analysis. All data were collected, transferred (using a
study identifier), cleaned and stored to comply with good clinical practice and data protection legislation.
Efficacy
Efficacy was assessed by comparing the data collected from the CGM in the CGM and standard-care
arms of the study.
Safety
Safety was assessed in three areas: (1) incidence of hypoglycaemia, measured as part of clinical care
(blood glucose levels) and after review of sensor glucose data; (2) device safety through adverse device
effect (ADE) reporting; and (3) acute mortality and morbidity outcomes as part of the CRF.
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Utility
Nursing staff and parents caring for the infants in the CGM arm of the study were asked to complete a
study-specific questionnaire.
Health economic evaluation
Data were collected on the health service resources used in the treatment of infants during the
period between randomisation and 36 weeks’ gestational age, and based on the British Association
of Perinatal Medicine standard criteria for level of care,38 as well as neonatal complications. Current
UK unit costs were applied to each resource item and a per diem cost for each level of neonatal care




The primary outcome was defined as the percentage of time that the sensor glucose level was in the
target range of 2.6–10 mmol/l. This was selected as the internationally most widely accepted clinical
target range for glucose control in this population.
(a) (b)
(c)
FIGURE 4 The MiniMed 640G System (courtesy of Medtronic plc). (a) The Enlite glucose sensor; (b) the Enlite glucose
sensor with the Guardian 2 Link transmitter attached; and (c) the MiniMed 640G.
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l Percentage of time sensor glucose level is in the target range of 4–8 mmol/l.
l Mean sensor glucose level during the first 6 days.
l Sensor glucose level variability within infants (as assessed by within-infant SD).
l Percentage of time that glucose levels are in hyperglycaemic range (i.e. a sensor glucose level
> 15 mmol/l).
Safety
l Incidence of moderate hypoglycaemia, defined as any episode of blood glucose > 2.2 mmol/l and
< 2.6 mmol/l.
l Incidence of severe hypoglycaemia, defined as any episode of blood glucose ≤ 2.2 mmol/l.
l Incidence of continuous hypoglycaemia, defined as a continuous episode of sensor glucose level
< 2.6 mmol/l for > 1 hour.
Utility
l The questionnaire comprised key questions that were scored using a Likert scale.
Health economic outcomes
Cost-effectiveness was expressed in terms of incremental cost per additional case of adequate glucose
control between 2.6 and 10 mmol/l.
Exploratory outcomes
Exploratory outcomes included mortality before 36 weeks’ corrected gestational age, maximum
severity of ROP, bronchopulmonary dysplasia (BPD) (i.e. the need for supplemental oxygen or
respiratory support at 36 weeks’ corrected gestational age), microbiologically confirmed or clinically
suspected late-onset invasive infection, necrotising enterocolitis (NEC), patent ductus arteriosus (PDA)
requiring medical or surgical treatment, maximum grade of intracranial haemorrhage (Papile and
Burstein grading), growth (weight, length and head circumference at the end of week 1 and at
36 weeks’ corrected gestational age), nutritional intake during the first week of life (carbohydrate,
protein and lipid), and use of insulin during the first and second week of life.
Sample size
The sample size was based on data from the REACT feasibility study and historical control data, which
conservatively assumed that the SD of the primary end point (i.e. time in sensor glucose target range
of 2.6–10 mmol/l over a 6-day period) would be 22%. A sample size of 200 participants would enable
a treatment effect of a 10% increase in the mean value of the primary end point to be detected with
90% power using a two-sided 5% significance test in the primary analysis. Based on a consensus of
expert opinion, a difference of 10% was believed to be of clinical relevance. It was expected that a
small number of infants would be withdrawn from the study because of transfer to local units,
withdrawal of parental consent or death.
At an interim analysis, a revised blinded estimate of the SD for the primary end point suggested
that the original sample size would provide 92.5% power. After review of recruitment rates and
undertaking a revised power calculation using the revised blinded estimate of the SD for the primary
end point, a decision was made by the independent DMEC, TSC and sponsor to stop recruitment
when 182 infants had been recruited. At this time, it was considered that concluding the study with
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182 infants rather than the planned 200 would reduce the conservative estimate of power from
92.5% to 90%, which was felt to be an acceptable compromise to be able to report trial results
within the desired timelines.
Statistical analyses
Efficacy analyses
Analyses were predetermined to be undertaken based on ‘full analysis’ (primary outcome) and ‘per-
protocol’ populations to compare the CGM group with the standard-care group and were prespecified
in the statistical analysis plan. Linear regression was used to estimate the absolute difference in the
percentage of time that the sensor glucose level was in the target range of 2.6–10 mmol/l, adjusting
for baseline variables (i.e. centre and gestation). Estimates of treatment effect, with 95% CIs and
p-values, were calculated. Secondary end points that were continuous variables were analysed in a
similar fashion and binary/ordinal variables were analysed using logistic/ordinal logistic regression.
To control the study-wide significance level to 5%, a Benjamini–Hochberg multiple testing procedure
was applied to three end points of equal importance (i.e. the percentage of time that the sensor glucose
level was in the target range of 2.6–10 mmol/l, the percentage of time that the sensor glucose level was
in the target range of 4–8 mmol/l and mean sensor glucose level), followed by a gatekeeping sequence
applied in the following order: sensor glucose variability, as assessed by within-infant SD; and percentage
of time that glucose levels were in the hyperglycaemic range (i.e. sensor glucose level > 15 mmol/l).
Nominal p-values and CIs are presented, unless otherwise stated.
Predefined subgroup analyses were undertaken by estimating, using the regression framework in
an exploratory, non-confirmatory manner, treatment interaction effects with the following baseline
variables: centre, sex, corrected gestational age, birthweight standard deviation score (SDS), use of
antenatal steroids, maternal chorioamnionitis, maternal diabetes and first sensor glucose level.
Utility analyses
Acceptability of the intervention was assessed by a specifically designed staff questionnaire, which
was completed anonymously by staff caring for an infant in the CGM arm on days 3 and 7, and by a
similar parent questionnaire (completed on day 7). Compliance in the CGM group was assessed as a
percentage of time that sensor glucose readings were recorded on the CRF and when the insulin rate
of infusion was recorded if the sensor glucose > 8 mmol/l. In the standard-care group, non-compliance
was defined as 12 or more CGM readings available during the time between the tamper tag being
broken and resealed on at least one occasion.
Cost-effectiveness analyses
An incremental cost-effectiveness analysis was performed, details of which are presented in Chapter 5.
Study management
The study was co-ordinated and monitored by the Cambridge Clinical Trials Unit (Cambridge, UK) in
accordance with international guidelines. The study was adopted onto the National Institute for Health
Research Clinical Research Network portfolio of studies.
Regulatory requirements
Ethics and regulatory approvals were obtained and the protocol is in the public domain (ISRCTN12793535),2
with a list of protocol amendments provided in Appendix 1. A DMEC and TSC were appointed and
reviewed the data in accordance with their formal charters (see Appendices 2 and 3). Research teams
at each site were required to have up-to-date good clinical practice training and have undertaken
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training in study procedures, including the use of the CGMs and Nova Biomedical POC devices.
Paper and online resources, as well as a call line, were available to support the research teams.
Clinical trial authorisation was granted by the Medicines and Healthcare products Regulatory Agency
(MHRA) (reference CI/2016/0011). Written approvals were received from individual hospital sites
prior to recruitment. Approvals were also obtained from the Medical Ethics Review Committee (Vrije
Universiteit University Medical Centre, Amsterdam, the Netherlands) and Heath Care Inspectorate
(Heerlen, the Netherlands) (reference 2017-1 398434/VlO 14949), the Research Ethics Committee,
Sant Joan de Déu Research Foundation (Barcelona, Spain), and the Ministry of Health Social Services
and Equality (reference 591/16/EC) (Madrid, Spain). The trial was conducted in accordance with the
principles of the Declaration of Helsinki40 and in conformity with the European Union medical devices
regulations and any relevant amendments.41
Monitoring
Data returns were continually monitored by the central team for the completeness and timeliness
of all data returned. Compliance with intervention strategy in each study arm was also reviewed to
ensure that there was no ‘crossover’ between study arms. A monitoring plan was in place, determining
frequency and scope of site monitoring based on continuing risk review. Face-to-face monitoring visits
were initially undertaken within the first 6 months; the interval between visits was then adjusted
following assessment of recruitment rate and the number of data queries and serious adverse event
(SAE) reports. The study sites were provided with direct access to all trial-related source data and
reports for the purpose of monitoring and auditing by the central study team, sponsor and regulatory
authorities, as required.
Data and safety monitoring
The DMEC chairperson was responsible for safeguarding the interests of the trial participants and
making recommendations to the TSC. The REACT DMEC roles and responsibilities and operating
procedures are defined in the REACT DMEC Charter (see Appendices 2 and 3). The DMEC was
composed of three independent multidisciplinary experts who were not involved in the conduct of
the trial in any way. They met prior to the initiation of enrolment and determined a plan to review the
protocol, compliance, safety and adverse events (AEs), and outcome data after a prespecified number
of infants had been recruited. The TSC was composed of six independent members, whose roles and
responsibilities were defined by a charter. The TSC provided advice, through its chairperson, to the
chief investigator and reported to the trial sponsor and trial funder.
Safety was assessed continuously during each infant’s stay in NICU. The frequency of AEs and SAEs
that would normally require reporting within a clinical trial, as defined by the International Council
for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use,42 was anticipated
to be high in the population being studied, despite the low risk of the study intervention. Following
discussions with the MHRA and in accordance with regulatory guidance that allows for exceptions in
such circumstances, a modified reporting plan was agreed.
Any ADE was recorded and reported to the co-ordinating centre. All device deficiencies that might
have led to a SADE if suitable action had not been taken, the intervention had not been made or
if circumstances had been less fortunate were reported to the sponsor, as for SAEs and SADEs. AEs
were recorded in the notes and captured as exploratory outcomes as part of the CRF. SAEs are known
to be common in this population and, therefore, the MHRA requested the following expectations for
safety reporting.
During the intervention period of the study (study days 1–7)
The following expected SAEs were required to be recorded in the CRF (safety log) and reported,
using the CRF, to the sponsor within 24 hours of awareness of the event: (1) death, (2) culture-positive
infection, (3) severe hypoglycaemia (glucose level < 2.6 mmol/l), (4) seizures and (5) any other related SAE.
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Post intervention period (study day 8 until end of study)
It was agreed with the MHRA that important medical outcomes, including those normally considered
as a SAE for a clinical trial, would be captured in the CRF at the 36 weeks’ corrected gestational age
assessment (i.e. SAEs were viewed to be anticipated events for this study population and, therefore,
they were not required to be recorded or reported separately as a SAE, if judged by the clinical team
to be unrelated to the study).
Patient and public involvement
Members of the local parent support group were consulted to help inform trial design. Parents were
asked to provide feedback on study involvement as part of the protocol, through both formal review
of the protocol/patient information sheet and informal discussions at parent groups within the local
NICU. The TSC included a lay person. We sent newsletters to parents to update them on study
progress, and an end-of-study update for families.
Dissemination
The findings of the trial have been presented at national meetings, published in international journals
and communicated back to the families involved.
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Chapter 4 REACT trial results
Recruitment
A Consolidated Standards of Reporting Trials (CONSORT) flow diagram is presented in Figure 5. A total
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FIGURE 5 A Consolidated Standards of Reporting Trials (CONSORT) flow diagram. Reproduced with permission from
Beardsall et al.4 in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits
others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly
cited. See: http://creativecommons.org/licenses/by/4.0/. The figure includes minor additions and formatting changes to
the original figure.
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approached because of the short recruiting window of 24 hours. Of the remaining 360 families who
were approached, 182 consented, resulting in a consent rate of 51%. Two infants were excluded
prior to randomisation, as they were > 24 hours of age. One infant who was found to be ineligible
was excluded post randomisation. There were 11 withdrawals from the trial and eight deaths
(control, n = 6; intervention, n = 2).
Demographic details
Demographic details of all recruited infants are provided in Table 4. These data show no apparent
differences between study arms at baseline in terms of premorbidity and the results are in keeping
with what would be anticipated for this preterm population.
TABLE 4 Randomised controlled trial: demographic data
Variable Statistic Standard-care arm CGM arm
Gestational age (weeks) n 95 84
Mean (SD) 27.4 (1.9) 27.7 (2.1)
Sex, % (n/N) Male 47 (45/95) 54 (45/84)
Ethnicity, % (n/N) Asian 12 (11/95) 8 (7/84)
Black 8 (8/95) 8 (7/84)
Mixed 5 (5/95) 7 (6/84)
Other 5 (5/95) 4 (3/84)
White 69 (66/95) 73 (61/84)
Number of infants delivered, % (n/N) Singleton 74 (70/95) 77 (65/84)
Multiple 26 (25/95) 23 (19/84)
CRIB II score n 91 80
Mean (SD) 10 (2.9) 10 (2.9)
Median 10 10
Minimum, maximum 4, 19 4, 19
Birthweight (g) n 95 84
Mean (SD) 880 (180) 910 (160)
Median 920 930
Minimum, maximum 470, 1170 390, 1190
Birthweight SDS n 95 84
Mean (SD) –0.8 (0.92) –0.82 (0.98)
Median –0.66 –0.76
Minimum, maximum –2.6, 1.32 –2.97, 1.2
Use of antenatal steroids > 24 hours
prior to delivery, % (n/N)
Yes 73 (69/95) 82 (69/84)
Use of antibiotics in 24 hours prior to
delivery, % (n/N)
Yes 34 (32/94) 30 (25/84)
Maternal diabetes, % (n/N) Yes 8 (8/95) 6 (5/84)
Maternal chorioamnionitis, % (n/N) Yes 22 (21/95) 23 (19/84)
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Compliance with intervention and control procedures
The number of CGM data points in the CGM and standard-care arms was a comparable mean of 1538
(SD 341) and 1412 (SD 424), respectively (Figure 6).
In the CGM group, the median number of times sensor glucose was recorded per hour on the CRF was 0.98
(range 0.56–1.45) based on hours’ worth of data (number of CGM readings/12) and 0.90 (range 0.29–1.28)
based on total sensor duration (hours). The mean percentage of time that the insulin rate of infusion was
recorded when the sensor glucose was > 8mmol/l was 54% (SD 38%). Assessment of compliance with
blinding in the control study arm was recorded using a log of time between the tamper tag being opened
and resealed. Failure to comply with blinding [prespecified as 12 or more CGM readings available
(equivalent to 60 minutes of time) between the tag being opened and resealed] occurred in 15% (14/95)
of infants. The median length of time the tags were open for was 0.167 (range 0–23.9) hours, with a mean
of 0.377 (SD 1.34) hours. These figures are represented graphically in Figure 7.
0









Number of CGM data recorded
Standard care
CGM
2 days’ worth of data
FIGURE 6 Randomised controlled trial: CGM data recorded by treatment group.
TABLE 4 Randomised controlled trial: demographic data (continued )
Variable Statistic Standard-care arm CGM arm
Delivery mode, % (n/N) Spontaneous vaginal delivery 33 (31/95) 35 (29/84)
Caesarean section pre onset of labour 42 (40/95) 49 (41/84)
Caesarean section post onset of labour 23 (22/95) 1 (13/84)
Assisted vaginal delivery 2 (2/95) 1 (1/84)
CRIB II, Clinical Risk Index for Babies II.
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The primary results for the full analysis population demonstrated that the time during which sensor
glucose was in the target range of 2.6–10 mmol/l was 9% higher in the CGM arm than in the standard-
care arm (95% CI 3% to 14%; p = 0.002) (Table 5). Full model-fitting results exploring the effect of centre
and gestation ≥ 26 weeks (Table 6), and a range of sensitivity analyses (see Appendix 4, Tables 24 and 25),
all gave similar treatment effects, suggesting that the results are robust. In per-protocol analyses, CGM,
compared with standard control, resulted in a 10 percentage-point increase in the time that sensor
glucose was in the target range of 2.6–10 mmol/l (95% CI 4% to 17%; p = 0.002). Model-fitting results
for per-protocol analyses are provided in Appendix 4, Table 25.
Significant subgroup effects included sex (compared with standard care, CGM resulted in a 15 percentage-
point increase in the time that sensor glucose level was in the target range in male infants and a 2
percentage-point increase in female infants; see Appendix 4, Table 26).
TABLE 5 Randomised controlled trial: primary and secondary efficacy
Variable Statistic
Standard-
care arm CGM arm
Linear regression model
Adjusted mean
differencea (95% CI) p-value
Percentage of time sensor glucose
is in target range of 2.6–10 mmol/l
n 85 70 8.9 (3.4 to 14.4) 0.002
Mean (SD) 84 (22) 94 (11)
Median 97 99
Minimum, maximum 14, 100 51, 100
Mean sensor glucose level (mmol/l) n 85 70 –0.46 (–1 to 0.09) 0.99
Mean (SD) 7 (2.1) 6.5 (1.2)
Median 6.5 6.4
Minimum, maximum 3.1, 12.2 3, 9.9
Percentage of time sensor glucose
is in target range of 4–8 mmol/l
n 85 70 11.5 (3.7 to 19.2) 0.004
Mean (SD) 62 (29) 74 (20)
Median 65 78
Minimum, maximum 0, 100 16, 100
Sensor glucose variability (mmol/l) n 85 70 –0.01 (–0.15 to 0.13) 0.9
Mean (SD) 3.6 (4.3) 2.7 (3)
Median 2.1 1.9
Minimum, maximum 0.07, 22 0.6, 23.1
Percentage of time in hyperglycaemic
range (i.e. > 15mmol/l)
n 85 70 –0.92 (–2.03 to 0.19) 0.1
Mean (SD) 1.3 (4.2) 0.3 (2.1)
Median 0 0
Minimum, maximum 0, 24 0, 16
a Adjusted for centre and gestation (< 26 weeks’ gestation, ≥ 26 weeks’ gestation).
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Secondary outcome analyses showed that time in the target range of 4–8 mmol/ was 12 percentage-
points higher in the CGM arm than in the standard-care arm. The mean sensor glucose level, sensor
glucose variability and percentage of time sensor glucose level was > 15 mmol/l were all lower in the
CGM arm than in the standard-care arm, but none of these differences reached statistical significance.
Results are provided with multiple testing procedure data (see Appendix 4, Table 27).
Safety
Continuous glucose monitor data showed that more infants in the standard-care arm (15%) than in
the CGM arm (6%) were exposed to at least one episode of sensor glucose < 2.6 mmol/l for > 1 hour.
Safety outcome data are provided in Table 7. AEs and ADEs are reported in Tables 8 and 9, respectively.
The tables show that episodes of blood glucose levels ≤ 2.2 mmol/l and 2.2–2.6 mmol/l occurred in 7%
and 12%, respectively, of the standard-care group, and in 13% and 15%, respectively, of the CGM group.
Collection of the blood glucose data was biased by the result of a low sensor glucose level in the CGM
arm, prompting blood glucose to be checked, and is reflected in the higher percentage of infants in the
standard-care arm who were exposed to at least one episode of hypoglycaemia lasting > 1 hour. Owing
to the small numbers and interinfant variability, none of these differences was statistically significant.
The mean percentage of time for which sensor glucose level was < 2.6 mmol/l was 1% (SD 3.2%) in the
standard-care group and 1% (SD 5.3%) in the CGM group. The percentage of time that sensor glucose
level was < 2.6 mmol/l depended on the number of CGM data available, which explains why it is similar
in both groups, despite the total length of time that sensor glucose level was < 2.6 mmol/l being greater
in the standard-care arm. Further details of SAEs and SADEs are provided in Tables 8 and 9, and details
of withdrawals from the intervention or study, and deaths are shown in Appendix 4, Tables 28–30.
TABLE 6 Randomised controlled trial: model-fitting results – primary analysis
Outcome Covariate Estimate (SE) 95% CI p-value
Percentage of time sensor glucose is in the
target range 2.6–10mmol/l
Intercept 80.6 (3.7) 73.4 to 87.9 < 0.001
CGM vs. standard care 8.9 (2.8) 3.4 to 14.4 0.002
N36 (reference N01) –7.9 (12.3) –32.2 to 16.5 0.5
N42 7.6 (5.9) –4.1 to 19.3 0.2
N43 0.2 (4.2) –8.2 to 8.6 0.96
N68 0.2 (4.2) –8.1 to 8.5 0.97
N73 0.3 (5.5) –10.6 to 11.2 0.95
N74 10 (12) –14 to 34 0.4
N85 8.2 (6.9) –5.4 to 21.8 0.2
N86 –16 (8.9) –33.7 to 1.6 0.08
N87 –12.2 (12.4) –36.6 to 12.2 0.3
N88 –29 (8) –44.8 to –13.2 < 0.001
ND3 6.9 (6.9) –6.7 to 20.5 0.3
SP3 9.6 (8.9) –8 to 27.2 0.3
Gestation ≥ 26 weeks 4.9 (3.6) –2.1 to 12 0.2
RSD= 17.02
RSD, residual error standard deviation; SE, standard error.
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Utility
Table 10 shows summary statistics for the number of sensors used, the individual sensor duration and
the number of CGM data collected (hours). We received CGM data from 155 infants, with loss of data
due to reported failure of sensor insertion, calibration failure and lack of data at download. Insertion
of the first sensor failed in 18% of infants and, therefore, the average number of sensors needed per
infant was 1.2. Details of withdrawals are provided in Appendix 4, Tables 28 and 29. The success of
sensor insertion varied markedly between centres. Difficulties in calibrating the sensor with the blood
TABLE 7 Randomised controlled trial: safety analyses of CGM vs. standard care
Variable Statistic
Standard-




Blood glucose level range
2.2–2.6 mmol/l
12% (11/93) 15% (11/75) 1.2 (0.48 to 3.2) 0.7
Blood glucose level ≤ 2.2 mmol/l 7% (6/93) 13% (10/75) 2.2 (0.7 to 7.1) 0.2
Continuous episode of sensor
glucose < 2.6 mmol/l for > 1 hour
15% (13/85) 6% (4/70) 0.361 (0.0919 to 1.2) 0.1
Length of time sensor glucose
level is < 2.6 mmol/l (hours)
n 85 70
Mean (SD) 1.0 (3.2) 0.5 (1.7)
Median 0 0
Minimum, maximum 0, 22 0, 11.2
Percentage of time that the
sensor glucose level is
< 2.6 mmol/l
n 85 70
Mean (SD) 1.1 (3.2) 1 (5.3)
Median 0 0
Minimum, maximum 0, 17 0, 41
OR, odds ratio.
a Adjusted for centre and gestation (< 26 weeks’ gestation, ≥ 26 weeks’ gestation).
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AE description Culture-positive infection 0 (0/95) 1 (1/84) 1 (1/179)
Moderate hypoglycaemia (sensor): sensor glucose
2.2–2.6 mmol/l for > 1 hour
0 (0/95) 6 (5/84) 3 (5/179)
Moderate hypoglycaemia: blood glucose level range
2.2–2.6 mmol/l
9 (9/95) 6 (5/84) 8 (14/179)
Persistent pulmonary hypertension 1 (1/95) 0 (0/84) 1 (1/179)
Pulmonary haemorrhage 1 (1/95) 0 (0/84) 1 (1/179)
Seizures 1 (1/95) 0 (0/84) 1 (1/179)
Severe hypoglycaemia: blood glucose level ≤ 2.2 mmol/l 5 (5/95) 10 (8/84) 7 (13/179)
Severe prematurity 2 (2/95) 0 (0/84) 1 (2/179)
Transient: sensor glucose level < 2.6 mmol/l for < 1 hour 0 (0/95) 2 (2/84) 1 (2/179)
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glucose level were reported in 22% of infants and episodes where data could not be linked between
the transmitter and monitor occurred in 7% of infants. ADEs reported included bruising at the sensor
site in 3% of infants, and significant discrepancy between sensor glucose and blood glucose in seven
(4%) infants in the CGM study arm. In three infants, the sensor became displaced from under the
skin (fell out).
The staff and parent questionnaire results are presented in Figures 8 and 9, respectively. Most staff found
the devices easy to calibrate (86%) and did not think that the CGM device interfered with the infant’s
nursing care (87%) or caused any distress (94%). Seventy per cent of staff felt that the use of CGM
improved clinical care. The majority of parents reported that the CGM did not interfere with the infant’s
nursing care (96%) or cause any distress (89%), and 80% felt that the use of CGM improved clinical care.








ADE description Bruising at sensor site 3 (3/95) 4 (3/84) 3 (6/179)
Clinically significant discrepancy between sensor glucose
and blood glucose levels
0 (0/95) 8 (7/84) 4 (7/179)
Excoriated skin at sensor site 1 (1/95) 0 (0/84) 1 (1/179)
Failure to re-establish connectivity during intervention 4 (4/95) 2 (2/84) 3 (6/179)
Failure to transmit data to the MiniMed 640G because
of loss of connectivity
7 (7/95) 6 (5/84) 7 (12/179)
Pressure mark on skin 2 (2/95) 0 (0/84) 1 (2/179)
Sensor displaced 1 (1/95) 2 (2/84) 2 (3/179)
Sensor insertion failure 22 (21/95) 13 (11/84) 18 (32/179)
Transient: sensor glucose level < 2.6 mmol/l for < 1 hour 0 (0/95) 2 (2/84) 1 (2/179)
Unable to calibrate 23 (22/95) 20 (17/84) 22 (39/179)
User error 1 (1/95) 0 (0/84) 1 (1/179)
TABLE 10 Randomised controlled trial: duration of sensor use
Variable Statistic Standard-care arm CGM arm Total
Sensor duration (hours) n 92 81 173
Mean (SD) 128 (47) 127 (48) 127 (48)
Median 145 145 145
Minimum, maximum 4, 192 2, 191 2, 192
Number of CGM data (hours) n 85 70 155
Mean (SD) 118 (35) 128 (28) 122 (33)
Median 133 140 136
Minimum, maximum 6, 170 24, 155 6, 170
Number of sensors used n 95 84 179
Mean (SD) 1.25 (0.48) 1.13 (0.43) 1.20 (0.46)
Median 1 1 1
Minimum, maximum 0, 3 0, 2 0, 3
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Do you think the baby was distressed or
bothered by the sensor?
Do you think the device interfered with
the baby’s nursing care?
How did you f ind the monitor to read
and calibrate?
Did having the baby on the monitor
signif icantly affect your workload?
How do you think continuous monitoring















FIGURE 8 Randomised controlled trial: staff questionnaires of utility. Stacked bar chart showing proportion of response for each Likert question. Reproduced with permission from
Beardsall et al.4 in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work,













































































































































































































































































































































Do you think your baby was distressed or
bothered by the sensor?
Do you think the device interfered with
your baby’s nursing care?
Do you think monitoring the sugar levels











FIGURE 9 Randomised controlled trial: parent questionnaire of acceptability. Stacked bar chart showing proportion of response for each Likert question. Reproduced with permission
from Beardsall et al.4 in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work,







































Details of complementary medical treatment received during the intervention period in both study
arms are provided in Table 11. These data are in keeping with what would be considered standard
clinical care for this population and there were no apparent differences between study arms.
TABLE 11 Randomised controlled trial: medications given during days 1–7
Variable Statistic Standard-care arm CGM arm Total
Inotropes given (days) n 94 80 174
Mean (SD) 0.8 (1.6) 0.7 (1.5) 0.7 (1.5)
Median 0 0 0
Minimum, maximum 0, 7 0, 7 0, 7
Antibiotics given (days) n 94 80 174
Mean (SD) 4.3 (2.3) 4.5 (2.4) 4.4 (2.4)
Median 4 5 5
Minimum, maximum 0, 7 0, 7 0, 7
Caffeine given (days) n 94 80 174
Mean (SD) 6.4 (1.6) 6.6 (1.4) 6.5 (1.5)
Median 7 7 7
Minimum, maximum 1, 7 1, 7 1, 7
Morphine given (days) n 94 80 174
Mean (SD) 1.7 (2.5) 1.8 (2.6) 1.7 (2.5)
Median 0 0 0
Minimum, maximum 0, 7 0, 7 0, 7
Corticosteroids given (days) n 94 80 174
Mean (SD) 0.12 (0.53) 0.09 (0.51) 0.1 (0.52)
Median 0 0 0
Minimum, maximum 0, 4 0, 4 0, 4
Insulin given (days) n 94 80 174
Mean (SD) 1.6 (2.4) 2.6 (2.5) 2.1 (2.5)
Median 0 2.5 0
Minimum, maximum 0, 7 0, 7 0, 7
Insulin units, days 1–7 (per kg per day) n 94 80 174
Mean (SD) 0.6 (2.1) 0.6 (0.94) 0.6 (1.7)
Median 0 0.19 0
Minimum, maximum 0, 19.8 0, 5.39 0, 19.8
Insulin units, days 8–14 (per kg per day) n 88 75 163
Mean (SD) 0.15 (0.34) 0.16 (0.43) 0.16 (0.38)
Median 0 0 0
Minimum, maximum 0, 1.72 0, 2.83 0, 2.83
Glucose (g/kg/day) n 95 84 179
Mean (SD) 9.1 (2.6) 9.5 (3.1) 9.3 (2.9)
Median 9.3 10.1 9.9
Minimum, maximum 0, 14.9 0, 17.2 0, 17.2
continued
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Exploratory outcome measures
Further data on glucose profiles in the CGM and standard-care arms are provided in Figures 10 and 11,
respectively.
Exploratory analyses of the use of insulin can be found in Figure 12. Figure 12 shows that variability in
the use of insulin during study days 5–7 was greater in the standard-care arm than in the CGM arm.
There were no differences in any of the growth parameters between study arms at any study time points.
Details of causes of death are provided in Appendix 4, Table 30. Details of growth parameters are
provided in Appendix 4 for at birth (see Appendix 4, Table 31), day 7 (see Appendix 4, Table 32), day 14
(see Appendix 4, Table 33) and at 36 weeks’ corrected gestational age (see Appendix 4 Table 34).
Changes in growth SDS are provided from birth to 36 weeks’ corrected gestational age for weight
(Figure 13), body length (Figure 14) and head circumference (Figure 15).
TABLE 11 Randomised controlled trial: medications given during days 1–7 (continued )
Variable Statistic Standard-care arm CGM arm Total
Glucose (ml/kg/day) n 95 84 179
Mean (SD) 84 (24) 85 (28) 84 (26)
Median 86 92 88
Minimum, maximum 0, 143 0, 185 0, 185
Lipids (g/kg/day) n 92 80 172
Mean (SD) 1.95 (0.78) 1.89 (0.77) 1.92 (0.78)
Median 2.1 1.95 2
Minimum, maximum 0.04, 3.9 0.04, 4.7 0.04, 4.7
Lipids (ml/kg/day) n 92 80 172
Mean (SD) 9.9 (3.7) 9.7 (3.7) 9.8 (3.7)
Median 10.6 9.9 10.4
Minimum, maximum 1.8, 19.5 1.9, 23.7 1.8, 23.7
Amino acids (g/kg/day) n 94 81 175
Mean (SD) 2.2 (1.3) 2.2 (1.2) 2.2 (1.3)
Median 2.4 2.5 2.5
Minimum, maximum 0, 7.2 0, 6.1 0, 7.2
Oral nutrition (ml/kg/day) n 94 81 175
Mean (SD) 18 (23) 20 (21) 19 (22)
Median 11 14 12
Minimum, maximum 0, 108 0, 94 0, 108
Reproduced with permission from Beardsall et al.4 in accordance with the terms of the Creative Commons Attribution
(CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use,
provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/. The table includes minor
additions and formatting changes to the original table.
REACT TRIAL RESULTS






























0 100 200 0 100 200 0 100 200 0 100 200 0 100 200 0































































































































































































































































































































































0 100 200 0 100 200 0 100 200 0 100 200 0 100 200 0 100 200 0 100 200 0 100 200





























































































































FIGURE 12 Randomised controlled trial: mean (95% CI) insulin and sensor glucose against study day. (a) Sensor glucose;

















FIGURE 13 Randomised controlled trial: change in mean weight SDS over time. Error bars represent standard error of
the mean.
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Summary statistics of the exploratory clinical outcomes analyses and model fitting are provided in
Tables 12 and 13, respectively. More infants in the standard-care arm (12%) than in the CGM arm (5%)
required surgery for PDA, but the difference did not reach statistical significance. CGM was associated
with a significant reduction in the exploratory outcome of NEC as 28% of infants in the standard-care
arm were diagnosed with NEC, compared with 13% of infants in the CGM arm [odds ratio (OR) 0.33,
















































FIGURE 15 Randomised controlled trial: change in mean head circumference SDS over time. Error bars represent
standard error of the mean.
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TABLE 12 Randomised controlled trial: summary statistics of exploratory outcomes
Variable Statistic
Standard-
care arm CGM arm Total
Mortality, % (n/N) Yes 6 (6/95) 2 (2/84) 4 (8/179)
Maximum severity of ROP n 78 68 146
Mean (SD) 1.5 (3.6) 1.1 (3.8) 1.3 (3.7)
Median 0 0 0
Minimum, maximum 0, 22 0, 22 0, 22
Maximum severity of ROP
(categorical), % (n/N)
< 3 88 (69/78) 96 (65/68) 92 (134/146)
≥ 3 12 (9/78) 4 (3/68) 8 (12/146)
BPD, % (n/N) Yes 66 (56/85) 60 (45/75) 63 (101/160)
BPD severity, % (n/N) Mild 32 (18/56) 22 (10/45) 28 (28/101)
Moderate 46 (26/56) 64 (29/45) 54 (55/101)
Severe 21 (12/56) 13 (6/45) 18 (18/101)
Infection, % (n/N) Yes 62 (53/85) 68 (50/74) 65 (103/159)
NEC requiring medical or surgical
treatment, % (n/N)
Yes 28 (24/85) 13 (10/75) 21 (34/160)
NEC treatment, % (n/N) Medically managed 83 (20/24) 80 (8/10) 82 (28/34)
Surgically managed 17 (4/24) 20 (2/10) 18 (6/34)
PDA requiring medical or surgical
treatment, % (n/N)
Yes 31 (26/85) 26 (19/74) 28 (45/159)
PDA treatment, % (n/N) Medically managed 88 (23/26) 95 (18/19) 91 (41/45)
Surgically managed 12 (3/26) 5 (1/19) 9 (4/45)
Intracerebral pathology, % (n/N) Yes 32 (27/84) 33 (25/75) 33 (52/159)
Intracerebral pathology type, % (n/N) Germinal layer haemorrhage 44 (12/27) 40 (10/25) 42 (22/52)
IVH without ventricular dilatation 33 (9/27) 44 (11/25) 38 (20/52)
IVH with ventricular dilatation 26 (7/27) 32 (8/25) 29 (15/52)
Parenchymal involvement 22 (6/27) 12 (3/25) 17 (9/52)
IVH, intraventricular haemorrhage.
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TABLE 13 Randomised controlled trial: model-fitting results of exploratory outcomes
Model Outcome Covariate Estimate (SE)a 95% CI p-value
Linear
regression
Maximum ROP Intercept 2.53 (0.78) 0.98 to 4.08 0.002
CGM vs. standard care –0.26 (0.56) –1.37 to 0.85 0.6
Weight SDS, day 7 Intercept –0.88 (0.16) –1.19 to –0.57 < 0.001
CGM vs. standard care 0.05 (0.12) –0.19 to 0.28 0.7
Weight SDS, 36 weeks’
gestational age
Intercept –1.17 (0.21) –1.59 to –0.76 < 0.001
CGM vs. standard care –0.04 (0.15) –0.34 to 0.25 0.8
Body length SDS, day 7 Intercept –1.72 (0.22) –2.15 to –1.28 < 0.001
CGM vs. standard care –0.02 (0.17) –0.36 to 0.31 0.9
Body length SDS,
36 weeks’ gestational age
Intercept –4.05 (0.67) –5.4 to –2.7 < 0.001
CGM vs. standard care –0.38 (0.4) –1.19 to 0.42 0.3
Head circumference, day 7 Intercept –1.59 (0.17) –1.93 to –1.25 < 0.001
CGM vs. standard care 0.07 (0.14) –0.2 to 0.35 0.6
Head circumference,
36 weeks’ gestational age
Intercept –2.14 (0.4) –2.94 to –1.35 < 0.001
CGM vs. standard care 0.13 (0.29) –0.44 to 0.7 0.6
Daily glucose (g/kg) Intercept 9.53 (0.55) 8.44 to 10.6 < 0.001
CGM vs. standard care 0.42 (0.41) –0.39 to 1.22 0.3
Daily amino acids (g/kg) Intercept 2.59 (0.16) 2.29 to 2.9 < 0.001
CGM vs. standard care 0.17 (0.12) –0.06 to 0.4 0.2
Daily lipids (g/kg) Intercept 1.67 (0.12) 1.44 to 1.9 < 0.001
CGM vs. standard –0.04 (0.09) –0.21 to 0.13 0.6
Daily oral nutrition
(ml/kg/d)
Intercept 5.9 (3.8) –1.6 to 13.4 0.1
CGM vs. standard care 2 (2.8) –3.6 to 7.6 0.5
Total insulin, week 1
(units/kg)
Intercept 8 (2.3) 3.4 to 12.5 < 0.001
CGM vs. standard care 0.08 (1.7) –3.3 to 3.5 0.96
Total insulin, week 2
(units/kg)
Intercept 2 (0.58) 0.89 to 3.2 < 0.001
CGM vs. standard care 0.1 (0.44) –0.76 to 0.96 0.8
Logistic
regression
Mortality CGM vs. standard care 0.263 [0.23] 0.0353 to 1.3 0.1
Infection CGM vs. standard care 1 [0.4] 0.46 to 2.2 0.99
NEC CGM vs. standard care 0.328 [0.15] 0.129 to 0.78 0.01
PDA CGM vs. standard care 0.52 [0.243] 0.199 to 1.3 0.2
Intracerebral pathology CGM vs. standard care 1.02 [0.365] 0.51 to 2.1 0.9
Ordinal logistic
regression
BPD CGM vs. standard care 1.2 [3.2] 0.52 to 2.8 0.7
SE, standard error.
a OR [SE(OR)]. Analyses adjusted for centre and gestation.
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Chapter 5 REACT randomised controlled
trial health economic analyses
Parts of this text have been reprinted from Seminars in Perinatology, vol. 45, Petrou S, Kim S, Bond S,Allison A, Beardsall K, the REACT collaborative, Cost-effectiveness of real time continuous glucose
monitoring to target glucose control in preterm infants, pp. 151392, Copyright (2021),43 with
permission from Elsevier.
Introduction
The main goal of the health economic evaluation for the REACT RCTwas to evaluate the comparative
cost-effectiveness of the two interventions (CGM and standard care) in preterm infants weighing ≤ 1200 g
and aged ≤ 24 hours. The economic analysis adopted a NHS and Personal Social Services (PSS) perspective
in accordance with the National Institute for Health and Care Excellence (NICE) methodological
recommendations.44 For the purposes of the economic evaluation, cost-effectiveness was primarily
presented in terms of incremental cost per additional case of adequate glucose control during the first
6 days of life for the trial participants. However, clinical data were prospectively collected until 36 weeks’
corrected gestational age. As a result, the costs incurred until 36 weeks and secondary outcomes were
also reflected in the cost-effectiveness analysis. Study participants were hospitalised in a NICU and the
majority of participants were in hospital at the 36 weeks’ corrected gestational age assessment. The time
horizon covered the period from randomisation to the end of follow-up at the 36 weeks’ corrected
gestational age assessment. Costs and outcomes were therefore not discounted because of the short time
horizon of the economic evaluation, extending to either 7 days’ or 36 weeks’ corrected gestational age.
Methods
Measurement of resource use and costs
Health economic data were collected on:
l resource use and costs associated with CGM (i.e. direct intervention costs)
l broader health service use during the 36-week follow-up period.
All costs were presented in Great British pounds and valued in 2016–17 prices. If necessary, costs
were inflated or deflated to 2016–17 prices using the Hospital and Community Health Services Pay
and Price Inflation Index.45
Direct intervention costs
Direct intervention costs encompassed the costs associated with the application of the comparator
intervention (i.e. CGM with guideline) over and above the cost of standard care. Infants in the CGM
arm were fitted with Enlite glucose sensors, which were linked to a MiniMed 640G System and
calibrated with POC blood glucose levels. As a result, the costs of the intervention included the
cost of the Enlite sensor and MiniMed 640G System, the costs associated with fitting the device to
infants (hospital staff time) and the costs associated with the removal of sensors. The lifetime cost of
the Medtronic plc system was annuitised and then further adjusted to reflect the duration of use of
the device over the trial period. However, to reflect clinical practice outside the confines of a RCT, the
resource inputs associated with masked CGM and the use of associated devices were not costed in the
standard-care arm, although the relevant resource inputs were prospectively measured. The resource
use associated with the direct intervention costs was collected prospectively. Table 14 provides an
outline of the types of direct intervention-related resource inputs that were measured and the sources
of the unit costs of each resource input.
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Cost estimates for staff inputs associated with key clinical events, such as time associated with sensor
insertion and removal, were based on expert clinical advice about the duration of each event, and the
unit cost values for staff inputs were obtained from the NHS Agenda for Change 2016/17 pay scales.46
The total direct intervention cost for each participant was estimated by estimating the compound of
the associated resource use input values multiplied by their unit cost values.
Measuring broader resource use
The different types of resource categories for broader health-care costs and the sources of their unit
costs are presented in Table 15.
Broader resource use data were collected for each infant using data extraction sheets that were
completed by research nurses in each clinical centre. The nurses extracted the relevant data directly
from routine hospital systems and patient records following the final follow-up assessments at
TABLE 14 Randomised controlled trial: direct intervention costs
Resource type Resource use Unit cost source
Medtronic plc MiniMed 640G System and
Enlite sensors
Cost of MiniMed 640G System and
Enlite sensors
Manufacturers
Enlite sensor insertion and set-up of
MiniMed 640G System
Staff time NHS Agenda for Change46
and clinician’s advice
Sensor glucose monitoring Staff time NHS Agenda for Change46
and clinician’s advice
Removal of sensor Staff time NHS Agenda for Change46
and clinician’s advice
POC (StatStrip) Cost of Nova Biomedical devices Manufacturers
Reprinted from Seminars in Perinatology, vol. 45, Petrou S, Kim S, Bond S, Allison A, Beardsall K, the REACT
collaborative, Cost-effectiveness of real time continuous glucose monitoring to target glucose control in preterm
infants, pp. 151392, Copyright (2021),43 with permission from Elsevier.
TABLE 15 Randomised controlled trial: broader health-care and social costs
Resource type Resource use Unit cost source
Length of stay by level of care (e.g. intensive
care, special care)
Staff salaries, on-costs, equipment,
consumables, revenue and capital overheads
NHS reference costs47
Medications Cost of medications BNF48
Investigations Staff time to deliver the investigations,
associated costs
NHS reference costs47
Medical (surgical) treatment Staff time to deliver treatment,
associated costs
NHS reference costs47
Blood transfusion products Cost of blood transfusion products NHS Blood and Transplant
Price List 201749
Surgical procedures Staff time to deliver the interventions,
associated costs
NHS reference costs;47
NHS Agenda for Change46
Mode of discharge Mode and distance of transfer or discharge
to home
UK government50
BNF, British National Formulary.
Reprinted from Seminars in Perinatology, vol. 45, Petrou S, Kim S, Bond S, Allison A, Beardsall K, the REACT
collaborative, Cost-effectiveness of real time continuous glucose monitoring to target glucose control in preterm
infants, pp. 151392, Copyright (2021),43 with permission from Elsevier.
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36 weeks’ corrected gestational age. The CRFs recorded details of length of inpatient stays by
intensity of care, investigations performed [e.g. ultrasound scan, magnetic resonance imaging (MRI),
electrocardiography (ECG), computed tomography (CT) scan, X-ray, cranial ultrasound scan and
electroencephalography (EEG)], medications and procedures performed (e.g. lumbar punctures,
ventricular taps, long lines, surgical procedures and interventions for ROP treatment). The CRFs
also captured information surrounding transfers between hospitals, and the modes of transport used
for hospital transfers and at final hospital discharge. Distances associated with transfers between
hospitals were calculated using Google Maps (Google Inc., Mountain View, CA, USA).
Valuation of resource use
Unit cost data were mainly based on NHS reference costs.47
Costs for sensor insertion, sensor monitoring and sensor removal were calculated by multiplying the
duration of each activity, based on clinical advice, by the unit cost extracted from the NHS Agenda
for Change pay scales (2016/17).46 The costs of medications for infants were estimated based on the
doses and frequencies reported on the CRF, with medication costs obtained from the British National
Formulary.48 The costs of blood transfusion products, such as platelets, red blood cells and frozen plasma,
were obtained from NHS Blood and Transplant Price List 201749 and multiplied by the volume of each
product used.
When infants were transferred to another hospital, the distance (miles) between the study site
and transferred location was calculated using Google Maps and fuel costs were calculated using the
advisory fuel rates obtained from the UK government.50 The fuel costs applied to the distances of
hospital transfers in clinical sites located outside the UK were estimated in the same manner.
Measurement of outcomes
The primary clinical outcome measure for this study was the percentage of time sensor glucose
readings were within the target range of 2.6–10mmol/l during the first 6 days of life. Cost-effectiveness
was primarily expressed in terms of incremental cost per additional case of adequate glucose control
during the first 6 days of life. For the primary cost-effectiveness analysis, adequate glucose control was
defined as at least 80% of readings falling within the target range. However, to assess the robustness
of the cost-effectiveness results, a number of sensitivity analyses were also performed that varied
the threshold for number of readings falling within the target range of 2.6–10 mmol/l. Therefore,
adequate glucose control was re-estimated at alternative thresholds of 60%, 70% and 90% of readings
falling within the target range. Given the nature of the outcome measure used in this project and the
methodological constraints surrounding utility measurement in newborn infants, cost–utility analysis
using a preference-based measure, such as quality-adjusted life-years, was not performed.
The secondary clinical outcome measures selected for secondary expressions of cost-effectiveness
were NEC and BPD. Cost-effectiveness analyses using these secondary clinical outcome measures
were expressed using the incremental cost-effectiveness ratio (ICER), and expressed in terms
of incremental cost per case of NEC averted and incremental cost per case of BPD averted, using
imputed costs for the entire period extending to 36 weeks’ corrected gestation.
Cost-effectiveness analysis methods
Missing data
Missing data may be a particular issue for costs and the health outcome measures of interest;
therefore, it is important to deal with them in a standardised way. RCTs have been criticised in the
health economic literature for failing to use appropriate methods to address missing data.51
Multiple imputation was adopted to impute missing data and avoid biases associated with complete-
case analysis. Multiple imputation was conducted based on Rubin’s rule.52 Multiple imputation was
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carried out on the main and secondary clinical outcome measures, using Markov chain Monte Carlo
and predicted mean matching.53 Predicted mean matching is a semiparametric imputation approach and
generally performs better than linear regression, despite the similarities in method.54
It is recommended that potential predictors are incorporated into analytical models for multiple
imputation.55 Inclusion of explanatory variables enables the analyst to use multivariate imputation
through chained equations. In chained equations, missing values in variable X are replaced by draws
from the posterior predictive distribution of X and imputation is repeatedly performed using the
values of other independent variables.55 Consequently, the multiple imputation models used baseline
covariates (i.e. gestational age, sex, site and randomisation arm), as well as health outcomes and cost
components (i.e. glucose level, and costs associated with inpatient days, investigation, medical
treatment and surgical procedures).
For the CGM outcome, before implementing multiple imputation, linear interpolation using the known
values of CGM, before and after any missing values, was conducted first, given that the data followed a
time series format.56 Interpolation requires that the dependent variable be a function of independent
variables, so glucose level was also interpolated for values of the time that the glucose level was
checked.56,57 Then, likewise, the interpolated values were imputed using a chained equation with
baseline covariates and costs. Five imputed data sets were generated, as this has been considered to
be sufficient to obtain valid results.53
Regression analysis
Generalised linear modelling (GLM) was used to estimate total costs and effectiveness. GLM is an
estimation strategy well suited to modelling skewed data.58 Exponentiation of the mean of the logs
generates the geometric mean of the skewed dependent variable (in this case, costs), which is a
downwards-biased estimate of the arithmetic mean.58 In contrast, GLM predicts the mean of the log
without using a smearing factor and, therefore, tends to yield more consistent results. After conducting
statistical tests, such as the Pregibon link test and Pearson correlation test, on cost data, the gamma
family and log-link function were chosen as an appropriate generalised linear model for these trial data.
By specifying the treatment group as an indicator within the GLM, the incremental costs and outcomes
attributable to CGM were estimated, while controlling for baseline covariates (i.e. treatment arm,
study site, gestational age, sex, weight at birth, whether or not the mother received antenatal steroids
> 24 hours prior to delivery, and whether or not the mother had diabetes during pregnancy).
Presentation of cost-effectiveness results
Summary statistics were estimated for resource use variables by treatment allocation and duration,
covering either days 1–7 or the 36-week follow-up period. Between-group differences in resource
use and costs were compared using the two-sample t-test. Standard errors (SEs) are reported for
CGM and standard-care group means. Mean differences are reported with 95% CIs. When there was
evidence of non-normality in the continuous outcome measure, non-parametric bootstrapping with
1000 samples was used to estimate the effect of the intervention and bootstrapped 95% CIs for mean
differences are reported. Cost-effectiveness was estimated using a bootstrap method to minimise
sampling uncertainty. Non-parametric bootstrap methods generate multiple replications of the statistic
of interest by sampling replications from the original data.58,59 A total of 1000 bootstrap samples were
drawn and incremental effectiveness (with associated 95% CIs) was calculated. Estimates from each
imputed data set were used to run regressions using Rubin’s rule.52
To express uncertainty around ICERs and to display results across a range of cost-effectiveness
thresholds, cost-effectiveness acceptability curves (CEACs) were generated on the basis of bootstrapped
sample data.60,61 These curves show the probability that CGM is cost-effective at different levels of the
threshold based on modelled variation in observed patient outcomes.62
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To determine cost-effectiveness, the use of CGMs was compared with standard care on the basis of the
cost per additional case of adequate glucose control (ICER). An alternative that is less effective and more
costly, on average, than one or a linear combination of other alternatives is considered ‘dominated’ in
health economic terms and, therefore, it is not considered when estimating ICERs. An alternative that is
more effective (i.e. provides the greatest additional adequate glucose control) and offers an ICER less than
or equal to a benchmark value (the cost-effectiveness threshold) can be deemed ‘cost-effective’ compared
with other alternatives.62 However, there are currently no published cost-effectiveness thresholds for the
primary and secondary clinical outcomes of the REACT trial.We searched the stated and revealed
preference literature to identify any external evidence with respect to population preferences for health
changes associated with adequate glucose control and for health changes associated with the secondary
clinical outcomes, and no such preference values were revealed. Therefore, ranges of hypothetical
cost-effectiveness threshold values have been selected for our analyses. As a result, the net monetary
benefit (NMB) of CGM compared with standard care was calculated across three predetermined
cost-effectiveness thresholds, namely £1000, £5000 and £10,000 per additional case of adequate
glucose control.63 Additionally, alternative cost-effectiveness threshold values were introduced for the
secondary outcome analyses (£10,000, £30,000 and £50,000 cost-effectiveness thresholds). A positive
incremental NMB indicates that the CGM is cost-effective compared with standard care at the given
cost-effectiveness threshold.
Sensitivity and secondary outcomes analyses
Several sensitivity analyses were carried out to assess the robustness of the cost-effectiveness
estimates. These were conducted under the following scenarios: (1) restricting the analyses to
complete cases (i.e. those with complete cost and outcome data for the 7 days or up to 36 weeks’
corrected gestation); and (2) estimating the incremental cost-effectiveness using different thresholds
of 60%, 70% and 90% for adequate glucose control. The same sensitivity analyses described above
were repeated over alternative follow-up periods of the first 7 days of life or extending to 36 weeks’
corrected gestational age.
Two sets of prespecified subgroup analyses were conducted to explore the heterogeneity in the
cost-effectiveness results. Subgroup analysis was performed for each study site and for two gestational
age groups: extremely preterm (i.e. < 28 weeks’ gestation) and very preterm (i.e. 28–32 weeks’ gestation).
A post hoc subgroup analysis was subsequently carried out using sex as an additional subgroup category.
All subgroup analyses were based on cases with imputed cost and outcomes data at 7 days or 36 weeks’
corrected gestational age.
Results of economic analysis
Table 35 in Appendix 4 shows the completeness of health economic data by treatment allocation.
The table shows that there were no missing data for resource use. Likewise, there were no missing
data for the items such as use of the MiniMed 640G 3.0-ml insulin pump device, Guardian 2 Link and
the Generation Enlite single sensor. Cases with data that were not available or not applicable are also
reported if trial participants were withdrawn from the intervention and/or trial.
Health-care resource use
Table 16 shows resource use values for participants by trial group allocation and resource use category
over the 7-day intervention period and the entire follow-up period for complete cases. The resource
values are presented for subcategories of resource use, including hospital inpatient medications,
investigation, medical treatment and surgical procedures. Use of Enlite sensors and glucose monitoring
was reported for the 7-day intervention period only, as infants used the devices for this period only.
Clinical recording of sensor glucose values was performed, on average, 121 times in infants in the
CGM arm, but was not performed in infants in the standard-care arm, as the clinical team was masked
to the sensor data.
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Glucose monitoring (number of
activities)
Glucose sensor insertion 1.17 (0.04) n/a
Glucose sensor monitoring 121.14 (4.56) n/a
Glucose sensor removal 1.17 (0.04) n/a
POC testing: used to calibrate




20.28 (1.05) 15.59 (0.91) 17.75 (0.71)
Length of stay (days) Intensive care 6.01 (0.23) 5.95 (0.23) 5.98 (0.16)
High-dependency care 0.96 (0.23) 0.87 (0.21) 0.91 (0.15)
Special care 0.01 (0.01) 0.08 (0.08) 0.05 (0.05)
Transitional care 0.00 (0.00) 0.00 (0.00) 0.00 (0.00)
Medications (days of use
during intervention period)
Inotropes 0.59 (0.17) 0.69 (0.17) 0.64 (0.12)
Antibiotics 4.61 (0.29) 4.48 (0.24) 4.54 (0.18)
Caffeine 6.73 (0.13) 6.69 (0.11) 6.71 (0.09)
Morphine 1.77 (0.31) 1.67 (0.27) 1.72 (0.20)
Corticosteroids 0.04 (0.03) 0.06 (0.04) 0.05 (0.02)
Insulin (ml/kg) Insulin 0.02 (0.00) 0.01 (0.00) 0.01 (0.00)
Investigations (number of
items)
Cranial ultrasound 2.25 (0.12) 2.27 (0.12) 2.26 (0.08)
Other ultrasound 0.01 (0.01) 0.04 (0.02) 0.03 (0.01)
CT 0.00 (0.00) 0.00 (0.00) 0.00 (0.00)
X-ray 3.79 (0.27) 4.34 (0.29) 4.08 (0.20)
EEG 0.00 (0.00) 0.00 (0.00) 0.00 (0.00)
MRI 0.00 (0.00) 0.00 (0.00) 0.00 (0.00)
Echocardiography 0.58 (0.12) 0.63 (0.09) 0.60 (0.07)
ECG 0.00 (0.00) 0.00 (0.00) 0.00 (0.00)
Blood transfusion products
(number of products)
Platelets 0.15 (0.06) 0.14 (0.05) 0.15 (0.04)
Red blood cells 0.63 (0.12) 0.76 (0.13) 0.70 (0.09)
Fresh-frozen plasma 0.08 (0.04) 0.07 (0.03) 0.08 (0.02)
Medical treatment (number of
treatments)
Lumbar punctures 0.11 (0.04) 0.11 (0.04) 0.11 (0.03)
Ventricular taps 0.00 (0.00) 0.00 (0.00) 0.00 (0.00)
Long lines 0.93 (0.07) 0.90 (0.09) 0.92 (0.06)
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(n= 83), mean (SE)
Total (n= 154),
mean (SE)
Surgical procedures (number of
procedures)
Ventriculoperitoneal shunts 0.01 (0.01) 0.00 (0.00) 0.01 (0.01)
Surgical procedures for
central access
0.01 (0.01) 0.01 (0.01) 0.01 (0.01)
Interventions for ROP
treatment
0.01 (0.01) 0.00 (0.00) 0.01 (0.01)
Other procedures 0.00 (0.00) 0.06 (0.03) 0.03 (0.02)
n= 71 n= 82 n= 153
Day 8 to 36 weeks’ corrected gestation
Length of stay (days) Intensive care 13.15 (1.64) 16.71 (1.83) 15.06 (1.24)
High-dependency care 25.06 (2.00) 24.8 (1.51) 24.92 (1.23)
Special care 16.55 (1.68) 15 (1.51) 15.72 (1.12)
Transitional care 0.44 (0.25) 0.22 (0.11) 0.32 (0.13)
Medication (ml) Insulin (ml/g) 0.004 (0.00) 0.003 (0.00) 0.00 (0.00)
Investigations (number of
items)
Cranial ultrasound 2.87 (0.29) 3.02 (0.20) 2.95 (0.17)
Other ultrasound 0.17 (0.08) 0.38 (0.20) 0.28 (0.11)
CT 0 (0.00) 0.01 (0.01) 0.01 (0.01)
X-ray 3.87 (0.58) 4.93 (0.65) 4.44 (0.44)
EEG 0 (0.00) 0.01 (0.01) 0.01 (0.01)
MRI 0.01 (0.01) 0.05 (0.02) 0.03 (0.01)
Echocardiography 0.96 (0.17) 1.18 (0.17) 1.08 (0.12)
ECG 0.04 (0.02) 0 (0.00) 0.02 (0.01)
Blood transfusion products
(number of products)
Platelets 0.07 (0.03) 0.04 (0.02) 0.05 (0.02)
Red blood cells 1.75 (0.25) 2.23 (0.30) 2.01 (0.20)
Fresh-frozen plasma 0.11 (0.05) 0.11 (0.05) 0.11 (0.04)
Medical treatment (number of
treatments)
Lumbar punctures 0.1 (0.04) 0.23 (0.06) 0.17 (0.04)
Ventricular taps 0.27 (0.07) 0.5 (0.13) 0.39 (0.08)
Long lines 0 (0.00) 0.04 (0.03) 0.02 (0.01)
Surgical procedures (number of
procedures)
Ventriculoperitoneal shunts 0.03 (0.02) 0.05 (0.02) 0.04 (0.02)
Surgical procedures for
central access
0 (0.00) 0.02 (0.02) 0.01 (0.01)
Interventions for ROP
treatment
0 (0.00) 0.01 (0.01) 0.01 (0.01)
Other procedures 0.01 (0.01) 0.07 (0.03) 0.05 (0.02)
Transfers to other hospital
(number by mode)
Air ambulance transfers 0 (0.00) 0.02 (0.02) 0.01 (0.01)
Road transfers 0.49 (0.06) 0.43 (0.05) 0.46 (0.04)
n/a, not applicable.
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Economic costs
Table 17 summarises the total NHS and PSS costs associated with resource use during days 1–7,
day 8 to 36 weeks’ corrected gestational age and the entire study period for complete cases. Table 18
breaks these costs down by subcategory. The mean direct intervention costs over the first 7 days
were £11,198 in the CGM arm and £9934 for the standard-care arm; the mean difference was not
statistically significant at the 5% level. The cost of using the Enlite sensor and glucose monitoring was
not included in the standard-care arm, as it is not part of standard care. The total cost during the
period covering day 8 to 36 weeks’ corrected gestational age was higher in the standard-care arm
(£61,065 vs. £65,464), but the difference was not statistically significant at the 5% level. The main
driver for the higher cost in the standard-care arm during the follow-up period was the higher cost
of neonatal care. Likewise, the mean total NHS and PSS cost throughout the entire follow-up period
was higher in the standard-care group (£75,348) than in the CGM group (£71,909), but the mean
between-group cost difference of –£3439 was not statistically significant at the 5% level.
Cost-effectiveness results
The cost-effectiveness results are presented in Tables 19 and 20 for days 1–7 and the entire study
period, respectively. The associated CEACs and cost-effectiveness scatterplots are graphically
represented in Figures 16–19.
Base-case analysis
Two base-case analyses were performed. The first was imputed 7-day intervention costs and cases of
adequate glucose control (see Table 19), with an 80% threshold selected for definition of adequate
glucose control. The second was imputed costs and cases of adequate glucose control (80% threshold),
but with costs extending to 36 weeks’ corrected gestational age and outcomes restricted to the
intervention period (see Table 20). For the first base-case analysis, trial participants in the CGM arm
experienced a statistically significant increase in cases of adequate glucose control based on 1000
bootstrap simulations (i.e. a 23 percentage-point increase in the rate of adequate glucose control)
during the first 7 days. The mean NHS and PSS costs (see Table 19) were also lower in the standard-care
group (mean cost difference £605). The ICER for the base-case analysis in Table 19 indicates that using
CGM is, on average, more costly and more effective than standard care. Assuming cost-effectiveness
thresholds of £1000, £5000 and £10,000 per additional case of adequate glucose control, the probability
of cost-effectiveness for CGM reaches 90% at approximately £6000 (see Figure 16), whereas the NMB
associated with use of a CGM became positive at a cost-effectiveness threshold of £5000 (see Table 19).
For the second base-case analysis (see Table 20), the trial participants in the CGM arm experienced
lower costs (mean cost difference –£2877) and a 23 percentage-point increase in cases of adequate
glucose control, as before. CGM was not only less costly, but also the more effective strategy in
this second base-case analysis and, therefore, dominant in health economic terms. To summarise,
the base-case analyses reported in Table 20 show that CGM is the dominant strategy in health
economics terms.
Sensitivity analyses
It was found that the cost-effectiveness results from the sensitivity analyses using different analytical
scenarios (i.e. complete case and imputed costs with 60%, 70% and 90% thresholds selected for
definitions of additional adequate glucose control) generally supported the base-case findings.
In the complete-case analysis (see Table 19), mean costs were higher in the CGM arm (mean cost
difference £1104, 95% CI –£38.56 to £2247.11) than in the standard-care arm. The effectiveness
results followed the same pattern as that of the base-case analysis and showed that participants
in the CGM arm experienced a statistically significant increase in the proportion of glucose readings
within the target range over the 7-day intervention period (0.22, 95% CI 0.05 to 0.4). For the four
sets of sensitivity analyses (see Table 19), the probabilities of cost-effectiveness of using CGM
reach approximately 90% at cost-effectiveness thresholds of £10,000. Adopting 60%, 70% and 90%
thresholds for proportions of glucose readings within the target ranges, the costs for each group
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(n= 83), mean (SE) Total (n= 154), mean (SE) Mean difference Parametric 95% CI p-value Bootstrapped 95% CI
Days 1–7
Equipment 87 (2) n/a n/a n/a n/a n/a n/a
Monitoring 165 (6) n/a n/a n/a n/a n/a n/a
POC testing 6 (0.3) 5 (0.3) 5 (0.2) 1.4 0.6 to 2.2 0.001 0.6 to 2.2
Length of stay 8656 (97) 8534 (132) 8590 (84) 121 –213 to 455 0.5 –172 to 482
Medications 79 (2) 77 (1) 78 (1) –2.8 –2.8 to 5.3 0.5 –3.3 to 4.9
Investigation 571 (31) 630 (33) 603 (23) –59 –148 to 31 0.2 –148 to 32
Blood transfusion products 2 (2) 35.7 (34) 20 (19) –14 –63 to 35 0.4 –68 to 35
Medical treatment 92 (17) 106 (18) 100 (12) 17 –153 to 186 0.6 –139 to 196
Surgical procedures 544 (57) 527 (62) 535 (43) –34 –108 to 39 0.8 –132 to 2
Other procedures 2 (2) 36 (34) 20 (19) –34 –108 to 39 0.4 –144 to 3






(n= 82), mean (SE) Total (n= 153), mean (SE) Mean difference Parametric 95% CI p-value Bootstrapped 95% CI
Day 8 to 36 weeks’ corrected gestational age
Length of stay 59,901 (2296) 62,807 (2059) 61,458 (1533) –2906 –8983 to 3170 0.3 –9020 to 2400
Medication: insulin only 0.3 (0.1) 0.2 (0.1) 0.2 (0.1) 0.1 –0.1 to 0.4 0.2 –0.1 to 0.4
Investigation 677 (76) 841 (97) 765 (63) –165 –414 to 84 0.2 –443 to 53
Blood transfusion products 222 (34) 279 (39) 252 (26) –57 –161 to 47 0.3 –157 to 52
Medical treatment 244 (64) 531 (105) 398 (65) –287 –540 to –35 0.03 –535 to –65
Surgical procedures 20 (14) 909 (837) 496 (449) –889 –2667 to 889 0.3 –3289 to –21
Other procedures 0 (0) 94 (62) 50 (33) –94 –225 to 38 0.2 –244 to –5
Mode of transfers 2.8 (0.4) 3.6 (1) 3.2 (0.6) –0.8 –3.1 to 1.4 0.5 –3.3 to 0.8


















































































































































































































































































































































(n= 81), mean (SE) Total (n= 150), mean (SE) Mean difference Parametric 95% CI p-value Bootstrapped 95% CI
Entire study period
Equipment 87 (2) n/a n/a n/a n/a n/a n/a
Monitoring 165 (6) n/a n/a n/a n/a n/a n/a
POC testing 5.8 (0.3) 4.5 (0.3) 5.1 (0.2) 1.3 0.5 to 2.1 0.002 0.6 to 2.2
Length of stay 68,144 (2563) 71,273 (2101) 69,833 (1636) –3129 –9616 to 3358 0.3 –9577 to 3043
Medications 79 (2) 78 (1) 78 (1) –2.7 –2.7 to 5.5 0.5 –3 to 5.5
Investigation 1260 (94) 1471 (115) 1374 (76) –212 –513 to 89 0.2 –505 to 88
Blood transfusion products 320 (49) 387 (53) 356 (36) –67 –211 to 78 0.4 –203 to 71
Medical treatment 798 (99) 1062 (131) 941 (85) –264 –598 to 70 0.1 –587 to 45
Surgical procedures 1047 (994) 939 (848) 989 (645) 109 –2457 to 2674 0.9 –2313 to 3007
Other procedures 2 (2) 131 (72) 72 (39) –130 –284 to 25 0.1 –294 to –7
Mode of transfers 2.8 (0.4) 3.6 (1) 3.3 (0.6) –0.8 –3.1 to 1.5 0.5 –3.2 to 1
Total 71,910 (2779) 75,348 (2476) 73,767 (1849) –3439 –10,645 to 2939 0.4 –10,774 to 3896
n/a, not applicable.
Reprinted from Seminars in Perinatology, vol. 45, Petrou S, Kim S, Bond S, Allison A, Beardsall K, the REACT collaborative, Cost-effectiveness of real time continuous glucose monitoring


































































TABLE 18 Randomised controlled trial: cost (£) differences between trial arms
Cost Item
CGM arm (n= 71),
mean (SE)
Standard-care arm












MiniMed 640G 14 (0) n/a n/a n/a n/a n/a n/a
Guardian 2 Link 9 (0) n/a n/a n/a n/a n/a n/a
Generation Enlite single sensor:
MMT-7008B
64 (2.4) n/a n/a n/a n/a n/a n/a
Glucose monitoring Enlite sensor insertion 6 (0.2) n/a n/a n/a n/a n/a n/a
Enlite sensor monitoring 157 (6) n/a n/a n/a n/a n/a n/a
Enlite sensor removal 2.5 (0.1) n/a n/a n/a n/a n/a n/a
POC testing Nova Biomedical StatStrip
meter for calibration of
640G device
5.9 (0.3) 4.5 (0.3) 5.1 (0.2) 1.4 0.6 to 2.2 0.001 0.6 to 2.1
Length of stay Intensive care 7788 (304) 7708 (297) 7745 (212) 81 –762 to 923 0.9 –720 to 810
High-dependency care 859 (205) 778 (188) 816 (138) 81 –467 to 629 0.8 –416 to 648
Special care 8 (8) 49 (49) 30 (27) –41 –146 to 65 0.4 –167 to 17
Transitional care 0 (0) 0 (0) 0 (0) 0
Medications Inotropes 0.1 (0.0) 0.1 (0.0) 0.1 (0.0) 0 –0.1 to 0 0.7 –0.1 to 0.1
Antibiotics 3.5 (0.2) 3.4 (0.2) 3.4 (0.1) 0.1 –0.5 to 0.6 0.7 –0.5 to 0.6
Caffeine 74 (1.5) 73 (1.2) 74 (0.9) 0.5 –3.3 to 4.3 0.8 –3.4 to 4.1
Morphine 0 (0) 0 (0) 0 (0) 0 0 to 0 0.8 0 to 0.0
Corticosteroids 0 (0) 0 (0) 0 (0) 0 0 to 0 0.7 0 to 0.0













































































































































































































































































































































TABLE 18 Randomised controlled trial: cost (£) differences between trial arms (continued )
Cost Item
CGM arm (n= 71),
mean (SE)
Standard-care arm









Investigations Cranial ultrasound 159 (9) 160 (8) 160 (6) –0.8 –25 to 23 0.9 –27 to 23
Other ultrasound 1 (1) 2.6 (1.5) 1.8 (0.9) –1.6 –5 to 2 0.4 –4.9 to 2.1
CT 0 (0) 0 (0) 0 (0) 0
X-rays 360 (25) 412 (27) 388 (19) –52 –127 to 22 0.2 –121 to 25
EEG 0 (0) 0 (0) 0 (0) 0
MRI 0 (0) 0 (0) 0 (0) 0
Echocardiography 51 (10) 55 (8) 53 (6) –4 –30 to 21 0.7 –30 to 22
ECG 0 (0) 0 (0) 0 (0) 0
Blood transfusion
products
Platelets 14 (5) 13 (4) 14 (3) 0.9 –13 to 14 0.9 –12 to 14
Red blood cells 76 (14) 91 (15) 84 (10) –15 –56 to 26 0.5 –52 to 28
Fresh-frozen plasma 2.4 (1.1) 2.1 (0.8) 2.2 (0.7) 0.3 –2.3 to 3 0.8 –2 to 3.4
Medical (surgical)
treatments
Lumbar puncture 148 (50) 143 (51) 145 (36) 6 –136 to 147 0.9 –137 to 149
Ventricular tap 0 (0) 0 (0) 0 (0) 0
Long line 396 (30) 385 (40) 390 (25) 11 –89 to 111 0.8 –93 to 92
Surgical procedures Interventions for ROP
treatment
10 (10) 0 (0) 4.5 (4.5) 10 –8 to 28 0.3 0 to 36
Surgical procedures for central
access
22 (22) 19 (19) 20 (14) 3 –53 to 59 0.9 –51 to 65
Ventriculoperitoneal shunts 967 (967) 0 (0) 446 (446) 967 –799 to 2732 0.3 0 to 3550
Other procedures 1.5 (1.5) 36 (34) 20 (19) –34 –108 to 39 0.4 –144 to 2.6



































































CGM arm (n= 71),
mean (SE)
Standard-care arm









Day 8 to 36 weeks’ corrected gestational age
Length of stay Intensive care 17,036 (2119) 21,636 (2368) 19,501 (1611) –4600 –10,962 to 1762 0.2 –10,885 to 1774
High-dependency care 22,476 (1791) 22,250 (1352) 22,355 (1099) 226 –4143 to 4594 0.9 –3824 to 4645
Special care 9549 (970) 8655 (874) 9070 (648) 894 –1679 to 3467 0.5 –1649 to 3617
Transitional care 10,840 (1160) 10,266 (1037) 10,533 (772) 575 –2491 to 3640 0.7 –2274 to 3952
Medications Insulin 0.3 (0.1) 0.2 (0.1) 0.2 (0.1) 0.1 –0.1 to 0.4 0.2 –0.1 to 0.4
Investigations Cranial ultrasound 203 (21) 214 (14) 209 (12) –11 –59 to 38 0.7 –58 to 38
Other ultrasound 12 (6) 27 (14) 20 (8) –15 –46 to 17 0.4 –48 to 12
CT 0 (0) 1.4 (1.4) 0.8 (0.8) –1.4 –4.4 to 1.6 0.4 –6.1 to 0
X-ray 368 (56) 468 (61) 422 (42) –100 –266 to 66 0.2 –256 to 66
EEG 0 (0) 15 (15) 8.2 (8.2) –15 –48 to 17 0.4 –58 to 0
MRI 3.3 (3.3) 11 (6) 7.6 (3.4) –8 –21 to 5.2 0.2 –22 to 3.9
Echocardiography 85 (15) 104 (15) 95 (11) –20 –62 to 23 0.4 –60 to 24
ECG 5.6 (3.2) 0 (0) 2.6 (1.5) 5.6 –0.3 to 12 0.06 0 to 14
Blood transfusion
products
Platelets 10 (4.6) 9.9 (4.7) 10 (3.3) 0.3 –13 to 13 1.0 –14 to 13
Red blood cells 210 (31) 268 (36) 241 (24) –58 –154 to 37 0.2 –164 to 31
Fresh-frozen plasma 2 (0.9) 1 (0.6) 1.5 (0.5) 1 –1.1 to 3 0.4 –1 to 3.3
Medical (surgical)
treatments
Lumbar puncture 130 (47) 305 (80) 224 (49) –175 –366 to 16 0.07 –380 to –11
Ventricular tap 114 (32) 213 (55) 167 (33) –99 –230 to 33 0.1 –246 to 3.8













































































































































































































































































































































TABLE 18 Randomised controlled trial: cost (£) differences between trial arms (continued )
Cost Item
CGM arm (n= 71),
mean (SE)
Standard-care arm









Surgical procedures Interventions for ROP treatment 20 (14) 34 (17) 27 (11) –14 –58 to 29 0.5 –60 to 28
Surgical procedures for central
access
0 (0) 38 (26) 20 (14) –38 –93 to 19 0.2 –106 to 0
Ventriculoperitoneal shunts 0 (0) 837 (837) 449 (449) –837 –2615 to 941 0.4 –3566 to 0
Other procedures 0 (0) 93.7 (62) 50 (33) –94 –225 to 38 0.2 –241 to –5.3
Mode of transfers Air ambulance 0 (0) 0.9 (0.6) 0.5 (0.3) –0.9 –2.5 to 0 0.2 –2.2 to 0.5
Road 2.8 (0.4) 2.7 (0.5) 2.7 (0.3) 0.1 –1.3 to 1.5 0.9 –1.2 to 1.5
Total 61,065 (2376) 65,464 (2381) 63,423 (1690) –4399 –11,080 to 2283 0.2 –10,972 to 2187
Cost Item
CGM arm (n= 69),
mean (SE)
Standard-care arm












MiniMed 640G System 14 (0) n/a n/a n/a n/a n/a n/a
Guardian 2 Link 9 (0) n/a n/a n/a n/a n/a n/a
Generation Enlite single sensor
MMT-7008B
64 (2.4) n/a n/a n/a n/a n/a n/a
Glucose monitoring Enlite sensor insertion 6.1 (0.2) n/a n/a n/a n/a n/a n/a
Enlite sensor monitoring 157 (6) n/a n/a n/a n/a n/a n/a
Enlite sensor removal 2.5 (0.1) n/a n/a n/a n/a n/a n/a
POC testing Nova Biomedical StatStrip meter
for calibration of 640G device
5.8 (0.3) 4.5 (0.3) 5.1 (0.2) 1.3 0.5 to 2.1 0.002 0.5 to 2
Length of stay (days) Intensive care 25,149 (2273) 29,433 (2480) 27,463 (1702) –4284 –11,021 to 2452 0.2 –11,182 to 1828
High-dependency care 23,439 (1782) 22,946 (1339) 23,173 (1089) 494 –3839 to 4826 0.8 –3381 to 4696
Special care 8973 (998) 8669 (890) 8809 (662) 304 –2331 to 2938 0.8 –2138 to 2963



































































CGM arm (n= 69),
mean (SE)
Standard-care arm









Medications Inotropes 0.1 (0) 0.1 (0) 0.1 (0) 0 –0.1 to 0.1 0.7 –0.1 to 0.1
Antibiotics 3.5 (0.2) 3.4 (0.2) 3.4 (0.1) 0.1 –0.5 to 0.6 0.8 –0.5 to 0.7
Caffeine 74 (1.5) 73 (1.3) 74 (1) 0.5 –3.4 to 4.4 0.8 –4.2 to 4
Morphine 0 (0) 0 (0) 0 (0) 0 0 to 0 0.9 0 to 0
Corticosteroids 0 (0) 0 (0) 0 (0) 0 0 to 0 0.7 0 to 0
Insulin 1.5 (0.3) 0.6 (0.1) 1 (0.2) 0.8 0.2 to 1.6 0.01 0.2 to 1.5
Investigations Cranial ultrasound 365 (24) 375 (19) 370 (15) –9.7 –70 to 50 0.8 –65 to 58
Other ultrasound 13 (6.2) 30 (15) 22 (8.5) –16 –50 to 17 0.3 –57 to 8.3
CT 0 (0) 1.4 (1.4) 0.8 (0.8) –1.4 –4.5 to 1.6 0.4 –5 to 0
X-ray 734 (67) 877 (79) 811 (53) –143 –352 to 65 0.2 –336 to 55
EEG 0 (0) 16 (16) 8.4 (8.4) –16 –49 to 18 0.4 –53 to 0
MRI 3.4 (3.4) 12 (5.6) 7.7 (3.4) –8.1 –22 to 5.4 0.2 –21 to 3.7
Echocardiography 138 (21) 161 (20) 151 (15) –23 –81 to 35 0.4 –81 to 33
ECG 5.8 (3.3) 0 (0) 2.7 (1.5) 5.8 –0.2 to 12 0.06 1.8 to 14
Blood transfusion
products
Platelets 258 (8.7) 23 (7.9) 24 (5.8) 1.5 –22 to 25 0.9 –20 to 25
Red blood cells 290 (42) 360 (48) 328 (32) –70 –198 to 58 0.3 –203 to 47
Fresh-frozen plasma 4.5 (1.4) 3.2 (1) 3.8 (0.8) 1.4 –1.9 to 4.7 0.4 –1.6 to 5.4
Medical (surgical)
treatments
Lumbar puncture 286 (76) 455 (104) 377 (66) –169 –431 to 93 0.2 –432 to 74
Long line 512 (50) 594 (72) 556 (45) –82 –262 to 98 0.4 –266 to 64













































































































































































































































































































































TABLE 18 Randomised controlled trial: cost (£) differences between trial arms (continued )
Cost Item
CGM arm (n= 69),
mean (SE)
Standard-care arm









Surgical procedures Interventions for ROP treatment 30 (17) 35 (17) 33 (12) –4 –52 to 44 0.9 –54 to 42
Surgical procedures for central
access
22 (22) 57 (42) 41 (25) –35 –134 to 64 0.5 –143 to 47
Ventriculoperitoneal shunts 995 (995) 847 (847) 915 (645) 147 –2418 to 2713 0.9 –1716 to 3269
Other procedures 1.5 (1.5) 131 (72) 72 (39) –130 –284 to 25 0.10 –319 to –8.4
Mode of transfers Air ambulance 0 (0) 0.9 (0.6) 0.5 (0.3) –0.9 –2.2 to 0.4 0.2 –2.6 to 0
Road 2.8 (0.4) 2.8 (0.5) 2.8 (0.3) 0.1 –1.3 to 1.5 0.9 –1.5 to 1.4
Total costs 71,910 (2779) 75,348 (2476) 73,766.5 (1849) –3439 –10,645 to 2939 0.4 –10,774 to 3896
n/a, not applicable.
Note
Data presented by follow-up period and resource category for participants with complete data (2017 prices).
Reprinted from Seminars in Perinatology, vol. 45, Petrou S, Kim S, Bond S, Allison A, Beardsall K, the REACT collaborative, Cost-effectiveness of real time continuous glucose monitoring
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Stratification by gestational age at birth
Extremely preterm
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Secondary analysis










































a Subgroup analysis by site could not be performed for Oxford (N36), Surrey (N74), Barts (N85), Bristol (N86), Leeds (N87), Leicester (N88) or Barcelona (SP3) because of insufficient number of observations.
Reprinted from Seminars in Perinatology, vol. 45, Petrou S, Kim S, Bond S, Allison A, Beardsall K, the REACT collaborative, Cost-effectiveness of real time continuous glucose monitoring to target glucose
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Stratification by gestational age at birth
Extremely preterm
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a Subgroup analysis by site could not be performed for Oxford (N36), Surrey (N74), Barts (N85), Bristol (N86), Leeds (N87), Leicester (N88) or Barcelona (SP3) because of insufficient number of observations.
Reprinted from Seminars in Perinatology, vol. 45, Petrou S, Kim S, Bond S, Allison A, Beardsall K, the REACT collaborative, Cost-effectiveness of real time continuous glucose monitoring to target glucose
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FIGURE 16 Randomised controlled trial: (a) CEAC and (b) scatterplot at intervention period for 80% threshold of
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FIGURE 17 Randomised controlled trial (a) CEAC and (b) scatterplot at intervention period for 80% threshold of
adequate glucose control, complete case and covariate adjusted. (continued )
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FIGURE 17 Randomised controlled trial (a) CEAC and (b) scatterplot at intervention period for 80% threshold of






















































FIGURE 18 Randomised controlled trial: (a) CEAC and (b) scatterplot over entire follow-up period for 80% threshold of
adequate glucose control, imputed and covariate adjusted.
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remained similar, with £10,354 for the CGM group and £9749 for the standard-care group, but
effectiveness varied. However, the pattern of increased effectiveness of CGM remained consistent
across the scenarios when using different levels of adequate glucose thresholds. The results presented
in Table 20 support this finding. The notable difference is that CGM becomes the dominant strategy in
health economic terms in the sensitivity analyses (see Table 20) because of the lower costs of CGM
compared with standard care. In brief, the sensitivity analyses generally support the findings of the
base-case analyses.
Subgroup analyses
Subgroup analyses were performed using the variables of site, gestational age and sex. A few study
sites were dropped because the number of observations was insufficient. In all study sites presented
in Table 19, effectiveness was greater in the CGM arm than in the standard-care arm and costs were
also higher [except in site N42 (Norwich)] than in the standard-care group. Subgroup analyses based
on gestational age at birth and sex demonstrated the same pattern, that is that costs and effectiveness
were generally higher in the CGM arm than in the standard-care arm. Another notable finding was
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FIGURE 19 Randomised controlled trial: (a) CEAC and (b) scatterplot at entire follow-up period over 80% threshold of
adequate glucose control, complete case and covariate adjusted.
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Secondary outcome analyses
Secondary outcome analyses were performed using the two outcomes of NEC and BPD. For these
outcomes, increased effectiveness can be interpreted as reduced cases of NEC and BPD and, hence,
the denominator of the ICER has been inverted. The secondary outcome analyses revealed that, when
the analysis is restricted to the 7-day intervention period, CGM averts more cases of BPD and NEC,
but with higher costs, than standard care. Different cost-effectiveness threshold values were adopted
for the secondary outcome analyses, namely £10,000, £30,000 and £50,000. The secondary outcomes
displayed in Table 20 show that the probability of cost-effectiveness of CGM reached 80% at a
£10,000 cost-effectiveness threshold. In the secondary analyses reported in Table 19, mean costs were
higher in the CGM arm (mean cost difference £605, 95% CI –£379 to £1589) than the standard-care
arm. When valued over a time horizon extending to 36 weeks’ corrected gestational age (see Table 20),
the effectiveness followed the same pattern as the base-case analysis, but the costs were lower for
CGM (mean cost difference –£2877, 95% CI –£10,026 to £4272) than standard care, making CGM
dominant in health economic terms.
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Chapter 6 REACT trial discussion
Discussion
This study demonstrates that CGM can be used to guide the use of insulin in preterm infants. The
use of CGM leads to a reduction in exposure to hyperglycaemia and is also associated with a lower
incidence of prolonged periods of hypoglycaemia. Previous studies found that the use of insulin in
preterm infants led to an increased risk of hypoglycaemia, which was often clinically silent.21,64
In contrast, this study showed that CGM allowed the safe titration of insulin, as well as highlighting
clinically silent episodes of hypoglycaemia, in the standard-care group.
The strength of the study is that our findings on glucose exposure are not biased by the frequency
of blood glucose sampling, as continuous data were available in both study arms. The accuracy of
CGM at low glucose thresholds and the potential impact of glucose levels used for calibration remain
controversial. However, CGM provides more detailed data on both glucose variability and the duration
of exposure to any given target level, and it is increasingly apparent that these two parameters are
more important than any prespecified threshold. Further analyses will be undertaken to explore the
relationship between sensor and blood glucose levels in the trial.
The study highlights the wide variation in patterns of glucose control between infants and the
significant difficultly for clinical staff in managing these infants with infrequent intermittent blood
glucose monitoring. Furthermore, it demonstrates the challenges for staff in designing simple clinical
guidelines for management of glucose control when the responses to interventions can be so varied.
Comparison of mean daily sensor glucose and insulin infusion rates suggests that CGM led to earlier
use of insulin, which prevented the early rise in glucose levels. Those in the standard-care arm received
similar total levels of insulin during the intervention period but insulin was infused in the second half
of the week and was associated with higher glucose levels. The significant interaction effects between
treatment and both sex and first sensor glucose value are in keeping with expectations from clinical
practice. This suggests that the most significant benefits are achieved in male infants and those with
higher early glucose levels. The underlying pathophysiology driving this warrants further investigation.
The effect size is small, but similar to the clinically important difference of 10% that was prespecified
in the sample size calculation. The effect size may have been limited by a number of factors, including
compliance with the guideline for standard care, number of CGM data and improvements in standard
care over time. In this context, in the CGM group, the sensor glucose level was recorded on the
CRF > 90% of the time; however, the percentage of time during which the rate of insulin infusion
was recorded when the glucose was > 8 mmol/l was only 54%. This may be because the guideline
was designed to support clinical management, not to be a strict protocol. It may reflect the clinical
team choosing to change rates of dextrose infusion rather than starting insulin. Alternatively, in some
units that recruited only a few infants, proactive use of the CGM data and guideline was limited by
the nature of intensive care (i.e. where the study outcomes are dependent on a large number of
clinical staff being confident to deliver the study intervention over a 24-hour period). Increased use
in these units may have led to further increases in time in target range, with increasing confidence in
the accuracy of the sensor glucose level and the potential benefits of a more proactive approach
allowing even better targeting of glucose control.
However, an increase from this level is remarkable, given the higher than predicted percentage of time
within the target range of 84% (from 58% in initial masked data and 78% in the feasibility trial). This
increase in time in the target range in the standard-care arm may be the result of changes in clinical
practice either unrelated or related to the study. An increased emphasis placed on the importance of
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glucose control while undertaking the trial may well have had an impact on the care of infants in the
standard-care arm, a common phenomenon in the setting of a RCT.
Although not powered for clinical outcomes, a number of exploratory outcomes were explored. There
were more deaths in the standard-care arm than in the CGM arm (6% vs. 2%), but the difference did
not reach statistical significance. It was anticipated that the use of CGM might lead to increased insulin
treatment and nutritional intake, and therefore have an impact on growth. However, there were no
differences between study arms in total insulin infusion rates or nutritional intakes over the first week
of life, and there were no differences in growth parameters. More infants in the standard-care arm
(12%) than in the CGM arm (5%) required surgery for PDA, but the difference did not reach statistical
significance and might be related to differences in fluid management. In the case of the exploratory
outcome of incidence of NEC, CGM was associated with significantly reduced risk (OR 0.33, 95% CI
0.13 to 0.78; p = 0.01), with 28% of infants in the standard-care arm being diagnosed with NEC, compared
with 13% of infants in the CGM arm. There is evidence to link hyperglycaemia with increased risk of
microbial gut translocation.65 However, larger studies would be needed to confirm such a link.
Compared with the feasibility study, more difficulties with initial insertion and sensor calibration were
experienced in this trial.1 This was initially thought to be because of the lack of experience of the
procedure in the sites. Although site training was undertaken, and staff were provided with an online
training video and a 24-hour helpline, it was challenging to support staff remotely. This was particularly
the case given that this new procedure needed to be undertaken within a short, time-critical window
after birth. The MiniMed 640G System and Enlite sensor are not specifically designed for neonatal use
and this presents challenges to their use in this setting. The inserter provided cannot be used because
of the small amount of subcutaneous tissue in preterm infants as the normal insertion angle of 90°
would result in the needle passing through the subcutaneous tissue into muscle and other tissues below.
The rate of successful insertion varied between centres. It was difficult for some individuals to gain
significant experience and confidence within a study setting when undertaking a procedure infrequently.
In discussion with Medtronic plc, it was suggested that the introducer itself plays a role in optimising the
condition of the sensor after insertion by ensuring a rapid and smooth insertion technique.
Furthermore, because of the display of error codes on the MiniMed 640G System, it was difficult to always
be clear as to the primary reason for ‘sensor failure’ and whether this was failure of insertion or a calibration
error. There were substantially more calibration errors with the MiniMed 640G System than with the
Paradigm Veo System (used in the feasibility study). This was discussed and reviewed in collaboration with
Medtronic plc. A number of changes to the MiniMed 640G System algorithm were made to improve safety
and increase accuracy at low threshold. These included (1) the use of artefact detection, such that signal dips
that were deemed to not reflect true physiological glucose levels were filtered by the algorithm; (2) changes
to signal threshold limits, which is the allowable range of interstitial signal that the algorithm can use; and
(3) reduction in the calibration ratio limit (i.e. the difference between blood glucose and the sensor glucose).
These factors, combined with the introduction of a lockout following two consecutive error codes during
calibration, led to increased reports of failure to calibrate and loss of sensor data.
Lessons learned included the fact that the increased calibration error rate seen in some infants
(particularly in the first 24 hours after birth) may have been because of high glucose variability and not
failed sensor insertion. In some infants, the sensor was demonstrated to benefit from additional ‘wetting
time’ to be able to generate sufficient signal for a reading. In both situations, allowing additional time for
the sensor to settle in, either a few hours or, in the study setting, overnight, led to successful calibration
and further monitoring. This is similar to the situation in lipodystrophy patients, in whom more time
may be required prior to the first calibration to allow for ‘wetting’ of the sensor. In addition, staff
were advised to avoid calibration when glucose levels were changing rapidly or immediately after one
calibration error. This was counterintuitive in an intensive care setting, but prevented sensor lockout.
There were more deaths in the standard-care arm than in the CGM arm (six vs. two), but the difference
did not reach statistical significance. Importantly, there were no SAEs related to the use of the devices in
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this extremely vulnerable population or related to episodes of infection at the sensor site. Despite the
challenges for staff of undertaking the paperwork required for such a trial, both staff and parents reported
that they felt that CGM improved clinical care. The inclusion of a number of centres in both the UK and
Europe make these results generalisable to a range of neonatal units that care for extremely preterm infants.
Limitations of the study include potential bias to study recruitment resulting from a short recruitment
window of 24 hours, meaning that many infants’ parents were not approached. This may have biased
the study towards infants born in the local recruiting centre. We were unable to blind staff to the
study intervention, but compliance with blinding of the CGM data in the standard-care arm was good.
The lack of data for a number of infants could also lead to bias, but there was no significant difference
in the outcomes based on full analysis and per-protocol populations, suggesting that the findings are
robust. The study was limited by its dependence on a large number of clinical staff being confident
to deliver the study intervention throughout a 24-hour period. Rapid developments in sensor and
Bluetooth® technology (Bluetooth Special Interest Group, Kirkland, WA, USA), newer generations of
sensors that do not require calibration and centralised platforms for closed-loop insulin delivery may
further support the use of CGM in these infants.
Interpretation of the results of the economic evaluation was constrained by an absence of external
evidence, either from external guidelines, or from stated or revealed preference studies, on economic
values associated with health changes resulting from adequate glucose control or for health changes
associated with the secondary clinical outcomes. Consequently, our assessments of cost-effectiveness
rely on hypothetical cost-effectiveness threshold values for improvements in the relevant clinical
outcomes. Furthermore, the economic evaluation was limited to the time horizon of the trial, extending
to 36 weeks’ corrected gestational age. The effects of CGM for targeting glucose control in neonates
on longer-term economic costs and health consequences, including its potential to prevent the
sequelae of NEC and BPD, remain a topic for future research.
In conclusion, this study demonstrates that CGM can safely guide the use of insulin and lead to a
reduction in exposure to hyperglycaemia in extremely preterm infants. In addition, CGM is associated
with a high probability of cost-effectiveness. Despite challenges, both staff and parents reported that
they felt that CGM improved the clinical care of these infants. Further studies will be important to
evaluate the longer-term impact of targeting glucose control on clinical outcomes.
The trial results in context
This study is in keeping with previous studies that have used CGM in the newborn population to monitor
glucose levels and has highlighted clinically silent episodes of both hyperglycaemia and hypoglycaemia.37,66
However, previous studies of CGM in infants have been much smaller, single centre and included a very
small number of extremely preterm infants. These infants are those known to be most at risk of glucose
dysregulation, in whom glucose control is most challenging and who have the highest risk of mortality and
morbidity. It is these infants in whom any intervention has the potential to have the most clinical impact
(on both morbidity and mortality). In this context, the higher rate of NEC in the standard-care group
than in the CGM group, alongside evidence to link hyperglycaemia with increased risk of microbial gut
translocation, warrants further investigation,65 with larger studies needed to confirm such a link.
This study demonstrates that CGM can safely guide the use of insulin and lead to a reduction in
exposure to hyperglycaemia without increasing the risk of hypoglycaemia in extremely preterm infants.
The international multicentre design of this study suggests that the intervention can be safely applied
across a range of practices considered as standard neonatal care and outside centres specialising in
using CGM. Despite challenges, both staff and parents reported that they felt that the use of CGMs
improved the clinical care of these infants. Further studies will be important to evaluate the longer-
term impact of targeting glucose control on clinical outcomes.
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Chapter 7 Closed-loop study
Introduction
The wide variation in individual insulin sensitivity and limited staff resources within intensive care make
it challenging for the full potential of CGMs to be realised.1 Adaptive computerised algorithms utilising
blood glucose measurements have been evaluated in adults67–69 and neonates undergoing intensive
care.37,70 The addition of frequent glucose levels obtained by CGM allows the development of closed-
loop systems, as recently investigated in adult intensive care patients.71,72 This study hypothesised that
closed-loop insulin delivery, based on subcutaneous CGM, could be more effective in targeting glucose
control in extremely preterm infants than CGM with insulin therapy and a guideline.
Aim
To pilot the use of a closed-loop system for glucose control using CGM.
Methods
Study design
This was a single-centre feasibility study in infants recruited from the NICU at the Cambridge
University Hospitals NHS Foundation Trust. All parents of eligible infants admitted to the unit
within 48 hours of birth were approached (if a member of the research team was available to do so).
The study applied a randomised open-label parallel design, with infants randomised to CGM alone
supported by a guideline or to CGM with an additional intervention period of closed-loop CGM.
Research Ethics Committee approval and informed written parental consent were obtained prior to
study procedures. Eligibility criteria included birthweight ≤ 1200 g and aged ≤ 48 hours. Infants were
excluded if they had a major congenital malformation or an underlying metabolic disorder, or if the
mother’s pregnancy had been complicated by diabetes. Criteria were chosen based on previous data
that identified these infants as at most risk of glucose dysregulation, while avoiding potential bias.21
A real-time CGM device was inserted in all infants and remained in situ for up to 7 days. The guideline
advised on the use of insulin or additional dextrose support. For a prespecified period of 24 hours,
between 48 and 72 hours post birth, a closed-loop system controlled glucose in infants during the
closed-loop intervention, whereas infants in the control group continued to receive CGM alongside
the guideline. This window for closed-loop intervention was preselected to be a standard time from
birth in all infants to allow time for informed parental consent to be obtained and because previous
data (from masked CGMs) had shown this to be the time when hyperglycaemia is most prevalent.21
Randomisation applied the minimisation methods using the Minim randomisation software (version 1,
London School of Hygiene and Tropical Medicine, London, UK), with stratification according to
gestational age and birthweight.
Common study procedures
With the exception of glucose control over the prespecified period, all other aspects of care were identical
between treatment groups. Blood glucose monitoring was undertaken on the POC glucose StatStrip
meter. Actrapid® insulin (Novo Nordisk, Bagsværd, Denmark) at a concentration of 25 units/kg in 50 ml of
0.9% saline was used in both treatment groups. For CGM, an Enlite sensor was inserted by hand into the
lateral thigh of each infant and linked to the Paradigm Veo for display of the sensor glucose concentration.
Outside the intervention period (48–72 hours), CGM data were used in combination with the guideline by
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the clinical team to guide glucose control in all infants. Nurses calibrated the CGM device at least once
every 12 hours, with a blood glucose measurement taken on the POC glucose StatStrip meter.
Paper guideline
The guideline for insulin delivery has previously been described.1 It provided guidance based on
the absolute sensor glucose value, as well as glucose trends. If sensor glucose levels are outside the
target range, the guideline recommends review of clinical care and the dextrose infusion rate, and
that modification of insulin delivery be considered, which could be instigated by the nurse at cotside.
The insulin and dextrose were delivered by Alaris™ pumps (CareFusion, San Diego, CA, USA).
Closed-loop glucose control between 48 and 72 hours
The closed-loop system comprised (1) an Enlite sensor, (2) a laptop computer running a model
predictive control algorithm and (3) two Alaris syringe pumps. We used a control algorithm based on
the model predictive control approach,71,72 optimised and tuned in silico using a computer simulation
environment validated for glucose control in the critically ill,73 aiming to keep sensor glucose levels
between 4 and 8 mmol/l. The algorithm calculated insulin requirements or, at low glucose values,
20% dextrose infusion rates based on real-time sensor glucose values. A study nurse entered sensor
glucose values into the laptop and modified insulin and dextrose pumps, as directed by the control
algorithm, every 15 minutes. During the closed-loop intervention, Actrapid insulin in a concentration
of 25 units/kg in 50 ml of 0.9% saline was used to allow for finer-dose titration in accordance with the
algorithm. The algorithm calculations utilised a compartment model of glucose kinetics,74 describing the
effect of insulin on sensor glucose excursions. The algorithm was initialised using an infant’s weight and
adapted itself to a particular infant by updating two model parameters: (1) a rapidly changing glucose
flux, correcting for errors in model-based predictions; and (2) a slowly changing estimate of an insulin
rate to maintain normoglycaemia. The individualised model forecasted plasma glucose excursions over
a 1.5-hour prediction horizon when calculating the insulin rate and a 30- to 40-minute horizon when
calculating the dextrose rate. Information about enteral or parenteral nutrition was not provided to
the algorithm. A reference blood glucose value was used every 6 hours for calibration of the glucose
sensor. If sensor readings were not available because of sensor failure or loss of data capture, then
hourly blood glucose levels were used to inform the algorithm for up to 4 hours. At this time, the
algorithm continued to provide advice every 15 minutes.
Assessments and data collection
Demographic and clinical characteristics were collected with the following antenatal variables based
on clinical diagnoses recorded in the maternal medical file: antenatal steroids (having received at least
one dose prior to delivery), prolonged rupture of membranes (a rupture > 24 hours prior to delivery),
hypertension and chorioamnionitis. All blood glucose measurements, insulin administration, type and
volume of enteral and parenteral nutrition, and additional intravenous glucose administration were
recorded from the time of randomisation to the end of CGM.
Statistical analysis
The outcome measures and the statistical analysis plan were agreed in advance. The primary outcome
was a comparison of the time that sensor glucose was in the glucose target range of 4–8 mmol/l
between the study arms. Secondary outcomes were time spent with sensor glucose levels between
2.6 and 10 mmol/l, prevalence of hyperglycaemia (percentage of time sensor glucose is > 10 mmol/l) and
mean (and SD) sensor glucose level. Safety end points included frequency of hypoglycaemia (any blood
glucose levels < 2.6 mmol/l) and other AEs. Sample size was selected to reflect this study’s status as a
pilot to ensure that we had comparable control data, while minimising patient exposure. Formal power
calculations were not performed and all analyses were based on intention to treat. An independent
t-test was used to compare normally distributed variables. Non-normally distributed variables were
compared using a Mann–Whitney U-test. Calculations were carried out using IBM SPSS Statistics
version 23 (IBM Corporation, Armonk, NY, USA). Values are given as mean (SD) or median (IQR).
p-values < 0.05 were considered statistically significant.
CLOSED-LOOP STUDY
NIHR Journals Library www.journalslibrary.nihr.ac.uk
72
Results
Twenty-one infants were randomly assigned to the study arms, but one infant in the control group died
within 48 hours of birth and so was excluded from the analyses. The baseline characteristics of the two
groups (n = 20) were similar (Table 21). There were no significant problems with sensor insertion or
removal, with only one infant (in the control group) having to have a sensor replaced, as there was
no connection to the monitor. All 20 infants remained in the study throughout the intervention period
from 48 to 72 hours, with similar numbers of sensor glucose data available for analysis in each group
[for both study groups: median 24 (IQR 23.8–24) hours]. Control algorithm-directed insulin therapy
was followed, at all times, during the prespecified 48- to 72-hour period. The maximum period of
sensor signal loss during the closed loop was 3.5 hours, during which hourly blood glucose values
were used by the control algorithm. There was minimal loss of data for the remainder of the study.
One infant in the control arm was transferred out of the unit on study day 5 and one infant in the
closed-loop arm died on study day 6, and so no further data could be collected for either infant.
Therefore, the mean duration of collection of glucose data was 137 (SD 16.4) hours in the control
arm and 136 (SD 8.7) hours in the closed-loop arm.
Glucose control and insulin and dextrose administration between 48 and 72 hours
There was no difference between the study groups in the baseline (48 hours) mean sensor glucose
level (Table 22). During the intervention period, the median time spent in the target range of sensor
glucose level (i.e. 4–8 mmol/l) was significantly higher in the closed-loop arm (91%, IQR 78–99%) than
in the control arm (26%, IQR 6–64%) (p < 0.001). This was equivalent to 22 (IQR 19–24) hours in the
closed-loop group, compared with 6 (IQR 1–15) hours in the control group. Similarly, the time spent
in the wider target range of 2.6–10 mmol/l was higher in the closed-loop group (median 100% vs.
median 84%). This was because the median percentage of time with sensor glucose values > 10 mmol/l
was lower in the control arm than in the closed-loop arm (16% compared with 0%). There was no
difference in the time spent with sensor glucose levels < 2.6 mmol/l. The median sensor glucose level
was lower in the closed-loop arm (6.2 mmol/l, IQR 6.1–7.1 mmol/l) than in the control arm (8.6 mmol/l,
IQR 7.4–11.1 mmol/l) (p = 0.002). Glucose variability, as measured by the SD of sensor glucose, was
similar (p = 0.6).
TABLE 21 Closed-loop study: baseline demographic data3
Demographic data Closed-loop arm (N= 10) Control arm (N= 10)
Gestational age at birth (weeks), mean (SD) 27.0 (2.4) 27.5 (2.8)
Birthweight (g), mean (SD) 962 (164) 823 (282)
Sex (male-to-female) 5 : 5 5 : 5
Antenatal variable, n (%)
Antenatal steroids 10 (100) 9 (90)
Maternal smoking 1 (10) 2 (20)
Chorioamnionitis 2 (20) 3 (30)
PROMa 4 (40) 4 (40)
Hypertension 1 (10) 1 (10)
PROM, prelabour rupture of membranes.
a Defined as rupture of membranes for > 24 hours.
Reproduced with permission from Beardsall et al.3 This is an open access article distributed in accordance with the
Creative Commons Attribution (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and
build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and
indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/. The table includes minor
additions and formatting changes to the original table.
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Summative glucose profiles and insulin delivery are provided in Figure 20. Nine out of the 10 infants in
the closed-loop group had received insulin prior to the 24-hour intervention, with the one remaining
infant being started on insulin during the 24-hour closed-loop period. For comparison, four infants in the
control arm received insulin prior to the intervention period and eight infants received insulin during the
intervention period. Four infants in the closed-loop arm received additional 20% dextrose for short
periods during the intervention period (up to 3.5 hours). The mean infusion rate in these infants ranged
from 0.13 to 0.53 ml/kg/hour, with the highest rate being infused in an infant who was hypoglycaemic
prior to the start of the closed-loop intervention. There was no statistical difference in the total amount
of insulin infused or nutritional intake between the study groups during the 24-hour intervention period.
Glucose control and insulin and dextrose administration between 72 and 160 hours
In the post-intervention period, after 72 hours, there was a trend of increased time in both glucose
target ranges (i.e. 4–8 mmol/l and 2.6–10 mmol/l) in the closed-loop arm compared with the control
arm (Table 23), but these differences did not reach statistical significance.
Nutrition and clinical care
All infants received parenteral and enteral nutrition in accordance with the standard local neonatal unit
protocol. During the closed-loop intervention period, between 48 and 72 hours, four infants in each study
group were receiving minimal amounts of trophic feeds. In the post-intervention period, after 72 hours,
there was no difference between the two study groups in the volume of milk received (see Table 23).
TABLE 22 Closed-loop study: comparison of glucose control, insulin delivery and nutritional intake during the
intervention period (48–72 hours post birth)3
Variable Closed loop arm (n= 10) Control arm (n= 10) p-value
Time spent with sensor glucose level (%)
4–8 mmol/la 91 (78–99) 26 (6–64) < 0.001
2.6–10 mmol/l 100 (94–100) 84 (46–98) 0.1
> 10 mmol/l 0 (0–6) 16 (2–54) 0.1
< 2.6 mmol/l 0.0 (0.0–0.0) 0.0 (0.0–0.0) 0.7
Baseline sensor glucose level (mmol/l) 7.9 (6.9–11.5) 8.2 (7.0–12.4) 0.2
Mean sensor glucose level (mmol/l) 6.2 (6.1–7.1) 8.6 (7.4–11.1) 0.002
SD of sensor glucose level (mmol/l) 1.0 (0.8–1.9) 1.3 (0.9–2.5) 0.6
Episodes of blood glucose < 2.6 mmol/lb 1 0 1
Nutritional intake
Insulin (units/kg/hour) 0.04 (0.03–0.07) 0.02 (0.00–0.11) 0.4
Dextrose (mg/kg/minute) 8.4 (7.2–10.3) 8.5 (4.2–10.6) 0.6
Protein (g/kg/day) 3.2 (2.5–4.1) 3.5 (1.6–4.1) 1
Lipid (g/kg/day) 1.8 (1.0–1.8) 1.4 (0.9–2.2) 0.9
Trophic feeds 4 4 1
a Primary end point.
b Present at start of closed-loop study period prior to computer algorithm advice being initiated.
Notes
Data are presented as median (IQR).
Reproduced with permission from Beardsall et al.3 This is an open access article distributed in accordance with the
Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix,
transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence
is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/. The table
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None of the infants received hydrocortisone, but seven infants in the control arm and two infants in
the closed-loop arm received inotropes during the first week. During the intervention period, the
median number of blood glucose values taken per day was 5.5 (IQR 4.8–6.6) in the control arm and
6.3 (IQR 5.1–6.5) in the closed-loop arm. Over the whole study period, the median number of blood
glucose values taken per day was 5.1 (IQR 4.3–5.4) in the control arm and 5.3 (IQR 4.6–5.8) in the
closed-loop arm.
Safety
No reported concerns about the sensor site, in terms of inflammation or infection, were reported
either during the study or after removal of the sensor. Two infants in the closed-loop arm experienced
documented episodes of hypoglycaemia, with a blood glucose level < 2.6 mmol/l. One episode occurred
when checking the baseline blood glucose prior to the start of the closed-loop intervention. At that
time, maintenance fluids were being changed, but no insulin was being infused. The second episode
was on day 6 and, again, this was associated with a change of maintenance fluids. A further two infants
experienced periods (after the 72-hour closed loop) when sensor glucose levels fell below 2.6 mmol/l,
but the blood glucose level at that time was documented to be above 2.6 mmol/l. In the control arm,
no infants had a documented blood glucose value of < 2.6 mmol/l. One infant in the control arm
experienced an episode lasting 205 minutes when the sensor glucose fell to < 2.6 mmol/l (blood
glucose level was not checked at this time). None of the infants was on insulin and there was no
clinical evidence of hypoglycaemia in these infants during any of these episodes.
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FIGURE 20 Closed-loop study: glucose control and insulin delivery.3 Median (IQR) sensor glucose level and insulin
infusion rate in infants randomised to closed-loop management or CGM with paper guideline (control). The closed-loop
intervention period is denoted by the vertical lines and the glucose target range of 4–8 mmol/l is denoted by horizontal
lines. The shaded area represents the IQR of sensor glucose values and insulin infusion rates, respectively. Reproduced
with permission from Beardsall et al.3 This is an open access article distributed in accordance with the Creative Commons
Attribution (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for
any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes
were made. See: https://creativecommons.org/licenses/by/4.0/. The figure includes minor additions and formatting
changes to the original figure.
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Discussion
To the best of our knowledge, this study is the first to show that a closed-loop system utilising subcutaneous
glucose measurements to guide insulin delivery may improve glucose control in extremely preterm infants.
This new approach could represent a step change in care, providing greater safety and tighter control,
while minimising staff time at bedside and changes in fluid/insulin treatment. Compared with CGM
alone, the closed-loop intervention increased threefold the percentage of time when sensor glucose
was in the target range of between 4 and 8 mmol/l. In the high-intensity and high-cost setting of NICUs,
these preliminary data support further development of closed-loop systems with real-time glucose-
responsive insulin and dextrose delivery to support the care of these infants.
Reflecting the current controversy regarding optimal targets for glucose control in NICUs, we adopted a
moderate glucose target range of between 4 and 8 mmol/l, rather than the tight glycaemic regimen of KU
Leuven and Normoglycemia in Intensive Care Evaluation–Survival Using Glucose Algorithm Regulation
(NICE-SUGAR) studies.16,75,76 These moderate target ranges represent physiological in utero levels,77 and
the upper threshold reflects a postnatal glucose level that has been associated with increased mortality
and morbidity in preterm infants.10 However, the optimal target range for glucose levels in these infants
is still to be determined and this study does not resolve this long-standing debate in the field. Instead,
it shows how an automated system can be used to achieve control to a given target range.
Different strategies are currently utilised to target glucose control in the preterm infant, each with
different risks and benefits. A reduction in dextrose load risks compromised nutritional intake, whereas
insulin therapy can lead to hypoglycaemia. The level of insulin use in this study is likely to reflect both
TABLE 23 Closed-loop study: comparison of glucose control, insulin delivery and nutritional intake during the
post-intervention period (72–160 hours post birth)3
Variable Closed loop arm (n= 10) Control arm (n= 10) p-value
Time spent with sensor glucose level (%)
4–8 mmol/l 64 (39–90) 42 (30–55) 0.05
2.6–10 mmol/l 95 (79–97) 78 (61–97) 0.2
> 10 mmol/l 3 (1–21) 22 (3–36) 0.2
< 2.6 mmol/l 0.0 (0.0–0.8) 0.0 (0.0–0.2) 0.7
Mean sensor glucose level (mmol/l) 7.0 (6.8–8.5) 8.3 (7.3–9.2) 0.2
SD of sensor glucose level (mmol/l) 1.7 (1.5–2.1) 1.7 (1.3–2.8) 0.8
Episodes of blood glucose < 2.6 mmol/l 1 0 1
Nutritional intake
Insulin (units/kg/hour) 0.02 (0.00–0.04) 0.03 (0.00–0.05) 0.4
Dextrose (mg/kg/minute) 9.4 (7.0–10.6) 8.7 (5.4–10.9) 0.5
Protein (g/kg/day) 3.7 (2.7–4.3) 3.8 (2.9–4.4) 1
Lipid (g/kg/day) 2.0 (1.5–2.9) 1.8 (1.2–2.8) 0.6
Oral milk intake (ml/kg/day) 4.4 (3.5–11.5) 5.0 (0.5–13.0) 0.7
Notes
Data are presented as median (IQR).
Reproduced with permission from Beardsall et al.3 This is an open access article distributed in accordance with the
Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix,
transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence
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the extreme prematurity of the infants recruited and the current practice in the NICU, which aims to
‘optimise’ nutritional delivery. In this study, there were no episodes of hypoglycaemia related to advice
from the closed-loop algorithm, but CGM highlighted clinically silent episodes of hypoglycaemia in
both study arms, independent of insulin use. The prevalence of hypoglycaemia was comparable to that
reported by others in this population (27%)64 and to that reported using masked CGM, which highlights
prolonged periods of clinically silent hypoglycaemia.21
The CGM devices were calibrated using the StatStrip meter, which is validated for use in neonates
and has US Food and Drug Administration approval for use in intensive care.78 These meters are the
standard of care for clinical management in the neonatal unit. Although there remains controversy
regarding the clinical significance of clinically silent episodes of hypoglycaemia detected by CGM,
there is recent evidence of an association between these episodes and substantially increased risk of
impaired executive function and visual motor difficulty at 4.5 years.79,80
The frequency of blood glucose sampling in preterm infants is typically much lower than in adults
and children in intensive care, and therefore CGM has the potential to have an even greater impact.
Differences in frequency of blood glucose monitoring may have had an impact on the level of glucose
control. However, among infants in the control arm, more than four blood glucose samples were taken
every 24 hours in the first 3 days of life. Notably, the insulin administered in the intervention arm was
more diluted than that used in the control group to allow for more frequent changes in dose titration.
Despite randomisation, more infants in the control arm received inotropes during the first week, and
inotropic drugs will reduce insulin secretion and insulin sensitivity. However, given the pattern of
improved glucose control during the intervention period, we do not think that these differences can
account for the differences in glucose control that were observed.
Previous studies have explored the potential for CGM to guide changes in dextrose delivery,37 although
intervention still depended on staff responding to trends in sensor glucose or to alarms.37 In contrast, in the
present study, targeting of glucose control was proactively driven by the closed-loop algorithm, which
responded to frequently sampled sensor glucose data. This study is unique in exploring a control approach
belonging to the family of model predictive control algorithms and optimised on a validated computer
simulation environment73 prior to study commencement to ensure a favourable outcome.
The strengths of our study are the randomised controlled study design, and the comparability of the
study groups and nutritional intakes. The study limitations include a small sample size, which means
that, despite randomisation, baseline differences could remain between the study groups. Although
the study groups appeared comparable, more infants in the control group than in the closed-loop
group were on inotropes, and more infants in the intervention arm were on insulin at the start of
study intervention. With such a design, it was not possible to blind the clinicians to the intervention.
The study duration was short and, therefore, as it is known that insulin sensitivity varies over time
from birth, it is important to explore how the algorithm works over longer periods.
In addition, this was a single-centre study and, as nutritional policies and practices vary between
centres, it will be important to test the algorithm in different units with different nutritional strategies
to test its generalisability. The algorithm was not designed to alter nutritional delivery, as this was
predetermined by the clinical team, with the intervention designed as a simple adjunct to support
targeting glucose control, alongside the clinical plan for nutritional support. Alternative designs might
consider a combined approach to guide nutritional intake alongside insulin treatment. Further studies
are required to explore the impact of a fully automated system with infusion pumps providing insulin
and 20% dextrose under fully automated computer control.
To the best of our knowledge, this is the first randomised study to evaluate the feasibility of a
closed-loop control based on CGM in preterm infants to guide insulin delivery to support glucose
control. This closed-loop system appears to be a potential adjunct for targeting glucose control in
preterm infants requiring intensive care and warrants further study.
DOI: 10.3310/eme08160 Efficacy and Mechanism Evaluation 2021 Vol. 8 No. 16
© Queen’s Printer and Controller of HMSO 2021. This work was produced by Beardsall et al. under the terms of a commissioning contract issued by the Secretary of State
for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,




Implications for future health
These studies have demonstrated that CGM can support the targeting of glucose control in the
extremely preterm infant without increasing the risk of hypoglycaemia. Staff felt that CGM improved
the care of infants. The economic evaluation demonstrated that, over the first 7 days, CGM is, on
average, more costly and more effective than standard care. Assuming cost-effectiveness thresholds of
£1000, £5000 and £10,000 per additional case of adequate glucose control, respectively, the probability
of cost-effectiveness of CGM reached 90% at approximately £6000, while the NMB associated with
CGM became positive at a cost-effectiveness threshold of £5000. Over a time horizon extending to
36 weeks’ corrected gestational age, CGM was less costly and more effective, on average, than standard
care and was therefore dominant in health economic terms.
The international nature of the study means that the results are generalisable across a range of NICU
settings. The findings highlight the need for specific developments in the technology to improve the
utility of CGM devices for use in this unique population. They further demonstrate the potential of a
‘closed-loop’ system to support targeting of glucose control, which could help to reduce staff workload
and therefore cost.
The feasibility study highlighted the potential of CGM to identify infants at risk of incipient hypoglycaemia,
which may be silent in this population. This study was unusual in undertaking a robust assessment of a
new medical device in NICU patients before its introduction into clinical practice. The importance of
designing devices to address the unique physiological and pathological challenges presented by these
infants needs to be emphasised. More robust pathways are needed to encourage the development and
validation of devices for use in such vulnerable populations. It is also important to ensure that these
devices can be introduced into clinical practice in a robust manner, which requires adequate support
and training for staff so that the devices are used effectively and safely in this population. Further
developments in technology involving ‘closed-loop systems’ would be important in NICUs to limit blood
sampling and provide a more personalised approach to care.
Specific post-study reflections
Continuous glucose monitoring versus point-of-care blood glucose
Considerable controversy remains as to the best way to manage neonatal glucose control, primarily
because of a lack of good evidence on which to base clinical practice.81,82 Measurement of glucose
levels has evolved greatly over the last 40 years, with CGM being introduced in the last 20 years.
The increasingly rapid innovations in technology could open up the opportunity for better understanding
and management of the many infants who present with disordered glucose levels.
Current clinical care depends on a spectrum of medical devices and a range of clinical practices
regarding the frequency of glucose sampling. Standard care includes capillary, venous or arterial blood
sampling, and POC devices that have the advantage of rapid results and small samples compared with
the ‘gold standard’ of laboratory analyses, which can result in a significant delay before results are
available.83 CGM could provide consistency in terms of interstitial levels measured continuously in real
time. Over the course of our studies, the regulatory landscape for CGM models has changed during
the time of these studies from an adjunct to care (requiring confirmatory blood glucose levels) to one
where some CGM models are approved as being accurate enough to be a standalone guide to insulin
dosing in patients with diabetes.84
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The fact that CGM measures not blood but interstitial glucose levels has given rise to some concern about
its ‘validity’. Even when CGM devices are calibrated to blood glucose levels, there can be differences,
particularly in certain circumstances.85 However, it can be argued that interstitial glucose levels provide
much more useful physiological and, therefore, clinical information, as cellular glucose levels may be
particularly relevant to neuroglycopenia and the developing brain.85
The acknowledged lag of up to 15 minutes in sensor glucose level compared with blood glucose levels
needs to be placed in a clinical context. Although there may be a short lag of 15 minutes using CGM,
the system still provides a continuous trend in real time. In contrast, the current standard of care using
intermittent blood sampling can result in a delay of many hours between levels being checked. CGM
can therefore reveal significant periods of clinically silent hypoglycaemia.86,87 This was highlighted in
our studies, in which falling sensor values highlighted the need for blood glucose levels to be taken.1
However, there were no SAEs related to a ‘falsely’ reassuring sensor glucose level during an episode of
hypoglycaemia. The detection of clinically silent hypoglycaemic episodes may be the most useful impact
of CGM, highlighted by the association of such episodes with deficits in attention and visual acuity at
4.5 years.79 Although, theoretically, this could lead to overmedicalisation, the potential to prevent harm
should not be missed.
The unbiased nature of the CGM data also has the potential to help us better understand the physiology
and pathology of changes in glucose levels. However, CGM devices are not currently licensed for use
in the neonate and are not designed for ease of use with these infants. The next steps are to engage
with the industry to address issues specific to this population.
The use of paper and computerised algorithms
This programme of studies involved the use of CGM technology combined with a variety of algorithms,
both paper and computer based. The interventions should therefore be considered ‘combined interventions’.
We purposefully designed the paper algorithm as a guideline and not as a protocol. Although a
‘protocolised’ approach to ensure compliance may be considered optimal within a clinical trial, it was
clear that the complexity needed for such a paper protocol would have increased risk. This was based
on our previous experience, which highlighted wide variation in drug infusions, clinical complications
and interventions across multiple sites. During the feasibility study, the algorithm evolved, as early
iterations that aimed to avoid hypoglycaemia resulted in infusions being stopped and restarted more
often than was deemed optimal. The advice was simplified for use by nursing staff, without requiring
formal changes in prescriptions (similar to following a sliding scale). This was important as it provided a
safe framework for the nursing staff to be able to titrate insulin infusion rates based on sensor glucose
trends over short periods of time and nursing staff took ownership of decision-making, with a more
comprehensive approach to care.
The ‘closed-loop’ study was entirely exploratory, but dramatically demonstrated the potential impact of
combing the wealth of data from CGM with a computer-based algorithm. It provided a more personalised
approach to care. A fully automated system has the potential to optimise clinical care by targeting
glucose control and reducing workload. However, there are significant challenges to realisation, including
CGM technology designed for the preterm infant, manufacturing engagement with open access to sensor
and pump data, and regulatory hurdles. However, this route clearly could have significant impact for
infants and staff.
Device trials and future regulations
Large multicentre device trials are uncommon compared with drug trials, and very limited clinical data
are required for devices to obtain CE marking. This is particularly relevant for the neonatal population,
in whom the unique risks and benefits may not have been fully assessed.
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This trial highlighted some of the challenges of undertaking device trials, highlighting both practical
clinical complexities and the importance of working closely with the company, with complete
transparency about developments in the technology during the study.
Prior to starting the feasibility study, the sensor technology had been redesigned from the Medtronic
plc Sof-Sensor® to the Medtronic plc Enlite, with a change in the angle of insertion. This was an
advance for the adult market, but made sensor insertion more challenging in our preterm infants, who
have limited subcutaneous tissue. It was necessary to modify procedures and study guidance. Further
modifications were made to the Enlite sensor (from Enlite to Enlite plus) during the studies to improve
the accuracy of the sensor technology.
On completion of the feasibility study, a new monitor was due to be released to supersede the Paradigm
Veo. The advantages included better accuracy at low glucose levels and a clearer user interface.
Therefore, after consideration and discussion with the TSC about risk and benefits, a decision was
made to use the latest model. However, it became apparent that changes to the algorithm were having
an impact on the calibration frequency and lockout of sensors which then needed to be replaced.
Discussions with the company revealed that changes made to the algorithm to provide better accuracy
and safety led to increased error readings within our population. There were further modifications to
the algorithm to address some of these issues during the study. These potentially subtle changes from
a manufacturing perspective had a significant impact on our sensor failure rate at the beginning of the
study, but could not have been anticipated. This shows that the rapid advances in the technology
present clinical challenges and it is imperative that manufacturers and clinicians work together with
complete transparency.
Clinical aspects
Training the large number of staff within a busy intensive care unit to use devices as part of a clinical
trial requires significant resources, both financial and time. In our studies, the short recruitment
window increased this challenge for recruiting sites, and therefore the provision of on-site training
and an online training video, as well as a 24-hour helpline, was important. It was clear that the level
of support required for an interventional device trial was greater than that for an investigational
medicinal product study.
Recommendation for further research
The findings of the REACT project raise the following important questions that need to be addressed
in follow-on studies:
l What is the impact of ‘optimising’ glucose control on long-term health outcomes?
l What is the optimal glucose target range for preterm infants?
l What is the impact of silent hypoglycaemia in these preterm infants?
l Can we design a CGM that is better suited to the unique physiology and pathology of the newborn?
l What is the physiological basis for the differences found between sexes?
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Patient and public involvement
In each of the studies, families on the neonatal unit were asked individually and during informal family
meetings to review and advise on the language of the patient information sheets and consent forms.
There were two parents on the TSC throughout the multicentre trial who provided helpful insight into
optimising consent, including increasing engagement with midwifery colleagues. These parents also
provided advice on the content of parental newsletters prior to distribution. We have drafted a newsletter
in collaboration with the lay member of the TSC and will circulate this once we have confirmation of
publication, initially to a small group of families and then to all families who participated in the trial.
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Patient data
This work uses data provided by patients and collected by the NHS as part of their care and support.
Using patient data is vital to improve health and care for everyone. There is huge potential to
make better use of information from people’s patient records, to understand more about disease,
develop new treatments, monitor safety, and plan NHS services. Patient data should be kept safe
and secure, to protect everyone’s privacy, and it’s important that there are safeguards to make
sure that it is stored and used responsibly. Everyone should be able to find out about how patient
data are used. #datasaveslives You can find out more about the background to this citation here:
https://understandingpatientdata.org.uk/data-citation.
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Appendix 1 Summary of protocol amendments
Amendment
number Date of submission Details
1 17 December 2015 Protocol amendment (v2, dated 17 December 2015):
l Minor amendments to protocol
Parent information sheet (v4, dated 17 December 2015):
l Minor amendments
New study logo
2 4 August 2016 Protocol amendment (v3, dated 4 August 2015):
l Clarification of reportable safety events following discussion with the MHRA
(protocol, section 12)
3 4 August 2016 Addition of one site:
l John Radcliffe Hospital, Oxford
4 2 December 2016 Protocol amendment (v4, dated 7 November 2016):
l To enable the research team to receive parental/guardian verbal consent
5 16 December 2016 Addition of two sites:
l Evelina London Children’s Hospital, St Thomas’ Hospital, London
l Simpson Centre for Reproductive Health, Royal Infirmary of Edinburgh,
Edinburgh
6 9 March 2017 Addition of one site:
l New Cross Hospital, Wolverhampton
l Minor amendments to parent and clinical staff questionnaires
7 25 May 2017 Change of principal investigator at John Radcliffe Hospital, Oxford
8 28 July 2017 Request to extend study until 30 November 2018
9 14 September 2017 Addition of six sites:
l St Michael’s Hospital, Bristol
l St Peter’s Hospital, Chertsey
l Leeds General Infirmary, Leeds
l Leicester Royal Infirmary, Leicester
l The Royal London Hospital
l Princess Anne Hospital, Southampton
10 29 June 2018 Minor amendments, including:
l Poster
l QR code to access study video
l Certificates for infants joining the study
l Keep-in-contact card
11 7 August 2018 GDPR information sheet
12 21 September 2018 Request to extend study until 31 July 2019
13 6 December 2018 Minor amendments, including:
l Christmas card/seasonal news
l Short questionnaire for families to complete to confirm preferred method of
contact and thoughts about the design of a follow-up study
GDPR, General Data Protection Regulation; QR, quick response.
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Appendix 4 Randomised controlled trial:
additional analyses
TABLE 24 Randomised controlled trial: model-fitting results – sensitivity analyses of the primary outcome
Model Covariate Estimate (SE) 95% CI p-value
Linear regression weighted by number
of sensor glucose observations
Intercept 80 (3.4) 73.3 to 86.7 < 0.001
CGM vs. standard 8.5 (2.6) 3.4 to 13.6 0.001
N36 (reference N01) –5 (15) –34 to 25 0.8
N42 7.0 (5.5) –3.9 to 17.9 0.2
N43 –0.04 (3.8) –7.6 to 7.5 0.99
N68 1.7 (4.0) –6.1 to 9.5 0.7
N73 3.6 (5.4) –7.1 to 14.2 0.5
N74 10 (12) –15 to 35 0.4
N85 8.3 (6.4) –4.4 to 21 0.2
N86 –21 (8.7) –38.1 to –3.9 0.02
N87 –17 (12) –40 to 7 0.2
N88 –26.5 (7.2) –40.8 to –12.2 < 0.001
ND3 6.3 (6.2) –6 to 18.6 0.3
SP3 9.2 (7.6) –5.9 to 24.3 0.2
Gestation ≥ 26 weeks 6.1 (3.3) –0.4 to 12.6 0.07
RSD= 15.8
Linear regression adjusted for start
time of first sensor glucose and first
sensor glucose
Intercept 82.8 (4.7) 73.6 to 92 < 0.001
CGM vs. standard 9.1 (2.6) 3.9 to 14.3 < 0.001
Time from birth (hours) to first
sensor glucose measurement
0.04 (0.13) –0.23 to 0.3 0.8
First sensor glucose
measurement (mmol/l)
–2.3 (0.55) –3.4 to –1.21 < 0.001
N36 (reference N01) –12.8 (12.3) –37.1 to 11.6 0.3
N42 2.8 (6) –9.1 to 14.6 0.6
N43 0.005 (4) –8 to 8 0.999
N68 –2.8 (4.2) –11 to 5.5 0.5
N73 –0.4 (5.3) –10.9 to 10 0.9
N74 3.8 (12.2) –20.2 to 27.9 0.8
N85 4.9 (6.6) –8.1 to 18 0.5
N86 –14.6 (8.5) –31.4 to 2.3 0.09
N87 –16.4 (11.9) –39.9 to 7.2 0.2
N88 –26.9 (7.7) –42.2 to –11.6 < 0.001
ND3 2.7 (6.7) –10.6 to 16 0.7
continued
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TABLE 24 Randomised controlled trial: model-fitting results – sensitivity analyses of the primary outcome (continued )
Model Covariate Estimate (SE) 95% CI p-value
SP3 7.13 (8.5) –9.6 to 23.9 0.4
Gestation ≥ 26 weeks 1.3 (3.5) –5.7 to 8.2 0.7
RSD= 16.1
Linear regression with interaction
between time to first sensor glucose
and treatment
Intercept 82.6 (5.7) 71.3 to 93.9 < 0.001
CGM vs. standard 9.5 (6.8) –4 to 23 0.2
Time from birth (hours) to first
sensor glucose measurement
0.04 (0.18) –0.32 to 0.41 0.8
First sensor glucose
measurement (mmol/l)
–2.3 (0.56) –3.4 to –1.2 < 0.001
N36 (reference N01) –12.8 (12.4) –37.4 to 11.7 0.3
N42 2.7 (6.1) –9.4 to 14.8 0.7
N43 –0.007 (4.1) –8 to 8 0.999
N68 –2.8 (4.2) –11 to 5.5 0.5
N73 –0.5 (5.3) –11 to 10.1 0.9
N74 4.0 (12.4) –20.5 to 28.5 0.7
N85 4.9 (6.6) –8.2 to 18 0.5
N86 –14.6 (8.6) –31.7 to 2.4 0.09
N87 –17 (12) –40 to 7 0.2
N88 –27 (8) –42.7 to –11.2 < 0.001
ND3 2.7 (6.8) –10.6 to 16 0.7
SP3 7.1 (8.5) –9.7 to 23.9 0.4
Gestation ≥ 26 weeks 1.3 (3.5) –5.7 to 8.2 0.7
Treatment effect modification
[CGM – Standard : time from
birth (hours) to first sensor
glucose measurement]
–0.02 (0.24) –0.49 to 0.47 0.95
RSD= 16.2
Linear regression with interaction
between first sensor glucose
measurement and treatment
Intercept 80 (4.6) 70.8 to 89.1 < 0.001
CGM vs. standard 10.3 (2.6) 5.2 to 15.5 < 0.001
First sensor glucose
measurement (mmol/l)
–3.59 (0.67) –4.82 to –2.16 < 0.001
Time from birth (hours) to first
sensor glucose measurement
0.06 (0.13) –0.20 to 0.31 0.6
N36 (reference N01) –12 (12) –35 to 12 0.3
N42 1.8 (5.9) –9.8 to 13.4 0.8
N43 0.8 (3.9) –7 to 8.6 0.8
N68 –2.6 (4.1) –10.6 to 5.5 0.5
N73 –0.2 (5.2) –10.4 to 10 0.97
N74 2.7 (11.9) –20.8 to 26.1 0.8
N85 4.8 (6.4) –7.97 to 17.5 0.5
N86 –19.1 (8.5) –35.9 to –2.4 0.03
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TABLE 24 Randomised controlled trial: model-fitting results – sensitivity analyses of the primary outcome (continued )
Model Covariate Estimate (SE) 95% CI p-value
N87 –16.8 (11.6) –39.7 to 6.1 0.1
N88 –27.1 (7.5) –42 to –12.2 < 0.001
ND3 3.1 (6.5) –9.8 to 16.1 0.6
SP3 5.6 (8.3) –10.7 to 21.9 0.5
Gestation ≥ 26 weeks 3.4 (3.5) –3.5 to 10.3 0.3
Treatment effect modification
[CGM – Standard : first sensor
glucose measurement (mmol/l)]
3.1 (1) 1 to 5.1 0.004
RSD= 15.7
Generalised least squares regression
allowing for heteroscedastic variances
between treatment groups
Intercept 81.9 (3.4) 75.2 to 88.7 < 0.001
CGM vs. standard 8.9 (2.7) 3.6 to 14.2 0.001
N36 (reference N01) 2.9 (9.4) –15.5 to 21.3 0.8
N42 8.3 (5.2) –1.8 to 18.4 0.1
N43 3.9 (3.3) –2.6 to 10.3 0.2
N68 –0.08 (3.2) –6.4 to 6.2 0.98
N73 4.7 (4.2) –3.6 to 13 0.3
N74 9.2 (9.4) –9.2 to 27.6 0.3
N85 8.5 (5.5) –2.3 to 19.2 0.1
N86 –23.2 (8.2) –39.2 to –7.3 0.005
N87 –11.8 (15.7) –42.5 to 18.9 0.5
N88 –12.2 (6.5) –25 to 0.5 0.06
ND3 7.3 (5.5) –3.5 to 18.1 0.2
SP3 9 (6.8) –4.3 to 22.3 0.2
Gestation ≥ 26 weeks 1.5 (2.9) –4.2 to 7.3 0.6
RSD= 9.6
Random intercept for site Intercept 79.5 (4.1) 71.3 to 87.7 < 0.001
CGM vs. standard 9.3 (2.8) 3.8 to 14.8 0.001
Gestation ≥ 26 weeks 5.2 (3.6) –1.8 to 12.2 0.1
RSD= 17.2
Linear regression adjusting for
gestation only
Intercept 80.1 (3.5) 73.3 to 86.9 < 0.001
CGM vs. standard 9.4 (2.9) 3.7 to 15.1 0.001
Gestation ≥ 26 weeks 5.3 (3.6) –1.9 to 12.4 0.1
RSD= 17.8
RSD, residual error standard deviation.
Reproduced with permission from Beardsall et al.4 in accordance with the terms of the Creative Commons Attribution
(CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use,
provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/. The table includes minor
additions and formatting changes to the original table.
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TABLE 25 Randomised controlled trial: model-fitting results – per-protocol analysis of the primary outcome
Outcome Covariate Estimate (SE) 95% CI p-value
Percentage of time sensor
glucose is in the target range
2.6–10mmol/l
Intercept 79.3 (4) 71.3 to 87.2 < 0.001
CGM vs. standard 10.1 (3.3) 3.7 to 16.6 0.002
N36 (reference N01) –19 (18) –54 to 15 0.3
N42 9.4 (6.4) –3.3 to 22 0.1
N43 0.7 (4.7) –8.6 to 9.9 0.9
N68 5.47 (4.54) –3.53 to 14.5 0.2
N73 –3.4 (7.1) –17.5 to 10.6 0.6
N74 11 (13) –14 to 36 0.4
N85 8.5 (9.1) –9.6 to 26.6 0.4
N86 –23 (10) –44 to –3 0.03
N87 –11 (13) –35 to 14 0.4
N88 –27.7 (8.2) –43.9 to –11.5 < 0.001
ND3 8 (9.2) –10.1 to 26.2 0.4
SP3 16 (13) –9 to 41 0.2
Gestation ≥ 26 weeks 4.3 (3.9) –3.5 to 12.2 0.3
RSD= 17.2
RSD, residual error standard deviation.
TABLE 26 Randomised controlled trial: model-fitting results – subgroup analyses of the primary outcome
Subgroup Covariate Estimate (SE) 95% CI p-value
Site Intercept 82.7 (4.2) 74.3 to 91 < 0.001
CGM vs. standard 5.8 (4.7) –3.6 to 15.1 0.2
N36 (reference N01) –23 (17) –57 to 11 0.2
N42 7 (7.2) –7.3 to 21.1 0.3
N43 –4.2 (5.7) –15.6 to 7.1 0.5
N68 1.3 (5.7) –10 to 12.7 0.8
N73 –4.8 (7.6) –19.9 to 10.3 0.5
N74 13 (17) –21 to 47 0.4
N85 8.7 (9.1) –9.3 to 26.6 0.3
N86 –10.8 (10.3) –31.3 to 9.6 0.3
N87 –14 (12) –38 to 11 0.3
N88 –47 (10) –68 to –27 < 0.001
ND3 7.2 (9.1) –10.7 to 25.1 0.4
SP3 12 (12) –12 to 37 0.3
Gestation ≥ 26 weeks 4.2 (3.6) –2.9 to 11.3 0.2
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TABLE 26 Randomised controlled trial: model-fitting results – subgroup analyses of the primary outcome (continued )
Subgroup Covariate Estimate (SE) 95% CI p-value
[CGM – treatment : N36
(reference N01) – site]
30 (24) –18 to 78 0.2
[CGM – treatment : N42 – site] 0.4 (13) –25 to 25 0.97
[CGM – treatment : N43 – site] 9.6 (8.4) –6.9 to 26.2 0.3
[CGM – treatment : N68 – site] –2.2 (8.2) –18.5 to 14.1 0.8
[CGM – treatment : N73 – site] 10.6 (10.8) –10.8 to 32.1 0.3
[CGM – treatment : N74 – site] –6 (24) –54 to 42 0.8
[CGM – treatment : N85 – site] –1 (14) –29 to 26 0.9
[CGM – treatment : N86 – site] –23 (20) –62 to 17 0.3
[CGM – treatment : N88 – site] 46 (16) 14 to 77 0.006
[CGM – treatment : ND3 – site] –0.9 (14) –28 to 26 0.95
[CGM – treatment : SP3 – site] –5 (18) –40 to 30 0.8
[CGM – treatment : N87 – site] n/a to n/a
RSD= 16.9
Sex Intercept 86.8 (4.1) 78.6 to 94.9 < 0.001
CGM vs. standard 2.3 (3.9) –5.4 to 10 0.6
Male vs. female –11.3 (3.7) –18.7 to –3.9 0.003
N36 (reference N01) –11 (12) –35 to 13 0.4
N42 5.7 (5.8) –5.8 to 17.2 0.3
N43 –0.7 (4.1) –8.9 to 7.5 0.9
N68 1.1 (4.1) –7 to 9.2 0.8
N73 –0.1 (5.4) –10.9 to 10.6 0.98
N74 12 (12) –12 to 36 0.3
N85 9.6 (6.7) –3.7 to 22.9 0.2
N86 –17.5 (8.7) –34.8 to –0.3 0.05
N87 –13 (12) –36 to 11 0.3
N88 –28.2 (7.8) –43.6 to –12.8 < 0.001
ND3 7.9 (6.8) –5.5 to 21.4 0.2
SP3 6.9 (8.8) –10.5 to 24.2 0.4
Gestation ≥ 26 weeks 4.8 (3.5) –2.1 to 11.7 0.2
[CGM – treatment : Male – sex] 12.6 (5.5) 1.8 to 23.5 0.02
RSD= 16.6
Sexa Intercept 86.8 (4.1) 78.6 to 94.9 < 0.001
Male vs. female –11.3 (3.7) –18.7 to –3.9 0.003
N36 (reference N01) –11 (12) –35 to 13 0.4
N42 5.7 (5.8) –5.8 to 17.2 0.3
N43 –0.7 (4.1) –8.9 to 7.5 0.9
N68 1.1 (4.1) –7 to 9.2 0.8
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TABLE 26 Randomised controlled trial: model-fitting results – subgroup analyses of the primary outcome (continued )
Subgroup Covariate Estimate (SE) 95% CI p-value
N73 –0.1 (5.4) –10.9 to 10.6 0.98
N74 12 (12) –12 to 36 0.3
N85 9.6 (6.7) –3.7 to 22.9 0.2
N86 –17.5 (8.7) –34.8 to –0.3 0.05
N87 –13 (12) –36 to 11 0.3
N88 –28.2 (7.8) –43.6 to –12.8 < 0.001
ND3 7.9 (6.8) –5.5 to 21.4 0.2
SP3 6.9 (8.8) –10.5 to 24.2 0.4
Gestation ≥ 26 weeks 4.8 (3.5) –2.1 to 11.7 0.2
[Female – sex : CGM – treatment] 2.3 (3.9) –5.4 to 10 0.6
[Male – sex : CGM – treatment] 14.9 (3.8) 7.4 to 22.5 < 0.001
RSD= 16.6
Sex (interaction with first
sensor glucose measurement
and treatment)
Intercept 89.2 (4) 81.3 to 97.2 < 0.001
CGM vs. standard 2.9 (3.6) –4.2 to 10 0.4
Male vs. female –11.7 (3.4) –18.4 to –4.9 < 0.001
First sensor glucose measurement
(mmol/l)
–1.23 (0.98) –3.16 to 0.7 0.2
N36 (reference N01) –13 (11) –35 to 9 0.2
N42 1.9 (5.3) –8.7 to 12.4 0.7
N43 –0.6 (3.8) –8.1 to 6.8 0.9
N68 –2.1 (3.8) –9.6 to 5.4 0.6
N73 0.2 (5) –9.6 to 10 0.97
N74 5 (11) –18 to 25 0.8
N85 4.1 (6.2) –8.2 to 16.3 0.5
N86 –19 (8.1) –35.1 to –3 0.02
N87 –17 (11) –38 to 5 0.1
N88 –28.5 (7.2) –42.6 to –14.3 < 0.001
ND3 3.6 (6.3) –8.9 to 16.1 0.6
SP3 5.1 (8) –10.6 to 20.9 0.5
Gestation ≥ 26 weeks 2.2 (3.4) –4.5 to 8.9 0.5
[CGM – treatment : Male – sex] 13.2 (5) 3.2 to 23.1 0.01
[CGM – treatment : First sensor
glucose measurement]
0.6 (1.4) –2.2 to 3.4 0.7
[Male – sex : First sensor glucose
measurement]
–3.8 (1.3) –6.3 to –1.2 0.004
[CGM – treatment : Male – sex :
First sensor glucose measurement]
3.8 (2) –0.07 to 7.7 0.05
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TABLE 26 Randomised controlled trial: model-fitting results – subgroup analyses of the primary outcome (continued )
Subgroup Covariate Estimate (SE) 95% CI p-value
RSD= 15
Corrected gestational age Intercept 111 (13) 85 to 137 < 0.001
CGM vs. standard –9 (19) –46 to 28 0.6
Corrected age 109 (52) 6 to 211 0.04
N36 (reference N01) –9 (12) –32 to 16 0.5
N42 6.9 (6) –5.1 to 18.8 0.3
N43 0.6 (4.2) –7.7 to 8.9 0.9
N68 0.6 (4.2) –7.6 to 8.9 0.9
N73 –1.4 (5.6) –12.5 to 9.7 0.8
N74 9.4 (12.3) –14.9 to 33.6 0.4
N85 7.7 (6.9) –6 to 21.3 0.3
N86 –17.7 (8.9) –35.3 to –0.01 0.05
N87 –12 (12) –36 to 13 0.4
N88 –30.8 (8.1) –46.8 to –14.8 < 0.001
ND3 6 (6.9) –7.6 to 19.6 0.4
SP3 8.9 (8.9) –8.7 to 26.4 0.3
[CGM – treatment : corrected age] –72 (76) –223 to 79 0.4
RSD= 16.9
Birthweight SDS Intercept 83.6 (3.9) 75.8 to 91.3 < 0.001
CGM vs. standard 5.4 (3.7) –1.9 to 12.6 0.1
Weight SDS 5.3 (2.1) 1 to 9.5 0.02
N36 (reference N01) –4 (12) –28 to 20 0.8
N42 6.3 (5.9) –5.4 to 18.1 0.3
N43 –0.6 (4.2) –9 to 7.6 0.9
N68 –0.4 (4.1) –8.6 to 7.8 0.9
N73 2 (5.5) –8.8 to 12.8 0.7
N74 8 (12) –16 to 32 0.5
N85 8.9 (6.8) –4.5 to 22.3 0.2
N86 –13.9 (8.8) –31.4 to 3.5 0.1
N87 –20 (13) –44 to 5 0.1
N88 –29.3 (8.1) –45.3 to –13.3 < 0.001
ND3 6.7 (6.8) –6.7 to 20.1 0.3
SP3 9.5 (8.9) –8.1 to 27.1 0.3
Gestation ≥ 26 weeks 6.6 (3.6) –0.5 to 13.7 0.07
[CGM – treatment : weight SDS] –4.2 (3.1) –10.4 to 2 0.2
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TABLE 26 Randomised controlled trial: model-fitting results – subgroup analyses of the primary outcome (continued )
Subgroup Covariate Estimate (SE) 95% CI p-value
RSD= 16.8
Antenatal steroids Intercept 81.4 (3.9) 73.7 to 89 < 0.001
CGM vs. standard 7.5 (3.2) 1.2 to 13.9 0.02
Antenatal steroids (no vs. yes) –2.8 (4.7) –12 to 6.4 0.5
N36 (reference N01) –6 (13) –31 to 19 0.6
N42 8.3 (6.2) –4 to 20.5 0.2
N43 0.4 (4.6) –8.6 to 9.5 0.9
N68 0.5 (4.2) –7.9 to 8.9 0.9
N73 –0.08 (5.6) –11.1 to 11 0.99
N74 12 (13) –13 to 37 0.4
N85 9.4 (7.2) –4.8 to 23.6 0.2
N86 –15.5 (9) –33.3 to 2.3 0.09
N87 –13 (12) –37 to 12 0.3
N88 –28.5 (8.1) –44.4 to –12.6 < 0.001
ND3 7.3 (7.1) –6.7 to 21.2 0.3
SP3 9 (9) –8.9 to 26.8 0.3
Gestation ≥ 26 weeks 4.7 (3.7) –2.5 to 11.9 0.2
[CGM – treatment : No – antenatal
steroids]
6 (7) –8 to 19.9 0.4
RSD= 17.1
Maternal chorioamnionitis Intercept 80.6 (4.9) 70.9 to 90.3 < 0.001
CGM vs. standard 10.8 (5.7) –0.5 to 22.1 0.06
Maternal chorioamnionitis
(no vs. yes)
–0.4 (4.6) –9.6 to 8.8 0.9
Maternal chorioamnionitis
(unknown vs. yes)
15 (13) –11 to 40 0.3
N36 (reference N01) –7 (12) –32 to 18 0.6
N42 8 (6) –3.8 to 19.8 0.2
N43 0.6 (4.3) –8 to 9.1 0.9
N68 0.4 (4.3) –8.2 to 8.9 0.9
N73 0.6 (5.6) –10.5 to 11.7 0.9
N74 11 (12) –14 to 36 0.4
N85 8.3 (7) –5.6 to 22.1 0.2
N86 –15.2 (9.1) –33.1 to 2.7 0.1
N87 –12 (13) –37 to 13 0.3
N88 –28.4 (8.2) –44.6 to –12.3 < 0.001
ND3 7.3 (7) –6.5 to 21.1 0.3
SP3 9.7 (9) –8.1 to 27.6 0.3
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TABLE 26 Randomised controlled trial: model-fitting results – subgroup analyses of the primary outcome (continued )
Subgroup Covariate Estimate (SE) 95% CI p-value
Gestation ≥ 26 weeks 4.5 (3.7) –2.7 to 11.8 0.2
[CGM – treatment : No –maternal
chorioamnionitis]
–2.1 (6.7) –15.3 to 11.1 0.8
[CGM – treatment :
Unknown –maternal
chorioamnionitis]
–19 (18) –55 to 18 0.3
RSD= 17.2
Maternal diabetes Intercept 78.7 (7.4) 64 to 93.4 < 0.001
CGM vs. standard 13 (11) –8 to 34 0.2
Maternal diabetes (no vs. yes) 2.1 (6.8) –11.2 to 15.5 0.8
N36 (reference N01) –8 (12) –33 to 17 0.5
N42 7.7 (6) –4.1 to 19.4 0.2
N43 0.2 (4.3) –8.3 to 8.6 0.97
N68 –0.1 (4.3) –8.6 to 8.3 0.98
N73 0.2 (5.6) –10.8 to 11.2 0.97
N74 10 (12) –15 to 34 0.4
N85 8.3 (7.2) –5.8 to 22.5 0.2
N86 –16.2 (9) –34 to 1.6 0.08
N87 –12 (13) –37 to 12 0.3
N88 –28.7 (8.1) –44.7 to –12.7 < 0.001
ND3 6.8 (7) –7 to 20.5 0.3
SP3 9.5 (9) –8.3 to 27.2 0.3
Gestation ≥ 26 weeks 5 (3.7) –2.2 to 12.2 0.2
[CGM – treatment : No –maternal
diabetes]
–5 (11) –27 to 17 0.7
RSD= 17.2
n/a, not applicable; RSD, residual error standard deviation.
a Model to investigate whether or not treatment effect differs depending on sex.




Hochberg Percentage of time sensor glucose is in the target range 2.6–10 mmol/l 0.002 1 Yes
Hochberg Percentage of time sensor glucose is in the target range 4–8 mmol/l 0.004 2 Yes
Hochberg Mean sensor glucose 0.099 3 No
Gate-keeping Sensor glucose variability (unconditional) 0.9 4 No
Gate-keeping Percentage of time sensor glucose is in the hyperglycaemic range
(> 15 mmol/l)
0.1 5 No
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TABLE 28 Randomised controlled trial: withdrawals from treatment only
Subject ID Group
Date of







N43-1032 Standard 26 April 2017 1 May 2017 Clinical decision Yes
N43-1034 Standard 4 May 2017 9 May 2017 Clinical decision No
N68-1091 Standard 1 March 2018 2 March 2018 Clinical decision 2 No
N74-1092 Standard 1 March 2018 3 March 2018 Clinical decision 2 No
N86-1131 Standard 13 July 2018 16 July 2018 Clinical decision 3 No
N87-1168 Standard 21 November 2018 28 November 2018 Clinical decision 6 No
N01-1083 Standard 5 February 2018 6 February 2018 Other Clinical decision. Third sensor failed and
inappropriate to attempt fourth sensor
2 No
N36-1021 Standard 25 January 2017 26 January 2017 Other Sensor would not work No
N36-1066 Standard 19 December 2017 20 December 2017 Other Unable to get sensor to calibrate 1 No
N36-1102 Standard 28 March 2018 29 March 2018 Other Unable to get sensor to calibrate 1 No
N42-1049 Standard 21 August 2017 27 August 2017 Other Sensor stopped working 6 No
N68-1068 Standard 22 December 2017 25 December 2017 Other Device-related issue 3 No
N68-1082 Standard 4 February 2018 6 February 2018 Other Infant transferred to another hospital and so sensor
was removed
2 No
N68-1107 Standard 10 April 2018 13 April 2018 Other Transferred to another hospital for intervention 4 No
N73-1090 Standard 27 February 2018 4 March 2018 Other Interstitial signal not recording and therefore
sensor removed
5 No
N73-1164 Standard 13 November 2018 17 November 2018 Other Infant transferred to Salisbury 5 No









































N01-1048 CGM 21 August 2017 22 August 2017 Clinical decision 1 Yes
N36-1022 CGM 25 January 2017 26 January 2017 Clinical decision No
N36-6022 CGM 1 November 2017 3 November 2017 Clinical decision 2 No
N43-1027 CGM 30 March 2017 31 March 2017 Clinical decision No
N43-1028 CGM 30 March 2017 2 April 2017 Clinical decision No
N68-1138 CGM 7 August 2018 10 August 2018 Clinical decision 3 No
N85-1175 CGM 15 January 2019 17 January 2019 Clinical decision 2 No
N01-1059 CGM 9 November 2017 11 November 2017 Other Failed sensor. Parents did not want a replacement
sensor inserted
3 No
N68-1080 CGM 1 February 2018 1 February 2018 Other Could not get a sensor into the infant 0 No
N73-1165 CGM 14 November 2018 17 November 2018 Other Sensor readings lost 4 No
N74-1128 CGM 23 June 2018 29 June 2018 Other Advice from trial team because the infant was 9 days
old (not 7 days) because of the delay in inserting
the sensor
5 No
N88-1173 CGM 18 December 2018 19 December 2018 Other Equipment malfunctioning. Could not get transmitters
to work despite good sensor placement
2 No














































































































































































































































































































































TABLE 29 Randomised controlled trial: withdrawals from the RCT
Subject ID Group
Date of
randomisation Date of withdrawal
Study
timing Reason Description
N01-1052 Standard 13 October 2017 13 October 2017 Days 1–7 Parental decision
N36-1117 Standard 22 May 2018 23 May 2018 Days 1–7 Parental decision





N87-1148 Standard 14 September 2018 15 September 2018 Days 8–14 Other No interstitial signal
or BMG reading
on MiniMed
N01-1144 CGM 1 September 2018 1 September 2018 Days 1–7 Parental decision
N01-1006 CGM 15 September 2016 18 September 2016 Days 8–14 Clinical decision
N36-1033 CGM 3 May 2017 4 May 2017 Days 8–14 Clinical decision
N73-1141 CGM 21 August 2018 22 August 2018 Days 8–14 Clinical decision
N42-1016 CGM 8 December 2016 12 December 2016 Days 8–14 Parental decision
N87-1142 CGM 23 August 2018 25 August 2018 Days 8–14 Parental decision




BG, blood glucose; ID, identification; IVH, intraventricular haemorrhage.
TABLE 30 Randomised controlled trial: listing of deaths
Subject ID Group Date of randomisation Date of death Study timing
N43-1038 Standard 29 May 2017 30 May 2017 Days 1–7
N73-1095 Standard 14 March 2018 15 March 2018 Days 1–7
N01-1147 Standard 10 September 2018 23 September 2018 Days 8–14
N36-1018 Standard 5 January 2017 2 February 2017 Post day 14
N43-1032 Standard 26 April 2017 13 May 2017 Post day 14
N68-1139 Standard 11 August 2018 26 August 2018 Post day 14
N01-1048 CGM 21 August 2017 7 October 2017 Post day 14
N01-1087 CGM 20 February 2018 10 March 2018 Post day 14
ID, identification.
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TABLE 31 Randomised controlled trial: growth parameters at birth
Variable Statistic Standard-care arm CGM arm Total
Birthweight (g) n 95 84 179
Mean (SD) 880 (180) 910 (160) 890 (170)
Median 920 930 930
Minimum, maximum 470, 1170 390, 1190 390, 1190
Birthweight SDS n 95 84 179
Mean (SD) –0.8 (0.92) –0.82 (0.98) –0.81 (0.95)
Median –0.66 –0.76 –0.74
Minimum, maximum –2.6, 1.32 –2.97, 1.2 –2.97, 1.32
Body length (cm) n 64 55 119
Mean (SD) 33 (2.5) 33.2 (2.8) 33 (2.6)
Median 33 33 33
Minimum, maximum 26, 38 24.5, 38 24.5, 38
Body length SDS n 64 55 119
Mean (SD) –1.54 (0.81) –1.56 (0.89) –1.55 (0.84)
Median –1.45 –1.41 –1.41
Minimum, maximum –3.87, –0.41 –3.73, 0.24 –3.87, 0.24
Head circumference (cm) n 87 75 162
Mean (SD) 24.1 (1.9) 24.5 (1.8) 24.3 (1.9)
Median 24.5 24.8 24.5
Minimum, maximum 19, 28 19, 28 19, 28
Head circumference SDS n 87 75 162
Mean (SD) –1.16 (0.86) –1.12 (0.99) –1.14 (0.92)
Median –1.14 –1.04 –1.1
Minimum, maximum –3.03, 0.82 –3.5, 1.11 –3.5, 1.11
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TABLE 32 Randomised controlled trial: growth parameters at day 7
Variable Statistic Standard-care arm CGM arm Total
Weight (g) n 87 76 163
Mean (SD) 890 (180) 930 (160) 910 (170)
Median 920 960 930
Minimum, maximum 480, 1220 450, 1220 450, 1220
Weight SDS n 87 76 163
Mean (SD) –1.3 (0.75) –1.26 (0.79) –1.28 (0.77)
Median –1.14 –1.19 –1.16
Minimum, maximum –3.11, 0.16 –3.2, 0.17 –3.2, 0.17
Body length (cm) n 63 56 119
Mean (SD) 33.7 (2.7) 33.8 (2.7) 33.7 (2.7)
Median 34 34 34
Minimum, maximum 24, 39.5 24.5, 39.3 24, 39.5
Body length SDS n 63 56 119
Mean (SD) –1.81 (1.07) –1.78 (0.87) –1.8 (0.97)
Median –1.59 –1.67 –1.6
Minimum, maximum –7.01, 0.16 –4.19, –0.28 –7.01, 0.16
Head circumference (cm) n 72 60 132
Mean (SD) 24.1 (1.8) 24.4 (1.6) 24.2 (1.7)
Median 24 24.5 24.3
Minimum, maximum 19.7, 28 20, 27.7 19.7, 28
Head circumference SDS n 72 60 132
Mean (SD) –1.84 (0.77) –1.76 (0.83) –1.81 (0.8)
Median –1.85 –1.56 –1.73
Minimum, maximum –3.6, 0.03 –3.91, 0.03 –3.91, 0.03
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TABLE 33 Randomised controlled trial: growth parameters at day 14
Variable Statistic Standard-care arm CGM arm Total
Weight (g) n 89 76 165
Mean (SD) 980 (200) 1020 (200) 1000 (200)
Median 980 1040 1000
Minimum, maximum 480, 1390 530, 1380 480, 1390
Weight SDS n 89 76 165
Mean (SD) –1.38 (0.76) –1.39 (0.77) –1.38 (0.76)
Median –1.35 –1.35 –1.35
Minimum, maximum –3.06, 0.21 –3.06, 0.31 –3.06, 0.31
Body length (cm) n 59 51 110
Mean (SD) 34.5 (2.6) 34.6 (2.7) 34.6 (2.6)
Median 35 35 35
Minimum, maximum 26.5, 40 26, 38.5 26, 40
Body length SDS n 59 51 110
Mean (SD) –1.98 (0.88) –1.96 (0.83) –1.97 (0.85)
Median –1.93 –1.94 –1.93
Minimum, maximum –4.71, –0.11 –3.89, –0.56 –4.71, –0.11
Head circumference (cm) n 74 66 140
Mean (SD) 25 (2.3) 25.4 (2.4) 25.2 (2.4)
Median 25 25.5 25.2
Minimum, maximum 19.2, 35.6 20.5, 36.5 19.2, 36.5
Head circumference SDS n 74 66 140
Mean (SD) –1.9 (1.1) –1.8 (1.2) –1.9 (1.2)
Median –2.1 –1.9 –1.9
Minimum, maximum –4.1, 3.5 –4.5, 4 –4.5, 4
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TABLE 34 Randomised controlled trial: growth parameters at 36 weeks’ corrected gestation
Variable Statistic Standard-care arm CGM arm Total
Weight (g) n 85 75 160
Mean (SD) 2030 (390) 2040 (360) 2030 (380)
Median 2050 2020 2050
Minimum, maximum 1130, 2820 1160, 2980 1130, 2980
Weight SDS n 85 75 160
Mean (SD) –1.54 (0.94) –1.56 (0.93) –1.55 (0.93)
Median –1.47 –1.57 –1.5
Minimum, maximum –3.83, 0.45 –3.92, 0.65 –3.92, 0.65
Body length (cm) n 41 27 68
Mean (SD) 41.3 (3.4) 40.7 (3.9) 41.1 (3.6)
Median 42 41 41
Minimum, maximum 34, 47 29.6, 47 29.6, 47
Body length SDS n 41 27 68
Mean (SD) –2.6 (1.6) –2.9 (1.8) –2.7 (1.6)
Median –2.3 –2.8 –2.6
Minimum, maximum –6, 0.09 –7.8, 0.03 –7.8, 0.09
Head circumference (cm) n 71 59 130
Mean (SD) 30.9 (2.1) 31.2 (2.2) 31 (2.1)
Median 30.8 31 30.9
Minimum, maximum 25.6, 36 26.5, 39.7 25.6, 39.7
Head circumference SDS n 71 59 130
Mean (SD) –1.3 (1.6) –1.1 (1.7) –1.2 (1.6)
Median –1.4 –1.3 –1.3
Minimum, maximum –5.5, 2.8 –4.8, 5.6 –5.5, 5.6
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TABLE 35 Randomised controlled trial: completeness of data used for health economic evaluation
Data Item

























MiniMed 640G 3.0-ml insulin
pump
81 (96) 0 (0) 3 (4) 0 (0) 0 (0) 0 (0) 95 (100) 0 (0) 81 (45) 0 (0) 98 (55) 0 (0)
Guardian 2 Link 81 (96) 0 (0) 3 (4) 0 (0) 0 (0) 0 (0) 95 (100) 0 (0) 91 (45) 0 (0) 98 (55) 0 (0)
Generation Enlite single sensor:
MMT-7008B
81 (96) 0 (0) 3 (4) 0 (0) 0 (0) 0 (0) 95 (100) 0 (0) 91 (45) 0 (0) 98 (55) 0 (0)
Glucose monitoring Glucose sensor insertion 81 (96) 0 (0) 3 (4) 0 (0) 0 (0) 0 (0) 95 (100) 0 (0) 81 (45) 0 (0) 98 (55) 0 (0)
Glucose sensor monitoring 75 (89) 6 (7) 3 (4) 0 (0) 0 (0) 0 (0) 95 (100) 0 (0) 75 (42) 6 (3) 98 (55) 0 (0)
Glucose sensor removal 81 (96) 0 (0) 3 (4) 0 (0) 0 (0) 0 (0) 95 (100) 0 (0) 81 (45) 0 (0) 98 (55) 0 (0)
POC testing used to
calibrate MiniMed 640G
Nova StatStrip meter 75 (89) 0 (0) 9 (11) 0 (0) 93 (98) 0 (0) 2 (2) 0 (0) 168 (94) 0 (0) 11 (6) 0 (0)
Length of stay Total: days 1–7 83 (99) 1 (1) 0 (0) 0 (0) 94 (99) 1 (1) 0 (0) 0 (0) 177 (99) 2 (1) 0 (0) 0 (0)
Total: randomisation to 36 weeks 73 (87) 11 (13) 0 (0) 0 (0) 83 (87) 12 (13) 0 (0) 0 (0) 156 (87) 23 (13) 0 (0) 0 (0)
Medication Any medication use: days 1–7 81 (96) 3 (4) 0 (0) 0 (0) 94 (99) 1 (1) 0 (0) 0 (0) 175 (98) 4 (2) 0 (0) 0 (0)
Inotrope use 81 (96) 3 (4) 0 (0) 0 (0) 94 (99) 1 (1) 0 (0) 0 (0) 175 (98) 4 (2) 0 (0) 0 (0)
Antibiotic use 81 (96) 3 (4) 0 (0) 0 (0) 94 (99) 1 (1) 0 (0) 0 (0) 175 (98) 4 (2) 0 (0) 0 (0)
Caffeine use 81 (96) 3 (4) 0 (0) 0 (0) 94 (99) 1 (1) 0 (0) 0 (0) 175 (98) 4 (2) 0 (0) 0 (0)
Morphine use 81 (96) 3 (4) 0 (0) 0 (0) 94 (99) 1 (1) 0 (0) 0 (0) 175 (98) 4 (2) 0 (0) 0 (0)
Corticosteroid use 81 (96) 3 (4) 0 (0) 0 (0) 94 (99) 1 (1) 0 (0) 0 (0) 175 (98) 4 (2) 0 (0) 0 (0)
Insulin use 81 (96) 3 (4) 0 (0) 0 (0) 94 (99) 1 (1) 0 (0) 0 (0) 175 (98) 4 (2) 0 (0) 0 (0)
Insulin use over post-intervention
period














































































































































































































































































































































TABLE 35 Randomised controlled trial: completeness of data used for health economic evaluation (continued )
Data Item























Investigations Any investigation use 74 (88) 10 (12) 0 (0) 0 (0) 85 (89) 10 (11) 0 (0) 0 (0) 159 (89) 20 (11) 0 (0) 0 (0)
Cranial ultrasound 74 (88) 10 (12) 0 (0) 0 (0) 85 (89) 10 (11) 0 (0) 0 (0) 159 (89) 20 (11) 0 (0) 0 (0)
Other ultrasound 74 (88) 10 (12) 0 (0) 0 (0) 85 (89) 10 (11) 0 (0) 0 (0) 159 (89) 20 (11) 0 (0) 0 (0)
CT 74 (88) 10 (12) 0 (0) 0 (0) 85 (89) 10 (11) 0 (0) 0 (0) 159 (89) 20 (11) 0 (0) 0 (0)
X-ray 74 (88) 10 (12) 0 (0) 0 (0) 85 (89) 10 (11) 0 (0) 0 (0) 159 (89) 20 (11) 0 (0) 0 (0)
EEG 74 (88) 10 (12) 0 (0) 0 (0) 85 (89) 10 (11) 0 (0) 0 (0) 159 (89) 20 (11) 0 (0) 0 (0)
MRI 74 (88) 10 (12) 0 (0) 0 (0) 85 (89) 10 (11) 0 (0) 0 (0) 159 (89) 20 (11) 0 (0) 0 (0)
Echocardiography 74 (88) 10 (12) 0 (0) 0 (0) 85 (89) 10 (11) 0 (0) 0 (0) 159 (89) 20 (11) 0 (0) 0 (0)
ECG 74 (88) 10 (12) 0 (0) 0 (0) 85 (89) 10 (11) 0 (0) 0 (0) 159 (89) 20 (11) 0 (0) 0 (0)
Blood transfusion
products
Any product use 74 (88) 10 (12) 0 (0) 0 (0) 85 (89) 10 (11) 0 (0) 0 (0) 159 (89) 20 (11) 0 (0) 0 (0)
Fresh-frozen plasma 74 (88) 10 (12) 0 (0) 0 (0) 85 (89) 10 (11) 0 (0) 0 (0) 159 (89) 20 (11) 0 (0) 0 (0)
Red blood cells 74 (88) 10 (12) 0 (0) 0 (0) 85 (89) 10 (11) 0 (0) 0 (0) 159 (89) 20 (11) 0 (0) 0 (0)
Platelets 74 (88) 10 (12) 0 (0) 0 (0) 85 (89) 10 (11) 0 (0) 0 (0) 159 (89) 20 (11) 0 (0) 0 (0)
Medical treatment Any medical treatment use 74 (88) 10 (12) 0 (0) 0 (0) 85 (89) 10 (11) 0 (0) 0 (0) 159 (89) 20 (11) 0 (0) 0 (0)
Lumbar puncture 74 (88) 10 (12) 0 (0) 0 (0) 85 (89) 10 (11) 0 (0) 0 (0) 159 (89) 20 (11) 0 (0) 0 (0)
Ventricular tap 74 (88) 10 (12) 0 (0) 0 (0) 85 (89) 10 (11) 0 (0) 0 (0) 159 (89) 20 (11) 0 (0) 0 (0)
Long line 74 (88) 10 (12) 0 (0) 0 (0) 85 (89) 10 (11) 0 (0) 0 (0) 159 (89) 20 (11) 0 (0) 0 (0)
Surgical procedures Any surgical procedure use 74 (88) 10 (12) 0 (0) 0 (0) 85 (89) 10 (11) 0 (0) 0 (0) 159 (89) 20 (11) 0 (0) 0 (0)
Ventriculoperitoneal shunts 74 (88) 10 (12) 0 (0) 0 (0) 85 (89) 10 (11) 0 (0) 0 (0) 159 (89) 20 (11) 0 (0) 0 (0)
Surgical procedures for central
access
74 (88) 10 (12) 0 (0) 0 (0) 85 (89) 10 (11) 0 (0) 0 (0) 159 (89) 20 (11) 0 (0) 0 (0)
Interventions for ROP treatment 74 (88) 10 (12) 0 (0) 0 (0) 85 (89) 10 (11) 0 (0) 0 (0) 159 (89) 20 (11) 0 (0) 0 (0)
Mode of discharge if
infant is transferred to
another hospital (n= 75)a
38 (100) 0 (0) 0 (0) 0 (0) 37 (100) 0 (0) 0 (0) 0 (0) 75 (100) 0 (0) 0 (0) 0 (0)
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